{"title": "PDF", "author": "PDF", "url": "https://www.fhi.no/contentassets/4df2902e8492453bb22c219bf69d8f71/191303_legemiddelstatistikk2019.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "The Norwegian Prescription Database 2014-2018 Christian Lie Berg Kristine Olsen Solveig SakshaugUtgitt av Folkehelseinstituttet / Published by Norwegian Institute of Public Health Omr\u00e5de for Helsedata Kristine Olsen ned som pdf p\u00e5 Folkehelseinstituttets nettsider: / The Health Postboks 222 Sk\u00f8yen N-0213 Oslo use in the elderly 2013: Legemiddelstatistikk the D\u00f8gndose (DDD) .................................................................................................................................... 13 1.6 WHO Collaborating Centre for Drug Statistics Methodology .............................................................................. 14 2. Reseptregisteret 19 2.3 av hovedtabellene ............................................................................................................................ 20 2.4 ATC main groups .................................................................................................................................................. 24 2.5 ATC group A - Alimentary tract and metabolism ................................................................................................. 25 2.6 ATC group B - Blood and bloodforming organs ................................................................................................... 36 2.7 ATC group C - Cardiovascular system .................................................................................................................. 39 2.8 ATC group D - Dermatologicals ........................................................................................................................... 47 2.9 ATC group G - Genito urinary system and sex hormones .................................................................................... 53 2.10 ATC group H - Systemic hormonal preparations, excl. sex hormones and insulins ............................................. 58 2.11 ATC group J - Antiinfectives for systemic use ...................................................................................................... 61 2.12 ATC group L - Antineoplastic and immunomodulating agents ............................................................................ 68 2.13 ATC group M - Musculo-skeletal system ............................................................................................................. 71 2.14 ATC group N - Nervous system ........................................................................................................................... 74 2.15 ATC group P - Antiparasitic products, insecticides and repellents ...................................................................... 84 2.16 ATC group R - Respiratory system ....................................................................................................................... 86 2.17 ATC group S - Sensory organs ............................................................................................................................. 91 2.18 ATC-group V - Various ......................................................................................................................................... 95 og ............................................................................................................................................................................. General information about the Norwegian Prescription Database (NorPD) and drug statistics ................................. 8 1.1 About the NorPD ................................................................................................................................................... 8 1.2 Prescription statistics in the other Nordic countries ........................................................................................... 11 1.3 The Norwegian Drug Wholesales Statistics ........................................................................................................ 12 1.4 The Anatomical Therapeutic Chemical (ATC) classification system ..................................................................... 12 1.5 The Defined Daily Dose (DDD) ............................................................................................................................. 13 1.6 WHO Collaborating Centre for Drug Statistics Methodology .............................................................................. 14 2. The Norwegian Prescription Database (NorPD) 2014-2018 ........................................................................................ 15 2.1 Selected key figures from the NorPD ................................................................................................................... 15 2.2 Prescription categories and re imbursement of medicinal expenses .................................................................. 19 2.3 Description of the main tables ............................................................................................................................ 20 2.4 ATC main groups .................................................................................................................................................. 24 2.5 ATC group A - Alimentary tract and metabolism ................................................................................................. 25 2.6 ATC group B - Blood and bloodforming organs ................................................................................................... 36 2.7 ATC group C - Cardiovascular system .................................................................................................................. 39 2.8 ATC group D - Dermatologicals ........................................................................................................................... 47 2.9 ATC group G - Genito urinary system and sex hormones .................................................................................... 53 2.10 ATC group H - Systemic hormonal preparations, excl. sex hormones and insulins ............................................. 58 2.11 ATC group J - Antiinfectives for systemic use ...................................................................................................... 61 2.12 ATC group L - Antineoplastic and immunomodulating agents ............................................................................ 68 2.13 ATC group M - Musculo-skeletal system ............................................................................................................. 71 2.14 ATC group N - Nervous system ........................................................................................................................... 74 2.15 ATC group P - Antiparasitic products, insecticides and repellents ...................................................................... 84 2.16 ATC group R - Respiratory system ....................................................................................................................... 86 2.17 ATC group S - Sensory organs ............................................................................................................................. 91 2.18 ATC-group V - Various ......................................................................................................................................... 95 Some abbreviations and definitions ................................................................................................................................ 97 Population in Norway 2014-2018 (as of 1st July) ............................................................................................................ 98 Population by age in 2018 (as of 1st July) ........................................................................................................................ 98 List of publications based on data from the Norwegian Prescription Database (NorPD) as of 21.02.2019 ................... 99ContentsLegemiddelstatistikk 2019:2 Folkehelseinstituttet 7Sammendrag Since the Norwegian Prescription Database (NorPD) was established on 1 January 2004 5.8 million individuals have been included in the database with at least one drug dispensed from a pharmacy. The number of drugs dispensed to patients in the same period is about 620 millions. NorPD contains information from all Norwegian pharmacies regarding the dispensing of drugs to individuals, to prescribers' own practice and to insti - tutions. In 2018, about 97% of the drugs registered in NorPD (measured in DDD) were dispensed to individuals. Sales of over-the-counter drugs are not included in NorPD. General information about the NorPD, drug statistics, classification of drugs and measurement methods is included in part 1 of the report. Part 2 contains selected key figures from the NorPD and the main tables with information about the number of indi - viduals who had drugs dispensed from pharmacies in Norway during the last five years (2014-2018). In 2018, 70% of the Norwegian population received at least one prescription drug, 77% of the women and 64% of the men (Table 2.1.a). The one-year prevalence in the population who had at least one drug dispensed in 2018 was lowest in the age group 5-9 years for both women and men (Figure 2.1). Between 92% and 95% of the individuals aged 70 and older were dispensed at least one drug. Table 2.1.b shows the one-year prevalence in the population for each of the 14 ATC main groups; total and the distribution between women and men. The three drug groups most commonly used by both women and men are anti-infectives (ATC group J), drugs affecting the nervous system (ATC group N) and drugs used for respiratory diseases (ATC group R). Table 2.1.c gives an overview of the most commonly used drugs (number of users/prevalence, defined as ATC 5th levels) in Norway in 2018. The NorPD has a website where you can find addi - tional information: www.norpd.no (English version) or www.reseptregisteret.no (Norwegian version). Department of Pharmaceutical Statistics, Norwegian Institute of Public Health, June 2019Siden Reseptregisteret ble opprettet 1. rundt % av legemidlene i fikk minst ett legemiddel p\u00e5 resept, kvinner og menn 2.1). 92 % og 95 % av som ATC 5. General information about the Norwegian Prescription Database (NorPD) and drug statistics 1.1 About the NorPD From March 1st 2001 the new legislation in the Norwegian pharmacy sector came into force. This legislation obliged all pharmacies in Norway to forward prescription data to a new national drug database. The regulation covering the \u00abcollection and handling of health information in the Norwegian Prescription Database (Reseptregisteret)\u00bb, under the provision of the Personal Health Data Filing System Act, was approved in October 2003 (1). The regula- tion states which information the register can collect from the pharmacies and administrative registers. The objectives of the NorPD, as defined in authorative regulations, are to collect and process data on drug use in individuals and animals in Norway to: 1. map usage trends and monitor trends over time 2. be a resource for research in order to see positive and negative effects of drug consumption 3. give health authorities a statistical manage- ment tool for quality control of drug use and for steering and planning 4. give prescribers a basis for internal control and quality improvement of their prescribing practices1. Generelt om kraft 1. alle apotek i Norge til \u00e5 utredning kvalitetsforbedringPart 1 Del 1Legemiddelstatistikk 2019:2 Folkehelseinstituttet 9Data collection and variables in the NorPD Since January 1st 2004, the Norwegian Institute of Public Health (NIPH) has received data on prescrip- tions and requisition from all Norwegian pharmacies (2). Monthly electronically reports are automatically generated in all pharmacies, thus avoiding extra work for the pharmacy. The NorPD contains information about all drugs prescribed and dispensed to individual patients living outside institutions, i.e. ambulant care. Unli - censed drugs are also included if they are regis- tered in \u00abVareregisteret\u00bb (the Norwegian Article Number Registry) (https://www.farmalogg.no/en/ The-Article-Number-Register/). Drugs sold over- the-counter (OTC) are not recorded in the NorPD. However if the OTC drugs are prescribed by a physi - cian and dispensed, then they will be recorded in the database. The key data in the NorPD are based on prescriptions to individual humans, but dispensed prescriptions to animals from veterinarians and drugs delivered to a prescriber's own practice are also collected in the registry. For patients in nursing homes and hospitals, the register collects data on drug use at the level of the institution or the department, i.e. on an aggregate level. The NorPD contains the following variables: Patient Person-identifier (encrypted), month/year of birth, month/year of death, gender and place of resi- dence (municipality & county) Prescriber Person-identifier (encrypted), year of birth, gender, profession and speciality Drug Article number, brand name, strength, dosage form, package size, ATC code, DDD value and DDD unit, prescription category and pharmacy retail price Information about each dispensed drug Number of packages dispensed, number of Defined Daily Doses (DDD), prescription category (see chap. 3.2), prescription regulation, reimbursement code (see below), dispensing date, price per filled prescription and species of animal (if prescription from a veterinary) Pharmacy Name, license number, municipality and countyDatainnsamling og variabler tilrettelagt the key link to other registries providing detailed information about the drugs. The NorPD also contains information on reimburse- ment codes registered associated with general reimbursement prescriptions (according to the \"Blue prescription Regulation\") and Health Trust Financed Prescriptions (according to the \"Regulation for Health Trust Financed medicinal products\"). General reim- bursement prescriptions were previously registered with general and wide reimbursement codes, which in some cases could act as a proxy of diagnosis for certain drugs. New reimbursement regulations came into force in March 2008 and was fully implemented from March 2009. Under the new reimbursement regulation, valid reimbursement codes are available on a separate reimbursement list. Reimbursement codes are based on either the International Classifica- tion of Diseases version 10 (ICD-10) or International Classification of Primary Care Version 2 (ICPC-2). In addition, NoMA assigns special codes for general reimbursement. For Health Trust Financed Prescrip- tions there are no list of pre-approved reimbursement codes. This means that all codes in the International Classification of Diseases version 10 (ICD-10) or International Classification of Primary Care version 2 (ICPC-2) can be used. The first reimbursement codes for Health Trust Financed Prescriptions were regis- tered in the NorPD in August 2016. About 60 percent of all Health Trust Financed Prescriptions in 2018 were registered with a reimbursement code in the NorPD. Data protection As illustrated in figure 1.1 the pharmacy\u00b4s records of dispensed drugs are automatically transferred (electronically) through Statistics Norway before they arrive at NIPH and are included in the NorPD. Statistics Norway act as so-called \"trusted third part\" Varenummeret i kraft mars 2008, og ble fullstendig implementert fra mars 2009. I of Diseases versjon 10 (ICD-10) eller International Classification of Primary Classification of Diseases versjon 10 (ICD-10) eller International Classification of 2018 er det registrert refusjonskode for omtrent 60 % av Reseptregisteret. SSB Figure 1.1. Data flow, the Norwegian Prescription Database (NorPD).All pharmacies in NorwayDispensed prescriptions encryptedPrescriptions with pseudo- nymised transform Institute of Public Health NorPDLegemiddelstatistikk 2019:2 Folkehelseinstituttet 11part of the data protection to ensure confidentiality of personal information. Statistics Norway only has access to the patients\u00b4s Personal Identity Number and the prescriber's health personnel number and replaces both with a pseudonymised identifier. Statistics Norway cannot read any other prescription data because this information is encrypted before Statistics Norway receives the data. When Statistics Norway sends the data including the pseudonymised identifiers to the NIPH, the NIPH is allowed to decrypt the prescription information again. The principle of pseudonymisation is that no one, not even the trusted third part should have simultaneously access to pseud- onym, health data and the person's identity. In the regulation of the NorPD, pseudonymous health data is defined as: \u00abHealth information where the identity is encrypted or otherwise concealed, but nonethe- less individualized so that it is possible to follow each person without disclosing the identity\u00bb. This means that the identity of patients and prescribers has been encrypted according to Norwegian legislation, but nonetheless individualized, so that it is possible to follow individuals over time and perform record- linkage studies. Data linkage is based on the unique identification number system which is available in all the Nordic countries. 1.2 Prescription statistics in the other Nordic countries During the late 1980s, pharmacies in the Nordic countries gradually computerized their records of dispensed prescriptions which made it possible to collect data efficiently. Although healthcare systems are not organized identically in the Nordic countries, all five countries have a tax-supported public health service with universal coverage. All citizens, indepen- dent of socioeconomic status, have access to health services, including partial or complete reimburse- ment of purchased medicines. National prescription databases, containing data on drugs dispensed at pharmacies (exposure data) to individuals receiving ambulatory care, have been available since 1994 in Finland and Denmark, since 2004 in Norway, since 2005 in Sweden and since 2006 in Iceland. The data- bases together cover 26 million inhabitants (Denmark: 5.8 million; and Sweden: 10 million) and have the potential to link these data to different health outcomes and other data based on the unique personal identity code which all residents in these countries have. The databases serve as a resource for conducting longitudinal and record-linkage studies with health surveys and other registries. They also fungerer som en s\u00e5kalt tiltrodd tredjepart 2004 Norge, siden 2005 i Legemiddelstatistikk 2019:2 Folkehelseinstituttet 12offer a sound evidence base for national decision-making in the field of drug utilization. An article from 2010 provides an overview of the data collection procedures and content of the Nordic countries' prescription data- bases (3). 1.3 The Norwegian Drug Wholesales Statistics Statistics based on total sales of drugs from whole- salers to pharmacies, hospitals/nursing homes has been available in Norway since the 1970s. The Norwegian Drug Wholesales Statistics database includes total sales of drugs from wholesalers to pharmacies, hospitals/ nursing homes and non-pharmacy outlets and others with permission to sell medicines. Total sales of prescription and non-prescription human and veterinary medicines are included in the statistics. The statistics give an overview of developments in drug consumption over time, both at county and country level. The statistics, however, contain no information about the individual drug user. Drug Consumption in Norway - published annually Data from the Norwegian Drug Wholesales Statis- tics Database have been published annually in Drug Consumption in Norway (4) since 1977. Each issue includes total sales data for 5 year periods for both prescription and non-prescription drugs in Norway. The report is available from the website drugconsumption. no. Further information on the Norwegian Drug Whole - sales Statistics database, including how to apply for data, can be found at the Norwegian Institute of Public Health's website www.fhi.no. 1.4 The Anatomical Therapeutic Chemical (ATC) classification system In the ATC system the drug substances are classified into groups at 5 different levels. The drugs are divided into fourteen main groups (1st level), with pharmacological/ therapeutic sub-groups (2nd levels). The 3rd and 4th levels are chemical/pharmacological/therapeutic sub-groups and the 5th level is the chemical substance. The ATC code A complete classification of the drug spironolactone (diuretic) with the ATC code C03DA01 illustrates the structure of the ATC system: C Cardiovascular system (1st level, anatomical main group) C03 Diuretics (2nd level, therapeutic Spironolactone (5th level, chemical substance) All medicinal products containing plain spironolactone (Spirix\u00ae and Spironolactone\u00ae) are thus assigned the code C03DA01. The ATC classification system makes it possible to compile drug consumption statistics on 5 different levels, i.e., figures showing total consumption of all preparations classified in main group C - Cardiovascular system (1st level), figures for the various sub-groups (2nd, 3rd and 4th levels), and down to figures showing consumption of each active ingredient. The ATC code for all pharmaceuticals on the Norwe- gian market can be retrieved from the pharmacy medicinal product register , SPC at the Norwegian Medicines Agency's website and at the Felles- katalogens website (http://felleskatalogen.no/ medisin/atc-register), lists all medicinal products belonging to each of the ATC 5th level codes. 1.5 The Defined Daily Dose (DDD) In some tables in part 3 in this book the sales volume of drug consumption is given in number of DDDs. Using DDDs as the unit of measurement allows better comparison between alternative medications, regardless of price differences. The evaluation of drug consumption volumes over time, nationally and internationally, is simplified and improved by the use of DDDs. A DDD is defined as the assumed average maintenance dose per day for a drug used on its main indication in adults . The DDDs are determined on the basis of evaluation of international use of the substance in question, bearing in mind that national therapy traditions (indications, dosages) often differ greatly. Each DDD should therefore be regarded as a technical measuring unit. Drugs used for more than one indication may cause particular problems which are important to consider when evaluating statistics based on DDDs. With the exception of a very few specially formulated pediatric preparations, adult dosages are used. The DDD for a substance will often be one and the same, irrespective of the route of administration. However, drugs with different bioavailabilities depending on their admin - istration route will have more than one DDD, each of C03D Kaliumsparende niv\u00e5), tall for de ulike undergruppene (2., 3. og 4. niv\u00e5) og ned to a specific dosage form. For medica- tions where a booster dose is followed by a smaller maintenance dosage, the maintenance dose will form the basis for determining the DDD. Whenever possible, the DDD is indicated as the quantity of active substance. When this is impossible, as is the case with combination preparations and some liquid prepara- tions, the DDD is indicated as the number of single doses (number of tablets, capsules, millilitres etc.). The DDDs are not necessarily the most frequently prescribed or used doses. This must be considered when evaluating the data. Accordingly it will often be difficult to estimate the number of users by using the DDD as the measuring unit. 1.6 WHO Collaborating Centre for Drug Statistics Methodology The WHO Collaborating Centre for Drug Statistics Methodology is responsible for the administration and development of the ATC/DDD system. The Centre is located at the Department of Drug Statistics at the NIPH. Further information about the ATC/DDD system is given in the publication Guidelines for ATC classification and DDD assignment (5). The ATC Index with DDDs which includes a list of all assigned DDDs can be ordered from the Centre (6). Both publications are available in English and Spanish. The website for the Centre is www.whocc.no. The ATC/DDD publica- tions can be ordered from the WHO Collaborating Centre for Drug Statistics Methodology. ATC and DDD changes are published annually and are made official by the end of the year. ATC/DDD version from January 2018 has been used in this book. former v\u00e6re like med unntak av der biotilgjengelig- heten mye etter WHO Collaborating Centre for Drug Statistics Methodology ATC-/DDD-systemet administreres og videreutvikles av WHO Collaborating Centre for Drug Statistics Methodology. Dette senteret er en del av publika- sjonen Guidelines for ATC classification and DDD assignment (5). ATC Index with DDDs, som inne - holder en liste over Collaborating Centre for Drug Statistics Methodology. ATC- og DDD-endringer som JE, Almarsdottir AB, S\u00f8rensen HT. The Nordic countries as research. Basic Clin Pharmacol Toxicol 2010;106(2):86-94. Norway 2014-2018. [Legemiddelforbruket i Norge 2014-2018] Oslo: Norwegian Institute of Public Health, 2019. 5. WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment 2019. Oslo, 2018. 6. WHO Collaborating Centre for Drug Statistics Methodology, ATC classification index with DDDs 2018. Oslo, 2018Legemiddelstatistikk 2019:2 Folkehelseinstituttet 15 2. The Norwegian Prescription Database (NorPD) 2014-2018 2.1 Selected key figures from the NorPD The NorPD contains information from all Norwegian pharmacies of drugs dispensed to individuals, to a prescriber's own practice and to institutions. In 2018, about 97% of DDDs in the NorPD were dispensed to individuals in ambulatory care. Deliveries to institutions (hospitals and nursing homes) amounted to 3% of the DDDs and about 0.4% of the DDDs were dispensed for use in the physician's practice. Sales of OTC medicines are not included in the NorPD. OTC sales constitute 11% of total sales of pharmaceuti cals in Norway in 2018, measured in DDDs (source: Norwegian Drug Wholesale Statistics, Norwegian Institute of Public Health). 2. Reseptregisteret av % 2.1.a. Number of individuals and one-year prevalence (%) of the population who had at least one drug dispensed in Norway 2014-2018. Women n (%)Men n (%)Both genders n (%) 2014 1 939 431 (75.9) 1 605 342 (62.1) 3 544 773 (69.0) 2015 1 956 001 (75.9) 1 622 534 (62.1) 3 578 535 (69.0) 2016 1 981 012 (76.2) 1 649 902 (62.6) 3 630 914 (69.3) 2017 1 680 866 688 097 (69.9) 2018 2 022 967 (76.8) 1 701 415 (63.6) 3 724 382 (70.1)Part 2 Del 2Legemiddelstatistikk 2019:2 Folkehelseinstituttet 16Since January 2004, approximately 5.8 million indi- viduals have been included in NorPD with at least one prescribed drug dispensed from a pharmacy. The number of drugs dispensed to patients in the same period (2004-2018) is about 620 millions. In 2018, 70.1% of the Norwegian population had at least one prescription dispensed, 76.8% of women and 63.6% of men (table 2.1.a). In 2004, the first operational year of NorPD, the proportion of prescriptions having invalid or missing personal identity number was 3.7%. In the period 2005-2007, the proportion was around 2%. The proportion of prescriptions with an invalid personal identity number has declined further to just below 1.4% in 2008 and 2009. In 2010-2018 the proportion was less than 1% (0.16% in 2018). The age-specific one year prevalence for being dispensed a drug in 2018 was lowest for women at about 5-9 years of age and for men at the same age (figure 2.1). Between 92 and 95 % of individuals in the aged groups 70 years and older received prescribed drugs. In the age groups 15-29 years 74 to 82% pf the women received prescribed drugs in 2018. If women who only received hormonal contraception (ATC code G02B and G03A) are excluded, the prevalence was 64 to 71%. The proportion of drug users among women over 15 years of age was still higher than in men.Reseptregisteret ble opprettet 1. januar 2009 har den ligget p\u00e5 i underkant samme (figur Mellom 92 og 95 om de ekskluderes.100 80 60 40 20 One-year prevalence (%) of the population who had at least one drug dispensed in 2018 in Norway according to age and gender. The pink line shows the one-year prevalence (%) for women excluding contraceptives for topical use (ATC code G02B) and hormonal contraceptives for systemic use (ATC code G03A). Women Men Women (excl. 2.1.b shows the one-year prevalence of the entire population, and among men and women, who received at least one drug in each of the main ATC groups. The three drug groups most used in both men and women are anti-infectives (ATC group J), drugs affecting the nervous system (ATC group N) and drugs used for respiratory diseases (ATC group R). Table 2.1.c shows an overview of medicines (defined as ATC 5th levels) with the highest number of users in Norway in 2018. Paracetamol (analgesic) is used by the highest numbers of individuals, followed by phenoxymethylpenicillin (antibiotic). Paracetamol is also sold OTC. This use is not covered by the NorPD. The list contains essentially the same drugs as in previous years, but there are some changes in order. Doxycycline (antibiotic) is not longer represented on the list of the 30 most prescribed medicine.Tabell 2.1.b viser legemidler. Table 2.1.b. One-year prevalence (%) of the population who had at least one drug dispensed in Norway in 2018 according to the main ATC groups. ATC Women %Men %Both genders % A Alimentary tract and metabolism 23.8 18.1 20.9 B Blood and blood forming organs 13.6 13.4 13.5 C Cardiovascular system 21.4 21.3 21.4 D Dermatologicals 16.1 13.0 14.5 G Genito urinary system and sex hormones 25.6 8.1 16.7 H Systemic hormonal preparations, excl. sex hormones and insulins 11.9 5.8 8.8 JAnti-infectives for systemic use 26.5 17.5 22.0 LAnti-neoplastic and immunomodulating agents 2.5 1.9 2.2 M Musculo-skeletal system 20.7 15.3 18.0 N Nervous system 32.9 22.7 27.7 P Anti-parasitic products, insecticides and repellents 2.2 1.4 1.8 R Respiratory system 29.7 22.9 26.3 S Sensory organs 14.6 10.8 12.7 V Various 0.7 0.7 0.7Legemiddelstatistikk 2019:2 Folkehelseinstituttet 18Table 2.1.c. Drugs with the highest number of users in Norway in 2018. ATC code Active ingredient UseNumber of individualsProportion (%) of the population 1 N02BE01 paracetamol 1) Analgesic 559 985 10.5 2 J01CE02 163 7.0 6.8 4 N02AJ06 Analgesic 339 932 6.4 5 C10AA05 atorvastatin Lipid modifying 329 576 6.2 6 M01AB05 NSAID/analgesic 307 370 5.8 7 285 653 5.4 705 5.3 9 cetirizine 1) A02BC02 pantoprazole 262 514 4.9 14 N02AX02 226 103 4.3 15 M01AE01 ibuprofen 1) NSAID/analgesic 221 288 4.2 16 H03AA01 supplement 212 354 4.0 194 098 3.7 18 S01AA01 Antibacterial drops 193 278 3.6 19 C10AA01 Lipid modifying 192 106 3.6 20 H02AB06 21 A02BC05 spray 176 300 3.3 23 amlodipine Antihypertensive/cardiac 155 136 with proton-pump inhibitor supplement 751 2.9 26 G03AA07 levonorgestrel Hormonal contraception osteoporosis142 825 135 934 2.6 29 C09CA06 744 2.4 30 A10BA02 122 463 2.3 1) The ATC-level comprises OTC-medicinal products. The number of individuals is registered prescription only.Legemiddelstatistikk imbursement of medicinal expenses NorPD contains information about dispensed prescriptions based on the following prescription categories: Non-reimbursed prescriptions General reimbursement prescriptions (according to the \"Blue Prescription Regulation\" (FOR-2007- 06-28-814)) Health Trust financed prescription (according to the \"Regulation for Health Trust Financed medicinal products\", FOR 2015-06-12-646) The following prescription categories are not included in the tables: Contribution to cover the cost of healthcare when expenses are not otherwise covered by other laws (according to the National Insurance Act \u00a7 5-22). Contribution to conscripted military and indi - viduals with occupational injury (according to the National Insurance Act \u00a7 5-25) Special contribution, for instance membership in Jernbanepersonalets Helsefond (Railways Workers Health Fund) See table 2.2 for the distribution of the different prescription categories. For more information regarding prescription categories, see e.g. https://www.helsedirektoratet.no/tema/legemidler/ legemiddelfinansiering/ refusjon-av-legemidler https://www.helsedirektoratet.no/tema/legemidler/ legemiddelfinansiering/helseforetaksfinansierte- legemidler-brukt-utenfor-sykehus-h-reseptlegemidler Table 2.2. Sales of drugs by prescription categories, overview 2018. Number of individuals Proportion (%) of the population Sales in 1000 NOK Non-reimbursable prescriptions 3 152 088 59,3 3 265 269 Reimbursement prescriptions 2 534 644 47,7 11 921 850 Health trust financed prescriptions 57 871 1,1 4 852 110Legemiddelstatistikk 2019:2 Folkehelseinstituttet som inkludert i og spesielt for i tabellen)2.3 Description of the main tables The tables in section 2 of this book provide an over- view of the number of individuals who have had drugs dispensed from pharmacies in Norway. Anyone who has had at least one drug dispensed is included and the data are given for each medicinal substance and for groups of medicines. Even if an individual has been given the same drug several times, he or she is counted as a user only once. Only dispensing datato individuals with a personal identity number are included in the tables. In NorPD the complete personal identity number is missing for 0.16% of the dispensed drugs to individuals in 2018. The tables contain figures for the period 2014-2018. In addition, the following information for 2018 includes: Prevalence per 1 000 inhabitants The number of individuals who have had at least one drug dispensed in the following age groups: <15, 15-44, 45-69, 70. If the number of individuals is less than five, <5 is used in the tables. Sales in 1 000 Norwegian kroner (NOK), i.e. for prescriptions dispensed to individuals with a personal identity number. The amount in NOK corresponds to the actual retail price from the pharmacy. The tables are arranged according to the ATC system (see further description in p. 12). The majority of ATC groups containing drugs on the Norwegian market are included. Drug use by individuals in hospitals and nursing homes is not included at the individual level in the Norwegian Prescription Database. The total number of drug users will therefore be higher than the figures in the tables for a number of drugs, particularly for drugs that are frequently used in hospitals or insti- tutions. We have chosen to exclude some ATC groups in this book that are mainly used in hospitals or other institutions. The following ATC groups have been omitted: B05 Blood substitutes and perfusion S01J Diagnostic agents S01L Ocular vascular disorder agents V Various (ATC group V01 Allergens and V03 All other therapeutic products i publikasjonen s. 2018 utgjorde reseptfrie lege - ATC levels comprices OTC products. The Number of individuals is registered for prescription sales only. Non-prescription drugs are sometimes prescribed, but the majority of the OTC drug sales will not be included in the tables in the Norwegian Prescrip - tion Database. Sales of OTC drugs are, however, included in the Norwegian Drug Wholesales Statis - tics database and the figures are published in \u00abDrug Consumption in Norway\u00bb (see also p. 13). In 2018, OTC medicines had a share of 11% of total sales measured in DDDs. This share has remained almost unchanged over time. Most prescribed drugs have an approved marketing authorisation in Norway. However, physicians can prescribe drugs without approved marketing authorisation. They must then apply for a licence from the Norwegian Medicines Agency. There are also some drugs that are part of a so-called \u00abnegative list\u00bb which can only be prescribed by special permission from the Medicines Agency. Drugs that are prescribed on licence or by special permission are included in the tables in the book. The number of individuals who are prescribed these drugs is often low. Many individuals use more than one drug . Please Figure 2.3. The report generator at www.norpd.no (Norwegian version at www.reseptregisteret.no) endringer i ATC-systemet nye be aware that it is not possible to add together the number of users of various drugs or drug groups in the tables to find the total number of users of two or more drugs. Statistics on the aggregate level in the tables will, however, include the use of at least one of the drugs in the included drug groups. For example, the figures in the tables show that the total number of users of hypnotics (ATC group N05C) is lower than the sum of the number of users of the individual drugs that are classified in N05C. This means that some individuals have been given more than one type of hypnotic during a year, either through the use of more than one simultaneously or by switching from one agent to another. Changes in ATC classification In ATC Index 2019 (current version of this report), ATC changes there are minor changes made of significance for statistics. The ATC code for dimethyl fumarate used in psoriasis and multiple sclerosis has been altered from N07XX09 to L04AX07. For more information regarding alterations in the ATC system and new ATC codes / DDD included in the 2019 Index, see updates on the WHO Centre's website www.whocc.no . Historical data has been updated in this report and the statistics bank (www.norpd.no). The NorPD website: www.norpd.no The Norwegian Prescription Database has its own website which can be used together with the tables in this report for complementary information. On the website (figure 2.3), one can create reports on the number of users of a particular drug or drug group. This can be done by searching for pre-defined drug groups, through the ATC system or by searching the active substance or product name.Legemiddelstatistikk 2019:2 Folkehelseinstituttet kroner som 1 134 322 x Antall innbyggere = 5 311 797 i 2018: 1 134 322 Antall innbyggere i Norge per 1. juli 2018: 5 311 av prevalens (per av 2018: P\u00e5 befolkningstallet slutten av \u00e5ret (utleverings\u00e5r minus f\u00f8dsels\u00e5r).The following data on drug use can be extracted from the website: Number of users, split by gender, 5-year age groups, county or health region Number of users per 1 000 population (prevalence per 1 000) Turnover in NOK (pharmacy retail price) Turnover in doses (DDD - defined daily doses) Population base for the statistics, split by gender, age, county or health region Data are available from 2004 with an annual update for the preceding year. The figures in this book may differ slightly from the numbers found on the website. This is because indi - viduals without known address are included in the tables in this book but not on the website. Reporting of data from the pharmacy to NorPD is delayed for a minor number of prescriptions. The delay may be a few months, meaning that reports of data from a year can arrive the following year. Access to data from NorPD It is possible to apply for data from the Norwegian Prescription Database for research or for other purposes which are according to the objectives of NorPD. Application forms are available on the website of NIPH (www.fhi.no) and all applications for access to data from NIPH should be sent to datatilgang@fhi.no. The data is free of charge, but fees for administration and file processing will be required. Calculation of prevalence per 1000 inhabitants Prevalence is often defined as the number of individuals per 1000 inhabitants who have had at least one drug dispensed in a pharmacy during a specific time period. Please read the following example for the calculation: 213.6 individuals per 1000 inhabitants The number of individuals x 1000 1 134 322 x 1000 The number of inhabitants = 5 311 797 = The number of individuals who had at least one cardiovascular drug dispensed (ATC group C) in Norway in 2018: 1 134 322 The number of inhabitants in Norway as of 1st July 2018: 5 311 797 Calculation of the prevalence (per 1000) of users of cardiovascular drugs in Norway in 2018: The population in Norway for the years 2014-2018 is shown on p. 98. The population of the four age groups in the tables is also provided. The population as of 1st July each year is used, calculated from the population figures by Statistics Norway from 1st January and 31st December. Age is defined as the age of the individual at the end of the year (year of dispensing minus birth year).Legemiddelstatistikk 2019:2 Folkehelseinstituttet 242.4 ATC main groups ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales in 1000 NOK<15 15-44 45-69 70 A ALIMENTARY TRACT AND METABOLISM 884 462 942 979 1 010 908 1 081 423 1 112 220 209.4 47 344 269 901 465 420 329 555 2 558 844 B BLOOD AND BLOOD FORMING ORGANS 640 857 658 268 678 638 699 782 714 990 134.6 5 359 82 587 280 709 346 335 1 989 763 C CARDIOVASCULAR SYSTEM 1 060 387 1 076 292 1 100 496 1 117 715 1 134 322 213.6 10 137 100 336 553 243 470 606 1 852 329 D DERMATOLOGICALS 674 324 686 931 713 156 747 278 772 456 145.4 113 072 282 360 245 067 131 957 441 597 G GENITO URINARY SYSTEM AND SEX HORMONES 814 987 835 159 859 381 876 623 889 096 167.4 4 102 443 058 285 681 156 255 1 147 178 H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS 437 511 445 610 452 531 463 794 469 293 88.4 18 156 112 666 198 712 139 759 548 811 J ANTIINFECTIVES FOR SYSTEMIC USE 1 252 912 1 239 430 1 209 403 1 177 724 1 167 183 219.7 117 077 451 075 380 772 218 259 1 284 841 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS 95 704 100 442 105 983 112 500 116 797 22.0 1 602 26 431 53 640 35 124 4 277 921 M MUSCULO-SKELETAL SYSTEM 928 438 942 110 946 467 963 353 954 846 179.8 15 248 318 251 441 641 179 706 495 981 N NERVOUS SYSTEM 1 353 896 1 380 464 1 411 698 1 450 416 1 473 116 277.3 33 128 465 180 625 750 349 058 3 168 219 P ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS 97 581 94 700 93 310 93 329 94 332 17.8 4 509 41 622 35 657 12 544 30 006 R RESPIRATORY SYSTEM 1 259 843 1 296 996 1 330 147 1 374 981 1 397 861 263.2 159 019 507 225 508 602 223 015 1 779 464 S SENSORY ORGANS 653 581 643 475 646 104 833 192 838 215 644 161 152 427 356 V VARIOUS 27 786 30 050 32 694 35 372 37 093 7.0 5 420 12 581 11 428 7 664 187 635Legemiddelstatistikk 2019:2 Folkehelseinstituttet 25A ALIMENTARY TRACT AND METABOLISM 884 462 942 979 1 010 908 1 081 423 1 112 220 209.4 47 344 269 901 465 420 329 555 2 558 844 A01 STOMATOLOGICAL PREPARATIONS 23 893 30 613 37 008 43 992 49 505 9.3 968 18 163 16 472 13 902 12 595 A01A STOMATOLOGICAL PREPARATIONS 23 893 30 613 37 008 43 992 49 505 9.3 968 18 163 16 472 13 902 12 595 A01AA Caries prophylactic agents 18 919 25 107 31 112 37 554 42 580 8.0 287 15 156 14 320 12 817 10 661 A01AA01 sodium fluoride 18 919 25 107 31 112 37 554 42 580 8.0 287 15 156 14 320 12 817 10 661 A01AB Antiinfectives and antisep - tics for local oral treatment 2 870 3 345 3 577 3 937 3 850 0.7 240 1 825 1 136 649 569 A01AB03 chlorhexidine 2 808 3 271 3 523 3 861 3 781 0.7 238 1 809 1 107 627 506 A01AB04 amphotericin B 29 28 24 30 25 0.0 0 5 10 10 22 A01AB09 miconazole 7 15 8 14 11 0.0 <5 <5 <5 <5 13 A01AB11 various 27 32 26 33 35 0.0 <5 9 15 10 28 A01AC Corticosteroids for local oral treatment 1 705 1 735 1 893 2 244 2 676 0.5 404 858 949 465 1 037 A01AC01 triamcinolone 1 651 1 677 1 772 2 098 2 458 0.5 401 404 603 A01AC03 hydrocortisone <5 5 <5 <5 0 0.0 0 0 0 0 0 A01AD Other agents for local oral treatment 534 593 629 563 689 0.1 42 402 164 81 328 A01AD01 epinephrine 10 15 8 6 9 0.0 0 <5 8 0 13 A01AD02 benzydamine 500 552 592 528 666 0.1 34 399 153 80 313 A01AD11 various 24 26 29 29 14 0.0 8 <5 <5 <5 2 A02 DRUGS FOR ACID RELATED DISORDERS 441 259 467 788 493 407 521 160 541 858 102.0 11 042 112 457 247 505 170 854 322 498 A02A ANTACIDS 5 498 6 151 6 361 6 351 6 488 1.2 125 1 183 2 135 3 045 12 432 A02AA Magnesium compounds 26 30 69 84 99 0.0 0 12 34 53 37 A02AA04 magnesium hydroxide 26 30 69 84 99 0.0 0 12 34 53 37 A02AC Calcium compounds 810 724 600 600 497 0.1 15 107 173 202 288 A02AC01 calcium carbonate 810 724 600 600 497 0.1 15 107 173 202 288 A02AD Combinations and complexes of aluminium, calcium and magnesium compounds 1 612 1 823 1 771 1 489 1 488 0.3 31 722 451 284 239 A02AD01 ordinary salt combinations 1 612 1 823 1 771 1 489 1 488 0.3 31 722 451 284 239 A02AH Antacids with sodium bicarbonate 3 258 3 707 3 996 4 249 4 444 0.8 38 337 1 511 2 558 11 238 A02B DRUGS FOR PEPTIC ULCER AND GASTRO- OESOPHAGEAL REFLUX DISEASE 438 040 490 594 518 289 538 917 101.5 10 948 111 965 246 609 169 395 310 065 A02BA H2-receptor antagonists 53 151 49 972 45 877 45 543 47 143 8.9 1 668 12 822 20 631 12 022 16 4772.5 ATC group A - Alimentary tract and metabolism ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales <5 <5 8 6 24 A02BA02 ranitidine 52 116 49 572 45 523 45 163 46 860 8.8 1 661 12 737 20 528 11 934 16 249 A02BA03 famotidine 1 103 630 434 441 303 0.1 7 93 111 92 204 A02BB Prostaglandins 358 264 371 476 512 0.1 37 161 A02BB01 misoprostol 358 264 371 476 512 0.1 <5 406 68 37 161 A02BC Proton pump inhibitors 402 262 433 695 461 724 490 510 510 637 96.1 9 697 103 858 235 067 162 015 291 856 A02BC01 omeprazole 44 226 43 649 42 405 41 463 39 402 7.4 3 446 8 225 15 670 12 061 35 894 A02BC02 pantoprazole 193 342 217 250 239 547 263 785 281 762 53.0 1 136 59 941 127 773 92 912 115 981 A02BC03 lansoprazole 40 451 38 478 36 516 34 983 33 068 6.2 340 4 649 16 240 11 839 22 616 A02BC05 esomeprazole 148 765 159 849 168 378 176 064 181 114 34.1 5 479 37 741 86 232 51 662 117 364 A02BX Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) 3 210 3 788 4 273 5 367 5 382 1.0 398 1 887 1 884 1 213 1 571 A02BX02 sucralfate 488 471 461 509 510 0.1 7 113 216 174 435 A02BX12 bismuth subnitrate 36 34 37 58 11 0.0 0 6 <5 <5 22 A02BX13 alginic acid 2 705 3 300 3 788 4 824 4 894 0.9 391 1 777 1 676 1 050 1 114 A03 DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISOR - DERS 67 041 66 795 68 127 70 684 72 780 13.7 969 24 734 27 069 20 008 15 765 A03A DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISOR - DERS 4 619 4 775 5 059 5 738 5 628 1.1 222 1 108 1 776 2 522 2 465 A03AA Synthetic anticholinergics, esters with tertiary amino group 35 41 36 56 77 0.0 <5 30 38 8 92 A03AA04 mebeverine 34 40 33 53 76 0.0 <5 29 38 8 72 A03AA05 trimebutine 0 0 <5 A03AB Synthetic anticholinergics, quaternary ammonium compounds 680 938 1 155 1 382 1 411 0.3 7 39 366 999 368 A03AB02 glycopyrronium bromide 676 932 1 148 1 373 1 401 0.3 7 33 363 998 344 A03AB05 propantheline <5 6 5 6 6 0.0 <5 0 0 9 A03AD Papaverine and derivatives 49 37 42 45 28 0.0 0 6 13 9 33 A03AD01 papaverine 49 37 42 45 28 0.0 0 6 13 9 33 A03AX Other drugs for functional gastrointestinal disorders 3 872 3 776 3 848 4 284 4 134 0.8 214 1 035 1 369 1 516 1 973 A03AX13 silicones 3 872 3 776 3 848 4 284 4 134 0.8 214 1 035 1 369 1 516 1 973 A03B BELLADONNA AND DERIVATIVES, PLAIN 2 517 2 603 2 680 3 108 3 398 0.6 18 1 458 1 368 554 1 536 A03BA Belladonna alkaloids, tertiary amines 1 857 1 879 1 850 1 919 2 096 0.4 10 923 806 357 848ATC group A ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales 70 Legemiddelstatistikk 2019:2 Folkehelseinstituttet atropine 28 21 21 8 13 0.0 0 <5 10 0 4 A03BA03 hyoscyamine 1 829 1 858 1 830 1 911 2 083 0.4 10 920 796 357 843 A03BB Belladonna alkaloids, semisynthetic, quaternary ammonium compounds 672 738 842 1 202 1 318 0.3 8 543 566 201 688 A03BB01 butylscopolamine 659 725 842 1 202 1 318 0.3 8 543 566 201 688 A03BB03 methylscopolamine 14 14 0 0 0 0.0 0 0 0 0 0 A03C ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS 17 14 19 22 19 0.0 0 <5 7 8 26 A03CA Synthetic anticholinergic agents in combination with psycholeptics 17 14 19 22 19 0.0 0 <5 7 8 26 A03CA02 clidinium and psycholeptics 17 14 19 22 19 0.0 0 <5 7 8 26 A03F PROPULSIVES 61 033 60 678 61 727 63 378 65 341 12.3 739 22 491 24 512 17 599 11 738 A03FA Propulsives 61 033 60 678 61 727 63 378 65 341 12.3 739 22 491 24 512 17 599 11 738 A03FA01 metoclopramide 60 932 60 583 61 627 63 262 65 211 12.3 719 22 459 24 469 17 564 11 471 A03FA02 cisapride 14 0 0 0 0 0.0 0 0 0 0 0 A03FA03 domperidone 96 97 110 133 141 0.0 21 39 46 35 254 A03FA05 alizapride 13 9 6 <5 5 <5 13 A04 ANTIEMETICS AND ANTINAUSEANTS 17 291 18 971 19 680 20 854 22 099 4.2 682 5 206 9 776 6 435 47 416 A04A ANTIEMETICS AND ANTINAUSEANTS 17 291 18 971 19 680 20 854 22 099 4.2 682 5 206 9 776 6 435 47 416 A04AA Serotonin (5HT3) antagonists 14 013 15 454 16 470 18 169 19 412 3.7 594 4 210 8 629 5 979 44 840 A04AA01 ondansetron 13 992 15 366 15 859 15 811 16 482 3.1 589 3 860 6 816 5 217 29 174 A04AA02 granisetron 13 62 80 85 113 0.0 25 <5 42 43 1 045 A04AA03 tropisetron <5 <5 0 0 0 0.0 0 0 0 0 0 A04AA05 palonosetron 51 107 83 52 16 0.0 0 <5 5 10 95 A04AA55 palonosetron, combinations 0 0 983 3 760 4 678 0.9 0 595 2 938 1 145 14 526 A04AD Other antiemetics 6 100 6 483 5 953 3 785 3 257 0.6 100 1 075 1 478 604 2 576 A04AD01 scopolamine 2 393 2 487 2 355 2 572 2 710 0.5 90 998 1 146 476 1 053 A04AD10 dronabinol 0 0 0 0 <5 - 0 0 0 <5 36 A04AD12 aprepitant 3 724 4 008 3 605 1 223 551 0.1 11 78 334 128 1 486 A05 BILE AND LIVER THERAPY 2 890 3 013 3 210 3 373 3 599 0.7 102 1 064 1 592 841 13 268 A05A BILE THERAPY 2 890 3 013 3 210 3 373 3 599 0.7 102 1 064 1 592 841 13 268 A05AA Bile acids and derivatives 2 890 3 013 3 210 3 373 3 599 0.7 102 1 064 1 592 841 13 268 A05AA01 chenodeoxycholic acid 0 0 <5 <5 0 0.0 0 0 0 0 0 A05AA02 ursodeoxycholic acid 2 890 3 013 3 209 3 373 3 595 0.7 102 1 064 1 590 839 8 273 A05AA04 obeticholic acid 0 0 0 7 30 0.0 0 <5 26 <5 4 979ATC group A ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales 65 798 73 418 83 960 94 189 102 443 19.3 21 525 16 770 28 629 35 519 79 041 A06A DRUGS FOR CONSTIPATION 65 798 73 418 83 960 94 189 102 443 19.3 21 525 16 770 28 629 35 519 79 041 A06AA Softeners, emollients 1 056 1 112 1 295 1 344 1 521 0.3 149 182 424 766 1 183 A06AA01 liquid paraffin 1 056 1 112 1 295 1 344 1 521 0.3 149 182 424 766 1 183 A06AB Contact laxatives 27 607 28 650 30 656 30 836 30 018 5.7 592 3 550 12 030 13 846 9 799 A06AB02 bisacodyl 5 701 5 586 5 667 5 533 5 642 1.1 129 759 1 907 2 847 1 923 A06AB06 senna glycosides 1 760 1 475 1 462 1 329 1 270 0.2 11 124 351 784 786 A06AB08 sodium picosulfate 14 083 15 122 16 038 16 766 17 244 3.3 381 2 108 5 960 8 795 4 614 A06AB20 contact laxatives in combination 27 22 21 16 0 0.0 0 0 0 0 0 A06AB56 senna glycosides, combinations 38 59 <5 0 0 0.0 0 0 0 0 0 A06AB58 sodium picosulfate, combinations 7 639 7 990 9 198 8 889 7 628 1.4 92 722 4 465 2 349 2 476 A06AC Bulk-forming laxatives 2 512 3 049 3 643 4 717 6 120 1.2 93 1 745 2 331 1 951 2 630 A06AC01 ispaghula (psylla seeds) 2 511 3 049 3 643 4 717 6 120 1.2 93 1 745 2 331 1 951 2 630 A06AC51 ispaghula, combinations <5 0 0 0 0 0.0 0 0 0 0 0 A06AD Osmotically acting laxatives 39 680 46 213 54 417 64 136 72 531 13.7 21 040 11 316 16 327 23 848 37 315 A06AD11 lactulose 16 269 16 713 17 324 18 482 18 532 3.5 911 2 556 6 199 8 866 5 730 A06AD12 lactitol 34 37 36 23 19 0.0 12 6 <5 0 22 A06AD15 macrogol 239 212 33 28 17 0.0 13 <5 0 0 78 A06AD17 sodium phosphate 1 687 1 055 671 801 729 0.1 0 189 361 179 151 A06AD65 macrogol, combinations 23 193 30 255 38 581 47 418 56 190 10.6 20 362 8 893 10 757 16 178 31 333 A06AG Enemas 6 203 6 105 6 254 6 790 6 748 1.3 772 1 497 A06AG02 bisacodyl 1 808 1 674 1 556 1 452 1 263 0.2 32 316 539 376 733 A06AG04 glycerol 939 905 819 1 024 1 069 0.2 194 310 268 297 7 926 A06AG06 oil 59 64 129 114 106 0.0 14 24 30 38 289 A06AG10 docusate sodium, incl. combinations 1 626 1 578 1 709 1 900 2 023 0.4 128 483 610 802 2 522 A06AG11 sodium lauryl sulfoacetate, incl. combinations 2 197 2 276 2 470 2 779 2 773 0.5 436 472 797 1 068 2 922 A06AH Peripheral opioid receptor antagonists 173 194 637 801 903 0.2 <5 113 412 377 4 776 A06AH01 methylnaltrexone bromide 173 138 153 132 82 0.0 0 7 38 37 1 565 A06AH03 naloxegol 0 59 498 693 836 0.2 <5 109 381 345 3 210 A06AX Other drugs for constipation 1 174 1 811 2 478 2 676 2 984 0.6 26 1 066 1 353 539 8 948 A06AX01 glycerol 0 40 137 134 128 0.0 14 <5 48 62 45 A06AX04 linaclotide 769 1 362 1 927 2 160 2 478 0.5 11 942 1 138 387 7 241 A06AX05 prucalopride 452 475 504 480 464 0.1 <5 159 204 100 1 662ATC group A ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales 037 83 057 85 501 88 869 92 403 17.4 9 227 23 539 36 219 23 418 204 594 A07A INTESTINAL ANTIINFECTIVES 35 631 35 536 36 202 36 965 37 503 7.1 8 722 8 553 11 790 8 438 20 116 A07AA Antibiotics 35 631 35 536 36 202 36 965 37 503 7.1 8 722 8 553 11 790 8 438 20 116 A07AA01 neomycin 28 <5 0 <5 0 0.0 0 0 0 0 0 A07AA02 nystatin 35 091 35 051 35 641 36 290 36 737 6.9 8 711 8 402 11 401 8 223 11 994 A07AA06 paromomycin 343 174 77 42 76 0.0 <5 42 26 <5 56 A07AA09 vancomycin 239 265 277 391 370 0.1 <5 71 146 152 1 258 A07AA11 rifaximin 174 197 276 303 403 0.1 7 62 258 76 6 762 A07AA12 fidaxomicin 6 8 5 11 <5 - 0 0 <5 <5 47 A07B INTESTINAL ADSORBENTS 127 176 173 196 261 0.1 6 109 104 42 60 A07BA Charcoal preparations 87 94 94 65 95 0.0 6 21 40 28 25 A07BA01 medicinal charcoal 87 94 94 65 95 0.0 6 21 40 28 25 A07BB Bismuth preparations 40 82 79 131 166 0.0 0 88 64 14 36 A07C ELECTROLYTES WITH CARBOHYDRATES 490 451 444 445 444 0.1 188 122 82 52 1 902 A07CA Oral rehydration salt formulations 482 441 427 426 420 0.1 166 121 82 51 369 A07D ANTIPROPULSIVES 19 771 20 595 21 467 23 288 25 560 4.8 111 4 766 10 963 9 720 14 756 A07DA Antipropulsives 19 771 20 595 21 467 23 288 25 560 4.8 111 4 766 10 963 9 720 14 756 A07DA01 diphenoxylate <5 <5 <5 0 0 0.0 0 0 0 0 0 A07DA02 opium 224 223 268 306 400 0.1 0 20 206 174 1 704 A07DA03 loperamide 19 567 20 232 21 098 22 778 24 846 4.7 111 4 476 10 693 9 566 11 090 A07DA06 eluxadoline 0 0 0 119 432 0.1 <5 253 132 45 1 810 A07DA53 loperamide, combinations 197 362 400 437 423 0.1 0 137 170 116 151 A07E INTESTINAL ANTI- INFLAMMATORY AGENTS 26 754 28 209 29 560 30 654 31 533 5.9 215 10 468 14 701 6 149 166 878 A07EA Corticosteroids acting locally 5 811 6 043 6 834 7 507 7 712 1.5 55 2 373 3 361 1 923 26 296 A07EA01 prednisolone 1 122 69 0 10 17 0.0 0 6 5 6 40 A07EA02 hydrocortisone 324 339 390 322 198 0.0 <5 49 112 35 338 A07EA06 budesonide 4 476 5 720 6 500 7 230 7 543 1.4 53 2 335 3 267 1 888 25 918 A07EB Antiallergic agents, excl. corticosteroids 43 46 42 47 53 0.0 6 15 26 6 1 428 A07EB01 cromoglicic acid 43 46 42 47 53 0.0 6 15 26 6 1 428 A07EC Aminosalicylic acid and similar agents 23 005 24 112 25 111 25 797 26 488 5.0 186 9 315 12 404 4 583 139 154 A07EC01 sulfasalazine 5 737 5 771 5 683 5 457 5 410 1.0 7 1 226 2 901 1 276 6 653 A07EC02 mesalazine 16 912 18 010 19 121 20 045 20 861 3.9 179 8 060 9 390 3 232 130 035ATC group A ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales 254 0.1 <5 45 150 57 908 A07EC04 balsalazide 555 528 479 471 388 0.1 0 91 210 87 1 558 A07F ANTIDIARRHEAL MICROORGANISMS 1 334 1 185 725 559 422 0.1 8 163 190 61 746 A07FA Antidiarrheal microorganisms 1 334 1 185 725 559 422 0.1 8 163 190 61 746 A07FA01 lactic acid producing organisms 882 742 370 294 215 0.0 7 96 96 16 616 A07FA02 saccharomyces boulardii 556 528 377 287 217 0.0 <5 71 99 45 110 A07FA51 lactic acid producing organisms, combinations 13 20 53 <5 <5 - 0 <5 0 <5 12 A07X OTHER ANTIDIARRHEALS 29 67 7 <5 0 0.0 0 0 0 0 0 A07XA Other antidiarrheals 29 67 7 <5 0 0.0 0 0 0 0 0 A07XA04 racecadotril 18 57 <5 0 0 0.0 0 0 0 0 0 A08 ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS 6 716 6 361 6 293 6 256 8 051 1.5 736 18 829 ANTIOBESITY EXCL. DIET PRODUCTS 6 716 6 361 6 293 6 256 8 051 1.5 <5 2 4 528 736 18 829 A08AA Centrally acting antiobesity products 0 0 0 265 3 072 0.6 0 1 314 1 663 95 8 153 A08AA62 bupropion and naltrexone 0 0 0 265 3 072 0.6 0 1 314 1 663 95 8 153 A08AB Peripherally acting antiobesity products 6 716 6 361 6 293 6 019 5 186 1.0 <5 1 558 2 977 650 10 676 A08AB01 orlistat 6 716 6 361 6 293 6 019 5 186 1.0 <5 1 558 2 977 650 10 676 A09 DIGESTIVES, INCL. ENZYMES 5 758 5 925 6 091 6 597 6 919 1.3 113 899 3 066 2 841 21 256 A09A DIGESTIVES, INCL. ENZYMES 5 758 5 925 6 091 6 597 6 919 1.3 113 899 3 066 2 841 21 256 A09AA Enzyme preparations 5 683 5 849 6 022 6 364 6 657 1.3 110 800 2 942 2 805 20 937 A09AA02 multienzymes (lipase, protease etc.) 5 676 5 839 6 012 6 359 6 648 1.3 110 797 2 936 2 805 20 918 A09AB Acid preparations 64 50 64 65 63 0.0 <5 14 25 23 66 A09AB01 glutamic acid hydrochloride 35 36 53 51 53 0.0 0 12 19 22 53 A09AB02 betaine hydrochloride 22 10 9 9 10 0.0 <5 6 <5 13 A09AB03 hydrochloric acid 7 <5 <5 5 0 0.0 0 0 0 0 0 A09AC Enzyme and acid prepara - tions, combinations 23 31 31 195 217 0.0 <5 92 104 19 254 A09AC01 pepsin and acid preparations 0 5 28 194 217 0.0 <5 92 104 19 254 A09AC02 multienzymes and acid preparations 23 26 <5 <5 0 0.0 0 0 0 0 0 A10 DRUGS USED IN DIABETES 170 495 176 615 183 452 192 542 199 563 37.6 2 106 26 643 99 204 71 610 1 080 419 A10A INSULINS AND ANALOGUES 59 804 61 559 63 529 65 733 68 136 12.8 2 081 15 460 29 349 21 246 474 171ATC group A ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales injection, fast-acting 39 557 40 730 42 145 43 534 45 172 8.5 2 078 13 898 18 971 10 225 171 970 A10AB01 insulin (human) 1 024 911 825 742 640 0.1 <5 47 326 266 1 476 A10AB04 insulin lispro 9 804 10 214 10 717 11 202 10 699 2.0 553 3 470 4 726 1 950 39 467 A10AB05 insulin aspart 29 231 30 073 31 059 32 700 35 590 6.7 1 742 11 111 14 595 8 142 129 764 A10AB06 insulin glulisine 419 430 456 459 385 0.1 <5 115 194 73 1 263 A10AC Insulins and analogues for injection, intermediate- acting 33 082 33 618 34 174 33 804 32 246 6.1 282 3 913 14 141 13 910 98 851 A10AC01 insulin (human) 33 082 33 618 34 174 33 804 32 246 6.1 282 3 913 14 141 13 910 98 851 A10AD Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting 6 561 5 938 5 323 4 678 4 081 0.8 <5 207 1 487 2 384 19 789 A10AD03 insulin (pork) <5 0 0 0 0 0.0 0 0 0 0 0 A10AD04 insulin lispro 616 541 481 405 342 0.1 <5 39 145 156 1 488 A10AD05 insulin aspart 5 957 5 404 4 853 4 278 3 741 0.7 <5 168 1 343 2 229 18 301 A10AE Insulins and analogues for injection, long-acting 18 621 19 708 21 381 25 315 29 213 5.5 1 055 8 897 13 432 5 829 183 561 A10AE02 insulin (beef) <5 0 <5 0 0 0.0 0 0 0 0 0 A10AE04 insulin glargine 12 570 13 617 15 044 16 352 16 677 3.1 455 5 350 7 507 3 365 74 025 A10AE05 insulin detemir 6 261 6 284 6 126 5 721 4 957 0.9 542 1 703 1 875 837 25 713 A10AE06 insulin degludec 5 127 1 087 3 386 5 938 1.1 103 2 232 2 706 897 34 966 A10AE54 insulin glargine and lixisenatide 0 0 0 0 32 0.0 0 <5 17 12 85 A10AE56 insulin degludec and liraglutide 0 0 46 1 642 3 459 0.7 0 276 2 184 999 48 771 A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS 133 286 139 072 145 510 154 588 160 950 30.3 32 13 169 84 997 62 752 606 248 A10BA Biguanides 108 031 110 646 113 917 120 061 122 463 23.1 23 11 124 65 846 45 470 62 587 A10BA02 metformin 108 031 110 646 113 917 120 061 122 463 23.1 23 11 124 65 846 45 470 62 587 A10BB Sulfonylureas 36 011 34 201 32 265 29 721 26 538 5.0 8 951 13 003 12 576 12 203 A10BB01 glibenclamide 981 813 677 615 530 0.1 5 26 218 281 285 A10BB07 glipizide 3 057 2 790 2 466 2 109 1 785 0.3 0 36 704 1 045 1 085 A10BB12 glimepiride 32 089 30 775 29 212 27 064 24 274 4.6 <5 889 12 105 11 277 10 834 A10BD Combinations of oral blood glucose lowering drugs 18 377 20 716 23 050 26 294 28 781 5.4 0 1 568 17 413 9 800 128 160 A10BD05 metformin and pioglitazone 34 36 27 23 27 0.0 0 <5 16 7 115 A10BD07 metformin and sitagliptin 7 749 9 169 10 815 13 391 15 199 2.9 0 834 9 195 5 170 63 303 A10BD08 metformin and vildagliptin 10 113 10 629 10 786 10 655 10 162 1.9 0 453 5 974 3 735 46 667 A10BD10 metformin and saxagliptin 81 109 117 110 112 0.0 0 7 70 35 504 A10BD11 metformin and linagliptin 369 533 632 669 726 0.1 0 35 436 255 3 148ATC group A ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales 588 852 1 166 0.2 0 108 789 269 5 484 A10BD19 linagliptin and empagliflozin 0 0 0 0 122 0.0 0 6 75 41 637 A10BD20 metformin and empagliflozin 0 <5 331 881 1 527 0.3 0 130 1 041 356 6 800 A10BD21 saxagliptin and dapagliflozin 0 0 0 91 201 0.0 0 18 115 68 1 449 A10BD23 metformin and ertugliflozin 0 0 0 0 <5 <5 4 A10BD24 sitagliptin and ertugliflozin 0 0 0 0 17 0.0 0 0 12 5 49 A10BF Alpha glucosidase inhibitors 519 495 463 442 416 0.1 0 40 202 174 550 A10BF01 acarbose 519 495 463 442 416 0.1 0 40 202 174 550 A10BG Thiazolidinediones 1 552 1 500 1 492 1 415 1 373 0.3 0 48 748 577 2 962 A10BG03 pioglitazone 1 552 1 500 1 492 1 415 1 373 0.3 0 48 748 577 2 962 A10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors 16 324 19 048 21 861 25 212 27 093 5.1 0 1 032 12 599 13 462 109 728 A10BH01 sitagliptin 8 852 10 158 12 060 14 903 16 770 3.2 0 762 8 460 7 548 65 886 A10BH02 vildagliptin 2 519 2 540 2 500 2 374 2 163 0.4 0 70 940 1 153 7 774 A10BH03 saxagliptin 1 547 1 438 1 351 1 233 1 087 0.2 0 31 589 467 5 017 A10BH05 linagliptin 3 716 5 225 6 268 7 066 7 333 1.4 0 174 2 691 4 468 31 101 715 11 074 12 861 14 626 2.8 <5 1 300 9 662 3 663 178 641 A10BJ01 exenatide 1 067 1 317 1 324 1 251 1 112 0.2 0 59 750 303 10 552 A10BJ02 liraglutide 6 715 7 488 7 980 9 083 10 119 1.9 <5 958 6 677 2 483 131 580 A10BJ03 lixisenatide 488 940 725 525 398 0.1 0 29 277 92 3 216 A10BJ05 dulaglutide 0 335 1 432 2 314 3 277 0.6 0 265 2 159 853 33 245 A10BJ06 semaglutide 0 0 0 0 18 0.0 0 8 9 <5 49 A10BK Sodium-glucose co-trans - porter 2 (SGLT2) inhibitors 5 713 9 442 14 041 20 330 25 613 4.8 0 1 700 16 949 6 964 111 161 A10BK01 dapagliflozin 5 713 8 475 9 437 10 588 11 297 2.1 0 725 7 619 2 953 47 184 A10BK03 empagliflozin 0 1 102 4 910 10 105 14 625 2.8 0 987 9 553 4 085 63 881 A10BK04 ertugliflozin 0 0 0 0 49 0.0 0 <5 34 11 96 A10BX Other blood glucose lowering drugs, excl. insulins 208 184 172 163 156 0.0 <5 <5 76 77 257 A10BX02 repaglinide 208 184 156 0.0 <5 <5 76 77 257 A11 VITAMINS 156 279 186 916 226 346 265 039 261 391 49.2 4 932 85 410 96 204 74 845 156 920 A11A MULTIVITAMINS, COMBINATIONS 162 175 183 223 227 0.0 108 103 16 0 1 099 A11AA Multivitamins with minerals 162 175 183 223 227 0.0 108 103 16 0 1 099 A11AA03 multivitamins and other minerals, incl. combinations 162 175 183 223 227 0.0 108 103 16 0 1 099 A11B MULTIVITAMINS, PLAIN 52 55 43 71 113 0.0 104 8 <5 0 55 A11BA Multivitamins, plain 52 55 43 71 113 0.0 104 8 <5 0 55ATC group A ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO 59 145 86 076 116 905 155 272 159 187 30.0 4 248 68 619 57 651 28 669 78 592 A11CA Vitamin A, plain 77 76 94 96 105 0.0 6 29 62 8 128 A11CA01 retinol (vit A) 58 64 79 85 96 0.0 6 25 58 7 78 A11CA02 betacarotene 19 12 15 11 9 0.0 0 <5 <5 <5 49 A11CC Vitamin D and analogues 59 091 86 035 116 856 155 234 159 147 30.0 4 243 68 610 57 631 28 663 78 464 A11CC01 ergocalciferol 26 44 35 115 239 0.0 6 113 101 19 128 A11CC03 alfacalcidol 4 733 4 850 4 880 4 960 4 911 0.9 105 588 1 816 2 402 7 483 A11CC04 calcitriol 2 972 3 119 3 265 3 267 3 101 0.6 6 379 1 237 1 479 3 865 A11CC05 colecalciferol 51 659 78 532 109 295 147 685 151 751 28.6 4 132 67 680 54 858 25 081 66 989 A11D VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 930 1 033 984 1 140 1 146 0.2 20 214 588 324 1 255 A11DA Vitamin B1, plain 920 1 024 976 1 131 1 143 0.2 20 214 586 323 1 253 A11DA01 thiamine (vit B1) 920 1 024 976 1 131 1 143 0.2 20 214 586 323 1 253 A11DB Vitamin B1 in combination with vitamin B6 and/or vitamin B12 10 9 8 9 <5 - 0 0 <5 <5 3 A11E VITAMIN B-COMPLEX, INCL. COMBINATIONS 100 038 107 798 120 911 126 088 118 406 22.3 433 21 657 45 040 51 276 72 934 A11EA Vitamin B-complex, plain 98 596 106 245 119 520 124 436 116 701 22.0 387 21 333 44 374 50 607 71 473 A11EB Vitamin B-complex with vitamin C 593 713 597 807 872 0.2 11 226 369 266 332 A11EX Vitamin B-complex, other combinations 961 944 897 976 974 0.2 35 111 361 467 1 129 A11G ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS 3 425 3 033 2 933 2 702 2 258 0.4 15 301 558 1 384 742 A11GA Ascorbic acid (vitamin C), plain 3 425 3 033 2 933 2 702 2 258 0.4 15 301 558 1 384 742 A11GA01 ascorbic acid (vit C) 3 425 3 033 2 933 2 702 2 258 0.4 15 301 558 1 384 742 A11H OTHER PLAIN VITAMIN PREPARATIONS 1 808 1 513 1 472 1 577 1 558 0.3 180 917 339 122 1 905 A11HA Other plain vitamin prepa - rations 1 808 1 513 1 472 1 577 1 558 0.3 180 917 339 122 1 905 A11HA01 nicotinamide 20 29 35 35 33 0.0 <5 11 12 9 22 A11HA02 pyridoxine (vit B6) 1 459 1 176 1 168 1 296 1 274 0.2 93 841 256 84 711 A11HA03 tocopherol (vit E) 266 257 222 195 194 0.0 64 45 59 26 626 A11HA04 riboflavin (vit B2) 20 18 18 15 27 0.0 5 11 8 <5 15 A11HA05 biotin 8 13 19 27 26 0.0 14 8 <5 0 428 A11HA06 pyridoxal phosphate 35 21 <5 - <5 0 0 0 74ATC group A ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales 70 Legemiddelstatistikk 2019:2 Folkehelseinstituttet 34A11J OTHER VITAMIN PRODUCTS, COMBINATIONS 70 74 71 70 70 0.0 53 13 <5 <5 328 A11JA Combinations of vitamins 63 71 71 70 70 0.0 53 13 <5 <5 328 A11JB Vitamins with minerals 7 <5 0 0 0 0.0 0 0 0 0 0 A12 MINERAL SUPPLEMENTS 141 418 149 619 159 592 169 017 175 598 33.1 448 11 617 69 569 93 964 147 090 A12A CALCIUM 120 026 128 588 138 349 147 490 153 648 28.9 221 10 155 62 404 80 868 117 706 A12AA Calcium 1 088 1 183 1 193 1 233 1 017 0.2 57 181 395 384 1 334 A12AA02 calcium glubionate <5 0 <5 0 0 0.0 0 0 0 0 0 A12AA03 calcium gluconate 0 <5 8 5 6 0.0 6 0 0 0 6 A12AA06 calcium lactate gluconate 1 083 1 175 1 184 1 228 1 012 0.2 52 181 395 384 1 328 A12AX Calcium, combinations with vitamin D and/or other drugs 119 209 127 683 137 414 146 576 152 946 28.8 167 10 025 62 135 80 619 116 372 A12B POTASSIUM 21 269 20 554 20 684 20 365 20 526 3.9 127 1 177 6 472 12 750 17 916 A12BA Potassium 21 269 20 554 20 684 20 365 20 526 3.9 127 1 177 6 472 12 750 17 916 A12BA01 potassium chloride 19 263 18 469 18 437 18 209 18 118 3.4 22 936 5 653 11 507 12 025 A12BA02 potassium citrate 2 358 3 048 2 705 2 647 2 898 0.6 115 301 954 1 528 5 850 A12BA30 potassium (different salts in combination) <5 6 <5 5 6 0.0 0 <5 <5 0 40 A12C OTHER MINERAL SUPPLEMENTS 6 770 7 483 8 088 8 996 9 500 1.8 142 619 2 953 5 786 11 468 A12CA Sodium 1 443 1 851 2 277 2 554 3 114 0.6 6 131 826 2 151 4 021 A12CA01 sodium chloride 1 443 1 851 2 277 2 554 3 114 0.6 6 131 826 2 151 4 021 A12CB Zinc 712 621 607 566 456 0.1 38 89 184 145 312 A12CB01 zinc sulfate 712 621 607 566 456 0.1 38 89 184 145 312 A12CC Magnesium 4 747 5 148 5 385 6 063 6 184 1.2 100 402 2 017 3 665 6 926 A12CC01 magnesium chloride 0 <5 0 0 0 0.0 0 0 0 0 0 A12CC04 magnesium citrate 0 18 27 53 80 0.0 15 7 32 26 162 A12CC10 magnesium oxide 158 189 222 289 399 0.1 14 37 121 227 445 A12CC30 magnesium (different salts in combination) 4 615 4 942 5 139 5 750 5 803 1.1 46 366 1 891 3 500 5 543 A12CX Other mineral products 7 10 16 17 15 0.0 <5 <5 <5 6 209 A13 TONICS 0 <5 0.0 0 0 0 0 0 A14 ANABOLIC AGENTS FOR SYSTEMIC USE 1 239 1 279 1 067 1 017 998 0.2 0 300 621 77 885 A14A ANABOLIC STEROIDS 1 239 1 279 1 067 1 017 998 0.2 0 300 621 77 885 A14AA Androstan derivatives 1 198 1 230 1 030 974 951 0.2 0 280 596 75 713 A14AA07 prasterone 1 198 1 228 1 028 973 951 0.2 0 280 596 75 713 A14AA08 oxandrolone 0 <5 <5 0 0 0 0 0 A14AB Estren derivatives 29 28 21 20 11 0.0 0 5 6 0 35 A14AB01 nandrolone 29 28 21 20 11 0.0 0 5 6 0 35ATC group A ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS 419 407 410 462 466 0.1 153 168 117 28 438 068 A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS 394 405 409 462 466 0.1 153 168 117 28 438 068 A16AA Amino acids and derivatives 186 200 208 229 205 0.0 107 65 24 9 27 046 A16AA01 levocarnitine 129 147 168 186 169 0.0 101 45 14 9 3 098 A16AA03 glutamine 14 16 7 5 <5 - 0 <5 <5 0 5 A16AA04 mercaptamine 9 9 10 10 10 0.0 <5 7 0 0 19 251 A16AA05 carglumic acid 0 0 <5 5 <5 - <5 0 0 0 3 441 A16AA06 betaine 23 25 23 24 24 0.0 <5 14 6 0 1 250 A16AB Enzymes 69 80 82 86 90 0.0 12 37 37 <5 228 671 A16AB02 imiglucerase 8 9 8 8 9 0.0 0 <5 <5 <5 23 235 A16AB03 agalsidase alfa 22 20 17 16 16 0.0 0 6 7 <5 28 762 A16AB04 agalsidase beta 30 39 40 41 43 0.0 0 20 23 0 70 082 A16AB05 laronidase <5 0 0 0 0 0.0 0 0 A16AB07 alglucosidase alfa <5 <5 <5 A16AB12 elosulfase alfa 0 <5 6 10 12 0.0 6 5 <5 0 74 319 A16AX Various alimentary tract and metabolism products 146 131 122 155 179 0.0 40 67 57 15 182 350 A16AX01 thioctic acid 82 64 41 42 35 0.0 0 8 20 7 46 A16AX03 A16AX04 nitisinone 17 16 15 16 17 0.0 9 8 0 0 15 415 A16AX05 zinc acetate 16 13 14 14 15 0.0 <5 8 <5 0 164 A16AX06 miglustat 5 6 6 8 10 0.0 5 <5 <5 0 8 417 A16AX07 sapropterin 23 21 22 33 36 0.0 10 23 <5 0 27 630 A16AX08 teduglutide 0 <5 10 26 45 0.0 11 9 17 8 79 812 A16AX10 eliglustat 0 <5 <5 A16AX12 trientine <5 8 12 14 14 0.0 0 7 7 0 38 500 A16AX14 0 0 0 <5 5 0.0 0 <5 <5 0 8 027 A16AX15 telotristat 0 0 0 0 <5 - 0 0 <5 0 30ATC group A ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales 70 Legemiddelstatistikk 2019:2 Folkehelseinstituttet 36B BLOOD FORMING ORGANS 640 857 658 268 678 638 699 782 714 990 134.6 5 359 82 280 709 346 335 1 989 763 B01 ANTITHROMBOTIC AGENTS 525 381 533 688 542 849 551 056 557 207 104.9 502 25 039 213 505 318 161 1 332 301 B01A ANTITHROMBOTIC AGENTS 525 381 533 688 542 849 551 056 557 207 104.9 502 25 039 213 505 318 161 1 332 301 B01AA Vitamin K antagonists 77 831 69 357 60 605 51 304 42 737 8.1 44 1 582 11 065 30 046 42 020 B01AA01 dicoumarol 63 51 47 39 33 0.0 0 5 11 17 199 B01AA02 phenindione <5 0 0 0 0 0.0 0 0 0 0 0 B01AA03 warfarin 77 769 69 306 60 561 51 268 42 704 8.0 44 1 577 11 054 30 029 41 821 B01AB Heparin group 50 696 54 116 56 268 56 928 56 295 10.6 198 13 026 24 340 18 731 142 604 B01AB01 heparin 1 209 1 180 1 184 1 327 1 230 0.2 119 175 573 363 1 609 B01AB04 dalteparin 27 592 31 785 34 748 36 168 36 792 6.9 39 7 251 16 547 12 955 90 904 B01AB05 enoxaparin 22 732 21 964 21 078 20 307 19 037 3.6 42 5 716 7 604 5 675 50 090 B01AB10 tinzaparin <5 0 0 0 0 0.0 0 0 0 0 0 B01AC Platelet aggregation inhibitors excl. heparin 397 622 396 119 395 053 393 102 390 695 73.6 276 9 353 160 669 220 397 291 555 B01AC04 clopidogrel 25 588 26 27 618 30 764 34 742 6.5 683 13 231 20 827 35 297 B01AC05 ticlopidine 180 132 108 104 81 0.0 0 <5 20 59 250 B01AC06 acetylsalicylic acid 373 995 370 946 368 557 364 426 359 317 67.7 275 8 817 149 113 201 112 98 922 B01AC07 dipyridamole 19 568 19 030 18 752 17 789 16 485 3.1 0 152 5 525 10 808 20 480 B01AC09 8 <5 5 - 0 0 <5 0 169 B01AC21 treprostinil 16 17 20 24 18 0.0 <5 6 8 <5 36 758 B01AC22 prasugrel 1 747 1 745 1 627 1 625 1 645 0.3 0 74 1 249 322 6 800 B01AC24 ticagrelor 8 738 9 022 9 476 9 588 9 654 1.8 0 313 6 169 3 172 52 676 B01AC27 selexipag 0 0 9 13 15 0.0 0 <5 9 <5 11 080 B01AC30 combinations 15 573 16 239 16 805 16 809 16 207 3.1 0 222 5 983 10 002 27 688 B01AD Enzymes <5 <5 160 B01AE Direct thrombin inhibitors 15 365 13 846 13 331 13 118 12 918 2.4 0 116 3 015 9 787 98 984 B01AE07 dabigatran etexilate 15 365 13 846 13 331 13 118 12 918 2.4 0 116 3 015 9 787 98 984 B01AF Direct factor Xa inhibitors 28 940 45 988 65 036 83 783 101 146 19.0 0 2 736 27 968 70 442 756 888 B01AF01 rivaroxaban 20 804 25 492 28 935 30 795 31 822 6.0 0 1 312 10 165 20 345 248 212 B01AF02 apixaban 8 651 21 514 37 297 54 002 69 381 13.1 0 1 443 17 773 50 165 499 658 B01AF03 edoxaban 0 0 15 448 1 479 0.3 0 18 458 1 003 9 018 B01AX Other antithrombotic agents 12 12 18 21 34 0.0 0 5 15 14 90 B01AX05 fondaparinux 12 12 18 21 34 0.0 0 5 15 14 90 B02 ANTIHEMORRHAGICS 13 825 13 700 13 711 14 447 14 723 2.8 365 7 406 6 154 798 346 797 B02A ANTIFIBRINOLYTICS 13 321 13 162 13 112 13 819 14 074 2.7 233 7 168 6 002 671 6 2432.6 ATC group B - Blood and bloodforming organs ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales 70 Legemiddelstatistikk 2019:2 Folkehelseinstituttet 37B02AA Amino acids 13 319 13 160 13 110 13 817 14 073 2.7 233 7 168 6 001 671 5 205 B02AA02 tranexamic acid 13 319 13 160 13 110 13 817 14 073 2.7 233 7 168 6 001 671 205 B02AB Proteinase <5 <5 K AND OTHER HEMOSTATICS 590 627 697 740 771 0.2 162 274 192 143 340 553 B02BA Vitamin K 259 260 280 269 283 0.1 70 105 48 60 140 B02BA01 phytomenadione 259 260 280 269 283 0.1 70 140 B02BB hemostatics <5 <5 0 0 0 0.0 0 0 0 0 0 B02BC30 combinations <5 <5 0 0 0 0.0 0 0 0 0 0 B02BD Blood coagulation factors 256 274 280 287 295 0.1 89 132 69 5 290 956 B02BD01 coagulation factor IX, II, VII and X in <5 <5 coagulation factor VIII 182 189 191 198 200 0.0 70 84 44 <5 214 090 B02BD03 factor VIII inhibitor bypassing activity 9 9 11 8 6 0.0 0 <5 <5 0 17 057 B02BD04 coagulation factor IX 38 47 49 51 58 0.0 14 30 12 <5 34 826 B02BD06 von Willebrand factor and coagulation factor VIII in combination 15 16 12 14 12 0.0 <5 B02BD08 coagulation factor VIIa 11 10 17 15 19 0.0 7 8 <5 0 12 0 6 201 B02BX Other systemic hemostatics 72 91 137 182 192 0.0 <5 37 74 77 49 178 B02BX04 romiplostim 17 23 30 41 45 0.0 0 7 22 16 18 465 B02BX05 eltrombopag 59 72 113 150 154 0.0 <5 31 56 63 30 713 B03 ANTIANEMIC PREPARATIONS 153 378 164 552 180 060 196 585 209 315 39.4 4 129 53 721 80 175 71 290 171 804 B03A IRON PREPARATIONS 30 391 33 866 38 027 41 525 44 374 8.4 2 457 15 981 9 554 16 382 17 822 B03AA Iron bivalent, oral preparations 28 833 32 306 36 331 39 712 42 478 8.0 2 456 15 021 8 921 16 080 15 416 B03AA01 ferrous glycine sulfate 8 744 9 522 11 113 10 275 12 755 2.4 877 5 002 2 734 4 142 6 328 B03AA02 ferrous fumarate 1 685 1 623 1 822 1 959 1 380 0.3 1 062 121 62 135 316 B03AA07 ferrous sulfate 18 758 21 566 23 850 28 907 29 018 5.5 599 10 073 6 232 12 114 8 772 B03AB Iron trivalent, oral preparations 0 0 0 0 10 0.0 0 5 <5 <5 9 B03AB10 ferric maltol 0 0 0 0 0.0 0 5 <5 <5 9 B03AC Iron, parenteral preparations 1 667 1 702 1 853 1 968 2 065 0.4 <5 1 036 668 358 2 397ATC group B ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales ACID 126 134 438 146 564 160 606 171 521 32.3 1 871 40 414 72 170 57 066 102 596 B03BA Vitamin B12 (cyanocobal - amin and analogues) 86 847 97 519 102 261 104 146 111 351 21.0 524 25 928 46 840 38 059 69 034 B03BA01 cyanocobalamin 12 834 15 171 14 032 20 180 39 217 7.4 279 11 277 16 511 11 150 17 952 B03BA02 cyanocobalamin tannin complex 9 833 0 <5 <5 0 0.0 0 0 0 0 0 B03BA03 hydroxocobalamin 68 907 85 109 91 031 87 855 76 289 14.4 254 15 809 32 201 28 025 51 014 B03BA05 mecobalamin 253 257 173 179 64 0.0 0 24 37 <5 66 B03BB Folic acid and derivatives 44 351 40 763 49 263 62 657 67 279 12.7 1 373 15 890 27 957 22 059 33 562 B03BB01 folic acid 44 351 40 717 49 204 62 614 67 205 12.7 1 372 15 863 27 921 22 049 33 506 B03X OTHER ANTIANEMIC PREPARATIONS 3 389 3 491 3 591 3 653 3 758 0.7 30 308 1 211 2 209 51 386 B03XA Other antianemic preparations 3 389 3 491 3 591 3 653 3 758 0.7 30 308 1 211 2 209 51 386 B03XA01 erythropoietin 267 284 259 237 254 0.1 <5 16 67 168 4 787 B03XA02 darbepoetin alfa 2 895 2 985 3 190 3 336 3 277 0.6 28 271 1 078 1 900 44 372 B03XA03 methoxy polyethylene glycol-epoetin beta 261 244 205 109 372 0.1 0 34 118 220 2 227 B06 OTHER HEMATOLOGICAL AGENTS 95 110 117 135 141 0.0 12 63 57 9 103 612 B06A OTHER HEMATOLOGICAL AGENTS 95 110 117 135 141 0.0 12 63 57 9 103 612 B06AA Enzymes 10 10 5 8 10 0.0 0 <5 5 <5 24 B06AA03 hyaluronidase 10 10 5 8 10 0.0 0 <5 5 <5 24 B06AB Other hem products 0 0 <5 <5 - 0 0 <5 0 332 B06AC Drugs used in hereditary angioedema 85 100 111 126 130 0.0 12 59 51 8 103 256 B06AC01 c1-inhibitor, plasma derived 58 63 72 88 90 0.0 10 43 32 5 75 551 B06AC02 icatibant 58 65 73 87 90 0.0 10 37 38 5 27 705 B06AC04 conestat alfa <5 0 0 0 0 0.0 0 0 0 0 0ATC group B ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales CARDIOVASCULAR SYSTEM 1 060 387 1 076 292 1 100 496 1 117 715 1 134 322 213.6 10 137 100 336 553 243 470 606 1 852 329 C01 CARDIAC THERAPY 113 053 108 891 110 225 109 551 109 087 20.5 7 618 10 967 35 464 55 038 111 572 C01A CARDIAC GLYCOSIDES 14 063 12 900 11 878 11 153 10 482 2.0 14 63 1 549 8 856 5 274 C01AA Digitalis glycosides 14 063 12 900 11 878 11 153 10 482 2.0 14 63 1 549 8 856 5 274 C01AA04 digitoxin 935 657 525 398 322 0.1 0 0 40 282 116 C01AA05 digoxin 13 215 12 279 11 377 10 769 10 167 1.9 14 63 1 510 8 580 5 158 C01B ANTIARRHYTHMICS, CLASS I AND III 14 593 15 234 16 006 16 810 17 401 3.3 92 619 7 470 9 220 44 196 C01BA Antiarrhythmics, class Ia 103 91 100 100 99 35 55 C01BA03 disopyramide 101 89 96 96 94 0.0 0 6 35 53 204 C01BB Antiarrhythmics, class Ib 26 33 37 39 45 0.0 0 12 21 12 1 046 C01BB02 mexiletine 26 33 37 39 45 0.0 0 12 21 12 1 046 C01BC Antiarrhythmics, class Ic 7 600 7 755 7 890 8 152 8 194 1.5 88 452 4 194 3 460 16 132 C01BC03 propafenone 6 5 5 7 5 0.0 0 <5 <5 <5 17 C01BC04 flecainide 7 594 7 750 7 885 8 145 8 190 1.5 88 451 4 192 3 459 16 115 C01BD Antiarrhythmics, class III 7 167 7 717 8 315 8 871 9 391 1.8 <5 164 3 404 5 820 26 781 C01BD01 amiodarone 5 784 5 978 6 232 6 551 6 813 1.3 <5 121 2 287 4 402 5 474 C01BD07 dronedarone 1 526 1 924 2 253 2 520 2 792 0.5 0 47 1 231 1 514 21 307 C01C CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES 22 904 21 929 25 873 27 585 29 479 5.6 7 506 9 538 9 441 2 994 31 504 C01CA Adrenergic and dopaminergic agents 22 904 21 929 25 873 27 585 29 479 5.6 7 506 9 538 9 441 2 994 31 504 C01CA01 etilefrine 116 80 66 59 58 0.0 <5 18 23 16 125 C01CA03 norepinephrine 0 0 <5 0 0 0.0 0 0 0 0 0 C01CA06 phenylephrine <5 0 0 <5 0 0.0 0 0 0 0 0 C01CA17 midodrine 29 44 54 69 72 0.0 0 21 15 36 568 C01CA24 epinephrine 22 754 21 811 25 751 27 454 29 347 5.5 7 505 9 499 9 401 2 942 29 794 C01CA26 ephedrine 8 <5 <5 5 5 0.0 0 0 5 0 2 C01CA27 droxidopa 0 0 0 <5 <5 - 0 0 <5 0 1 014 C01D VASODILATORS USED IN CARDIAC DISEASES 65 806 62 794 60 017 57 317 54 876 10.3 0 738 17 673 36 465 29 487 C01DA Organic nitrates 65 805 62 794 60 017 57 316 54 875 10.3 0 738 17 673 36 464 29 485 C01DA02 glyceryl trinitrate 736 48 662 46 507 44 297 42 413 8.0 0 701 15 286 26 426 9 186 C01DA08 isosorbide dinitrate 1 153 933 722 231 0 0.0 0 0 0 0 0 C01DA14 isosorbide mononitrate 27 093 25 701 24 237 23 752 22 774 4.3 0 96 4 755 17 923 20 298 C01DX Other vasodilators used in cardiac diseases ATC group C - Cardiovascular system ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales 70 Legemiddelstatistikk 2019:2 OTHER CARDIAC PREPARATIONS 62 84 172 286 289 0.1 6 63 165 55 1 111 C01EB Other cardiac preparations 62 84 172 286 289 0.1 6 63 165 55 1 111 C01EB09 ubidecarenone 0 0 0 0 10 0.0 5 <5 <5 <5 104 C01EB15 trimetazidine 5 5 6 10 7 0.0 0 0 7 0 12 C01EB17 ivabradine 42 59 141 249 241 0.1 <5 60 140 40 617 C01EB18 ranolazine 15 20 25 28 32 0.0 0 0 18 14 378 C02 ANTIHYPERTENSIVES 16 939 16 820 17 147 17 723 17 686 3.3 357 1 001 7 285 9 043 109 415 C02A ANTIADRENERGIC AGENTS, CENTRALLY ACTING 6 485 6 468 6 644 7 025 7 169 1.4 348 462 3 170 3 189 10 897 C02AB Methyldopa 65 58 57 46 40 0.0 0 21 12 7 119 C02AB01 methyldopa (levorotatory) 65 58 57 46 40 0.0 0 21 12 7 119 C02AC Imidazoline receptor agonists 6 430 6 419 6 592 6 982 7 132 1.3 348 441 3 160 3 183 10 779 C02AC01 clonidine 107 100 125 200 282 0.1 8 122 142 10 474 C02AC02 guanfacine 0 0 96 417 477 0.1 340 126 11 0 4 656 C02AC05 moxonidine 6 324 6 320 6 373 6 367 6 377 1.2 0 196 3 008 3 173 5 649 C02C ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING 10 638 10 486 10 610 10 818 10 630 2.0 <5 484 4 202 5 943 14 150 C02CA Alpha-adrenoreceptor antagonists 10 638 10 486 10 610 10 818 10 630 2.0 <5 484 4 202 5 943 14 150 C02CA01 prazosin 64 79 95 140 145 0.0 0 106 39 0 263 C02CA04 doxazosin 10 574 10 410 10 517 10 681 10 488 2.0 <5 379 4 165 5 943 13 888 C02D ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON 337 360 383 383 411 0.1 <5 25 142 243 605 C02DB Hydrazinophthalazine derivatives 306 312 330 322 363 0.1 <5 15 113 234 306 C02DB02 hydralazine 306 312 330 363 0.1 <5 15 113 234 306 C02DC Pyrimidine derivatives 31 48 56 62 50 0.0 0 10 31 9 299 C02DC01 minoxidil 31 48 56 62 50 0.0 0 10 31 9 299 C02K OTHER ANTIHYPERTENSIVES 230 268 304 326 337 0.1 8 76 169 84 83 763 C02KD Serotonin antagonists 12 11 11 10 10 0.0 0 <5 5 <5 378 C02KD01 ketanserin 12 11 11 10 10 0.0 0 <5 5 <5 378 C02KX Antihypertensives for pulmonary arterial hypertension 219 258 294 317 328 0.1 8 74 165 81 83 384 C02KX01 bosentan 133 117 111 106 103 0.0 8 31 45 19 18 898 C02KX02 ambrisentan 56 55 55 58 47 0.0 0 14 24 9 13 480 C02KX04 macitentan 38 87 114 144 155 0.0 <5 28 85 41 43 446 C02KX05 riociguat 7 11 19 21 28 0.0 0 <5 12 14 7 560 C03 DIURETICS 187 618 180 739 175 921 170 540 169 410 31.9 233 6 372 56 909 105 896 119 631ATC group C ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales 35 304 32 893 31 977 6.0 17 982 14 225 16 753 15 209 C03AA Thiazides, plain 13 434 12 993 12 857 12 495 13 253 2.5 12 530 6 054 6 657 3 806 C03AA01 bendroflumethiazide <5 2 C03AA03 hydrochlorothiazide 13 434 12 993 12 857 12 492 13 250 2.5 11 530 6 053 6 656 3 804 C03AB Thiazides and potassium in combination 27 546 24 716 22 519 20 465 18 795 3.5 5 459 8 201 10 130 11 403 C03AB01 bendroflumethiazide and potassium 27 546 24 716 22 519 20 465 18 795 3.5 5 459 8 201 10 130 11 403 C03B LOW-CEILING DIURETICS, EXCL. THIAZIDES 17 14 11 0 <5 <5 5 25 C03BA Sulfonamides, plain 17 14 11 7 8 0.0 0 <5 <5 5 25 C03BA04 chlortalidone 10 7 8 6 6 0.0 0 0 <5 5 C03BA08 metolazone 20 C03C HIGH-CEILING DIURETICS 122 417 119 815 118 174 115 668 116 446 21.9 198 4 086 33 504 78 658 58 135 C03CA Sulfonamides, plain 122 417 119 815 118 174 115 668 116 446 21.9 198 4 086 33 504 78 658 58 135 C03CA01 furosemide 86 842 82 939 79 694 75 970 74 596 14.0 197 3 161 23 508 47 730 19 599 C03CA02 bumetanide 40 285 41 465 42 921 44 130 46 219 8.7 <5 1 017 10 883 34 318 38 536 C03CA04 torasemide <5 <5 0 0 0 0.0 0 0 0 0 0 C03D POTASSIUM-SPARING AGENTS 19 299 20 004 21 421 22 492 24 209 4.6 44 1 416 8 991 13 758 15 680 C03DA Aldosterone antagonists 19 280 19 982 21 406 22 476 24 196 4.6 44 1 414 8 983 13 755 15 606 C03DA01 spironolactone 18 221 18 795 20 091 20 980 22 160 4.2 44 1 316 7 927 12 873 8 710 C03DA02 potassium canrenoate 0 <5 0 0 0 0.0 0 0 0 0 0 C03DA04 eplerenone 1 208 1 339 1 489 1 671 2 236 0.4 0 110 1 146 980 6 896 C03DB Other potassium-sparing agents 21 23 16 18 16 0.0 0 <5 10 <5 74 C03DB01 amiloride 21 23 16 18 16 0.0 0 <5 10 <5 74 C03E DIURETICS AND POTAS - SIUM-SPARING AGENTS IN COMBINATION 20 874 18 854 16 977 15 279 13 339 2.5 10 192 5 162 7 975 2 816 C03EA Low-ceiling diuretics and potassium-sparing agents 20 874 18 854 16 977 15 279 13 339 2.5 10 192 5 162 7 975 2 816 C03EA01 hydrochlorothiazide and potassium-sparing agents 20 874 18 854 16 977 15 279 13 339 2.5 10 192 5 162 7 975 2 816 C03X OTHER DIURETICS 61 55 78 160 187 0.0 0 43 87 57 27 766 C03XA Vasopressin antagonists 61 55 78 160 187 0.0 0 43 87 57 27 766 C03XA01 tolvaptan 61 55 78 160 187 0.0 0 43 87 57 27 766 C04 PERIPHERAL VASODILATORS 739 655 634 567 508 0.1 0 27 147 334 643 C04A PERIPHERAL VASODILATORS 739 655 634 567 508 0.1 0 27 147 334 643 C04AD Purine derivatives 737 654 631 565 507 0.1 0 27 146 334 581 C04AD03 pentoxifylline 737 654 631 565 507 0.1 0 27 146 334 581ATC group C ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales C05 VASOPROTECTIVES 72 133 71 938 69 823 55 313 49 437 9.3 581 20 710 18 891 9 255 13 664 C05A AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE 65 990 65 841 63 639 48 839 43 259 8.1 540 19 553 16 393 6 773 12 593 C05AA Corticosteroids 63 521 63 231 60 591 45 308 39 122 7.4 484 17 474 14 783 6 381 8 542 C05AA01 hydrocortisone 4 107 3 214 3 254 2 993 2 060 0.4 34 752 919 355 345 C05AA04 prednisolone 60 659 60 926 58 216 42 937 37 446 7.1 450 16 869 14 037 6 090 8 198 C05AE Muscle relaxants 4 037 4 287 4 826 4 896 5 320 1.0 47 2 723 2 080 470 3 933 C05AE01 glyceryl trinitrate 4 037 4 287 4 826 4 896 5 320 1.0 47 2 723 2 080 470 3 933 C05AX Other agents for treatment of hemorrhoids and anal fissures for topical use 160 62 76 86 432 0.1 18 199 150 65 117 C05AX03 other preparations, combinations 148 49 68 69 408 0.1 17 190 137 64 68 C05B ANTIVARICOSE THERAPY 6 393 6 338 6 407 6 680 6 366 1.2 41 1 205 2 569 2 551 1 050 C05BA Heparins or heparinoids for topical use 6 382 6 328 6 397 6 668 6 359 1.2 41 1 203 2 564 2 551 1 041 C05BA01 organo-heparinoid 6 382 6 328 6 397 6 668 6 359 1.2 41 1 203 2 564 2 551 1 041 C05BB Sclerosing agents for local injection 11 10 10 12 7 0.0 0 <5 5 0 8 C05BB02 polidocanol 11 10 10 12 7 0.0 0 <5 5 0 8 C05C CAPILLARY STABILIZING AGENTS 7 7 12 8 10 0.0 0 <5 <5 5 22 C05CA Bioflavonoids 7 7 12 8 10 0.0 0 <5 <5 5 22 C05CA01 rutoside 7 7 12 8 10 0.0 0 <5 <5 5 22 C07 BETA BLOCKING AGENTS 372 668 373 078 375 425 378 400 379 605 71.5 715 24 258 148 450 206 182 219 851 C07A BETA BLOCKING AGENTS 369 031 369 672 372 172 375 321 376 704 70.9 715 24 172 146 918 204 899 217 805 C07AA Beta blocking agents, non-selective 23 139 21 003 20 165 20 491 21 170 4.0 350 5 438 8 474 6 908 19 715 C07AA03 pindolol 11 12 13 11 7 0.0 0 <5 5 <5 14 C07AA05 propranolol 17 453 15 740 15 274 15 992 17 116 3.2 315 5 220 7 277 4 304 13 618 C07AA06 timolol 13 11 8 13 11 0.0 0 0 8 <5 137 C07AA07 sotalol 5 608 5 228 4 768 4 346 3 872 0.7 <5 119 1 142 2 607 2 697 C07AA12 nadolol 109 122 139 163 189 0.0 32 105 50 <5 3 249 C07AB Beta blocking agents, selective 328 613 330 834 333 820 336 587 337 155 63.5 372 16 348 131 117 189 318 181 648 C07AB02 metoprolol 274 751 277 459 280 496 283 411 285 653 53.8 333 14 182 112 127 159 011 152 857 C07AB03 atenolol 27 982 26 316 24 654 23 277 21 435 4.0 37 1 197 7 618 12 583 5 978ATC group C ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales 299 31 582 33 069 34 311 6.5 <5 1 144 12 784 20 381 22 761 C07AB12 nebivolol 36 22 41 79 98 0.0 0 23 59 16 52 C07AG Alpha and beta blocking agents 22 109 21 960 21 956 22 064 22 019 4.2 16 2 796 8 691 10 516 16 442 C07AG01 labetalol 2 469 2 671 2 789 2 819 2 963 0.6 <5 2 137 526 297 2 206 C07AG02 carvedilol 19 658 19 314 19 189 19 267 19 077 3.6 13 665 8 172 10 227 14 236 C07B BETA BLOCKING AGENTS AND THIAZIDES 4 030 3 729 3 563 3 342 3 113 0.6 0 90 1 625 1 398 2 047 C07BB Beta blocking agents, selec - tive, and thiazides 4 030 3 729 3 563 3 342 3 113 0.6 0 90 1 625 1 398 2 047 C07BB07 bisoprolol and thiazides 4 028 3 725 3 556 3 336 3 105 0.6 0 87 1 622 1 396 2 037 C07BB12 nebivolol and thiazides <5 <5 10 C08 CALCIUM CHANNEL BLOCKERS 237 478 241 894 249 493 256 070 260 260 49.0 156 9 965 113 737 136 402 148 850 C08C SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS 221 504 226 742 234 822 241 764 246 300 46.4 149 9 219 108 857 128 075 134 232 C08CA Dihydropyridine derivatives 221 504 226 742 234 822 241 764 246 300 46.4 149 9 219 108 857 128 075 134 232 C08CA01 amlodipine 129 550 131 318 134 703 137 090 155 136 29.2 133 5 312 68 949 80 742 52 017 C08CA02 felodipine 14 310 13 945 13 522 12 982 14 561 2.7 <5 295 5 588 8 677 9 170 371 C08CA05 nifedipine 38 829 42 101 46 124 50 280 47 653 9.0 17 3 123 21 242 23 271 47 893 C08CA06 nimodipine 38 41 31 45 35 0.0 <5 10 19 5 26 C08CA13 lercanidipine 41 539 42 239 43 626 44 738 51 137 9.6 0 1 390 22 503 27 244 24 630 C08D SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS 17 062 16 236 15 746 15 374 15 121 2.9 7 807 5 321 8 986 14 617 C08DA Phenylalkylamine derivatives 13 057 12 401 11 965 11 662 11 357 2.1 7 715 3 978 6 657 7 865 C08DA01 verapamil 13 057 12 401 11 965 11 662 11 357 2.1 7 715 3 978 6 657 7 865 C08DB Benzothiazepine derivatives 4 050 3 941 3 850 3 763 3 820 0.7 0 98 1 361 2 361 6 752 C08DB01 diltiazem 4 050 3 941 3 850 3 763 3 820 0.7 0 98 1 361 2 361 6 752 C09 AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM 565 340 577 002 592 066 607 098 620 693 116.9 571 30 101 312 754 277 267 545 401 C09A ACE INHIBITORS, PLAIN 134 833 134 856 135 955 137 321 138 648 26.1 398 6 526 61 846 69 878 67 563 C09AA ACE inhibitors, plain 134 833 134 856 135 955 137 321 138 648 26.1 398 6 526 61 846 69 878 67 563 C09AA01 captopril 1 718 1 535 1 381 1 339 1 205 0.2 169 66 391 579 3 354 C09AA02 enalapril 45 946 45 640 46 041 46 333 46 453 8.8 233 2 820 21 949 21 451 19 462 C09AA03 lisinopril 23 394 22 235 21 466 20 709 20 334 3.8 <5 939 9 256 10 137 9 254 C09AA04 perindopril 14 24 39 52 60 0.0 0 13 36 11 36 C09AA05 ramipril 64 292 65 938 67 562 69 406 71 098 13.4 <5 2 712 30 403 37 979 35 454 C09AA10 trandolapril 62 41 0 0 0 0.0 0 0 0 0 0ATC group C ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales 3 C09B ACE INHIBITORS, COMBINATIONS 32 710 31 299 30 217 29 243 28 185 5.3 0 715 12 922 14 548 21 936 C09BA ACE inhibitors and diuretics 31 140 29 646 28 485 27 337 26 093 4.9 0 620 11 816 13 657 19 446 C09BA02 enalapril and diuretics 18 916 18 210 17 658 17 149 16 553 3.1 0 443 7 745 8 365 13 104 C09BA03 lisinopril and diuretics 12 243 11 448 10 836 10 189 9 561 1.8 0 177 4 083 5 301 6 quinapril and diuretics 0 <5 - 0 0 <5 0 1 C09BB ACE inhibitors and calcium channel blockers 1 593 1 669 1 755 1 930 2 125 0.4 0 98 1 117 910 2 490 C09BB02 enalapril and lercanidipine 1 593 1 669 1 755 1 930 2 125 0.4 0 98 1 117 910 2 490 C09C ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN 215 131 225 379 236 972 248 444 261 041 49.1 187 17 490 136 694 106 670 172 050 C09CA Angiotensin II receptor blockers (ARBs), plain 215 131 225 379 236 972 248 444 261 041 49.1 187 17 490 136 694 106 670 172 050 C09CA01 losartan 64 088 65 539 66 606 67 344 69 440 13.1 35 3 262 35 469 30 674 33 707 C09CA02 eprosartan 1 285 1 183 1 105 988 902 0.2 0 8 321 573 1 775 C09CA03 valsartan 30 018 32 325 35 101 38 060 40 080 7.6 <5 2 008 21 277 16 794 45 176 C09CA04 irbesartan 18 711 18 445 18 209 17 853 17 579 3.3 0 509 8 315 8 755 16 791 C09CA06 candesartan 95 249 102 232 110 321 118 609 129 744 24.4 152 11 662 69 572 48 358 65 049 C09CA07 telmisartan 5 699 5 657 5 705 5 680 5 794 1.1 0 220 2 980 2 594 6 479 C09CA08 olmesartan medoxomil 1 600 1 555 1 542 1 538 1 644 0.3 0 79 884 681 3 073 C09D ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS 221 086 222 462 226 709 230 147 232 332 43.7 0 7 105 120 529 104 698 C09DA Angiotensin II receptor blockers (ARBs) and diuretics 181 504 178 645 178 238 176 742 173 718 32.7 0 4 396 87 135 82 187 133 697 C09DA01 losartan and diuretics 66 303 64 608 64 474 63 337 61 870 11.7 0 1 461 30 060 30 349 33 414 C09DA02 eprosartan and diuretics 1 394 1 267 1 201 1 113 1 024 0.2 0 21 457 546 2 212 C09DA03 valsartan and diuretics 26 794 26 698 26 633 26 833 26 530 5.0 0 678 13 473 12 379 30 160 C09DA04 irbesartan and diuretics 26 036 24 757 23 578 22 301 21 177 4.0 0 305 9 621 11 251 22 558 C09DA06 candesartan and diuretics 56 924 57 400 58 597 59 488 60 366 11.4 0 1 896 32 164 26 306 38 902 C09DA07 telmisartan and diuretics 3 689 3 548 3 414 3 266 3 131 0.6 0 75 1 545 1 511 4 419 C09DA08 olmesartan medoxomil and diuretics 1 087 1 020 992 972 973 0.2 0 14 497 462 2 031 C09DB Angiotensin II receptor blockers (ARBs) and calcium channel blockers 25 205 26 972 29 272 31 687 34 464 6.5 0 1 728 19 511 13 225 60 689 C09DB01 valsartan and amlodipine 24 907 26 659 28 939 31 375 34 097 6.4 0 1 712 19 297 13 088 59 802 C09DB02 olmesartan medoxomil and amlodipine 304 315 336 321 372 0.1 0 16 216 140 887ATC group C ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales 19 311 21 561 24 276 26 922 29 700 5.6 0 1 240 16 872 11 588 89 388 C09DX01 valsartan, amlodipine and hydrochlorothiazide 19 311 21 559 23 861 26 003 28 023 5.3 0 1 185 16 110 10 728 64 860 C09DX03 olmesartan medoxomil, amlodipine and <5 <5 2 C09DX04 valsartan and sacubitril 0 0 417 921 1 682 0.3 0 55 762 865 24 527 C09X OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM 53 40 35 32 10 0.0 0 0 5 5 77 C09XA Renin-inhibitors 53 40 35 32 10 0.0 0 0 5 5 77 C09XA02 aliskiren 53 40 35 32 10 0.0 0 0 5 5 77 C10 LIPID MODIFYING AGENTS 518 485 530 298 546 563 567 610 582 167 109.6 280 20 928 287 981 272 978 583 268 C10A LIPID MODIFYING AGENTS, PLAIN 514 628 524 937 536 005 553 452 573 452 108.0 280 20 546 283 011 269 615 505 471 C10AA HMG CoA reductase inhibitors 506 319 515 553 524 774 540 449 558 729 105.2 260 19 362 275 484 263 623 276 906 C10AA01 simvastatin 271 504 252 759 232 429 212 312 192 106 36.2 17 4 168 79 216 108 705 61 418 C10AA02 lovastatin 825 770 705 719 0 14 269 459 1 141 C10AA03 pravastatin 19 189 18 617 18 317 17 903 17 497 3.3 17 426 7 256 9 798 12 519 C10AA04 fluvastatin 7 432 7 590 7 731 7 469 5 152 1.0 0 396 2 696 2 060 9 626 C10AA05 atorvastatin 211 717 237 283 264 578 295 715 329 576 62.1 181 13 257 177 262 138 876 150 155 C10AA07 rosuvastatin 12 552 15 939 20 448 25 959 30 921 5.8 49 1 710 18 187 10 975 40 356 C10AA08 pitavastatin 24 32 49 48 30 0.0 0 <5 19 10 1 690 C10AB Fibrates 315 311 301 316 329 0.1 <5 42 232 54 1 615 C10AB02 bezafibrate 44 42 36 36 39 0.0 0 <5 27 11 158 C10AB04 gemfibrozil 90 74 68 67 61 0.0 0 9 40 12 567 C10AB05 fenofibrate 182 195 197 215 230 0.0 <5 32 166 31 889 C10AC Bile acid sequestrants 2 556 2 754 3 011 3 277 3 412 0.6 13 751 1 794 854 10 222 C10AC01 colestyramine 1 866 2 049 2 328 2 610 2 763 0.5 13 674 1 427 649 3 038 C10AC02 colestipol 268 256 242 216 83 93 536 C10AC04 colesevelam 454 471 464 478 478 0.1 0 63 296 119 6 647 C10AD Nicotinic acid and derivatives 25 20 15 13 10 0.0 0 <5 6 <5 346 C10AD02 nicotinic acid 18 14 11 7 0.0 0 <5 316 C10AD06 0 <5 0 31 C10AX Other lipid modifying agents 26 228 29 683 33 353 38 964 53 420 10.1 18 2 513 31 258 19 631 216 382 C10AX02 probucol 0 0 0 0 <5 - 0 0 <5 0 22 C10AX06 omega-3-triglycerides incl. other esters and acids 4 233 4 400 4 480 4 725 4 813 0.9 <5 535 3 275 999 38 009ATC group C ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales 25 884 29 420 34 729 49 074 9.2 14 1 978 28 342 18 740 123 539 C10AX12 lomitapide 0 0 <5 <5 0 0 6 891 C10AX13 evolocumab 0 45 217 317 484 0.1 <5 45 350 88 25 557 C10AX14 alirocumab 0 10 185 280 474 0.1 0 36 338 100 22 364 C10B LIPID MODIFYING AGENTS, COMBINATIONS 3 664 8 136 14 974 20 260 21 745 4.1 9 1 005 13 122 7 609 72 448 C10BA HMG CoA reductase inhibi - tors in combination with other lipid modifying agents 3 664 8 136 14 974 20 260 21 745 4.1 9 1 005 13 122 7 609 72 448 C10BA02 simvastatin and ezetimibe 3 664 4 127 4 251 4 555 4 629 0.9 0 131 2 487 2 011 20 602 C10BA05 atorvastatin and ezetimibe 0 4 136 10 871 15 847 17 293 3.3 9 882 10 746 5 656 51 846ATC group C ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales 772 456 145.4 113 072 282 360 245 067 131 957 441 597 D01 ANTIFUNGALS FOR DERMA - TOLOGICAL USE 138 096 141 400 145 187 150 144 153 601 28.9 14 255 55 982 54 885 28 479 40 761 D01A ANTIFUNGALS FOR TOPICAL USE 120 842 124 070 127 061 132 033 134 332 25.3 13 966 49 261 45 189 25 916 22 352 D01AA Antibiotics 43 32 13 27 41 0.0 7 19 5 10 11 D01AA01 nystatin 43 32 13 27 41 0.0 7 19 5 10 11 D01AC Imidazole and triazole derivatives 95 521 99 330 102 356 107 077 109 065 20.5 11 855 39 745 35 689 21 776 15 540 D01AC01 clotrimazole 9 356 9 703 10 096 10 505 10 533 2.0 1 600 3 808 2 587 2 538 1 842 D01AC02 miconazole 2 421 2 313 2 321 2 309 2 381 0.5 410 801 716 454 434 D01AC03 econazole 839 949 975 1 016 1 035 0.2 37 178 370 450 160 D01AC08 ketoconazole 18 365 18 825 19 256 20 378 21 874 4.1 1 490 10 556 6 950 2 878 4 331 D01AC20 imidazoles/triazoles in combination with corticosteroids 69 350 72 618 74 981 78 325 78 596 14.8 8 801 26 435 26 740 16 620 8 773 D01AE Other antifungals for topical use 28 894 28 407 28 410 28 823 29 125 5.5 2 477 10 948 10 806 4 894 6 801 D01AE02 methylrosaniline 878 908 812 873 586 0.1 155 116 163 152 85 D01AE14 ciclopirox 2 763 3 824 4 645 4 773 4 976 0.9 119 1 412 2 507 938 1 836 D01AE15 terbinafine 19 949 19 116 19 117 19 520 19 822 3.7 2 104 8 424 6 277 3 017 3 904 D01AE16 amorolfine 5 820 5 032 4 335 4 152 4 212 0.8 116 1 162 2 069 865 976 D01B ANTIFUNGALS FOR SYSTEMIC USE 21 538 21 816 22 551 22 760 24 057 4.5 488 8 650 11 755 3 164 18 409 D01BA Antifungals for systemic use 21 538 21 816 22 551 22 760 24 057 4.5 488 8 650 11 755 3 164 18 409 D01BA01 griseofulvin 30 22 19 33 23 0.0 17 5 0 <5 21 D01BA02 terbinafine 21 513 21 799 22 533 22 733 24 038 4.5 474 8 646 11 755 3 163 18 388 D02 EMOLLIENTS AND PROTECTIVES 3 153 3 500 28 189 75 655 111 674 21.0 50 883 29 398 19 887 11 506 104 314 D02A EMOLLIENTS AND PROTECTIVES 3 153 3 500 28 180 75 646 111 662 21.0 50 882 29 394 19 881 11 505 104 295 D02AB Zinc products 9 5 10 11 7 0.0 <5 <5 <5 <5 2 D02AC Soft paraffin and fat products 0 0 0 7 16 0.0 <5 6 <5 5 8 D02AE Carbamide products 1 423 1 665 26 158 73 598 109 617 20.6 50 431 28 935 19 192 11 059 103 525 D02AE01 carbamide 1 423 1 665 26 158 73 598 109 617 20.6 50 431 28 935 19 192 11 059 103 525 D02AF Salicylic acid preparations 1 398 1 422 1 611 1 651 1 709 0.3 163 434 692 420 406 D02AX Other emollients and protectives 353 463 641 881 966 643 132 98 93 354 D02B PROTECTIVES AGAINST UV-RADIATION 0 0 10 9 13 <5 7 <5 19 D02BA Protectives against UV-radiation for topical use 0 0 10 9 13 0.0 <5 <5 7 <5 192.8 ATC group D - Dermatologicals ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales 70 Legemiddelstatistikk 2019:2 Folkehelseinstituttet 48D03 PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS 71 63 47 67 147 0.0 5 46 54 42 40 D03A CICATRIZANTS 71 63 47 67 147 0.0 5 46 54 42 40 D03AX Other cicatrizants 71 63 47 67 147 0.0 5 46 54 42 40 D03AX03 dexpanthenol 71 63 47 67 147 0.0 5 46 54 42 40 D04 ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. 8 038 8 386 8 560 8 761 8 573 1.6 920 3 453 2 341 1 859 1 665 D04A ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. 8 038 8 386 8 560 8 761 8 573 1.6 920 3 453 2 341 1 859 1 665 D04AA Antihistamines for topical use <5 15 17 6 0 <5 <5 <5 2 D04AA13 dimetindene 0 <5 <5 <5 2 D04AB Anesthetics for topical use 6 538 6 757 6 809 6 949 6 599 1.2 563 2 893 1 883 1 260 1 333 D04AB01 lidocaine 6 538 6 757 6 809 6 949 6 599 1.2 563 2 893 1 883 1 260 1 333 D04AX Other antipruritics 1 522 1 644 1 765 1 838 2 000 0.4 360 568 465 607 330 D05 ANTIPSORIATICS 29 403 30 301 30 801 31 250 30 297 5.7 531 8 329 15 220 6 217 47 794 D05A ANTIPSORIATICS FOR TOPICAL USE 27 839 28 530 28 920 29 303 28 441 5.4 519 8 033 14 054 5 835 40 163 D05AA Tars 1 102 1 299 1 550 1 917 1 940 0.4 167 619 612 542 507 D05AC Antracen derivatives 11 10 <5 7 7 0.0 0 5 <5 <5 8 D05AC01 dithranol 11 10 <5 0 5 <5 <5 8 D05AD Psoralens for topical use 0 0 <5 - 0 <5 <5 0 1 0 <5 <5 0 1 D05AX Other antipsoriatics for topical use 26 883 27 416 27 610 27 683 26 768 5.0 363 7 511 13 553 5 39 648 D05AX02 calcipotriol 902 20 116 6 138 229 98 291 D05AX03 calcitriol 1 439 1 406 1 284 1 162 1 022 0.2 11 235 550 226 715 D05AX52 calcipotriol, combinations 25 685 26 546 26 701 26 676 25 818 4.9 350 7 280 13 053 5 135 38 642 D05B ANTIPSORIATICS FOR SYSTEMIC USE 2 117 2 360 2 446 2 519 2 463 0.5 13 425 1 538 487 7 630 D05BA Psoralens for systemic use 14 17 11 16 15 0.0 0 <5 6 8 11 D05BA02 methoxsalen 14 17 11 16 15 0.0 0 <5 6 8 11 D05BB Retinoids for treatment of psoriasis 2 047 2 277 2 361 2 442 2 412 0.5 13 414 1 507 478 6 163 D05BB02 acitretin 2 047 2 277 2 361 2 442 2 412 0.5 13 414 1 507 478 6 163 D05BX Other antipsoriatics for systemic use 60 71 78 66 38 0.0 0 10 25 <5 1 457 D05BX51 fumaric acid derivatives, combinations 60 71 78 66 38 0.0 0 10 25 <5 1 457ATC group D ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales 114 332 111 663 108 688 106 031 20.0 10 942 38 991 34 547 21 551 32 634 D06A ANTIBIOTICS FOR TOPICAL USE 58 416 57 378 56 016 54 255 53 256 10.0 9 319 16 699 16 514 10 724 5 202 D06AA Tetracycline and derivatives 3 258 3 340 3 230 3 226 3 276 0.6 358 945 1 218 755 573 D06AA02 chlortetracycline 25 26 16 29 28 0.0 <5 6 14 7 10 D06AA03 oxytetracycline 3 235 3 315 3 214 3 198 3 248 0.6 357 939 1 204 748 563 D06AX Other antibiotics for topical use 55 337 54 247 52 966 51 217 50 163 9.4 8 977 15 805 15 360 10 021 4 629 D06AX01 fusidic acid 51 972 50 693 48 979 47 857 47 490 8.9 8 256 14 914 14 769 9 551 4 249 D06AX05 bacitracin 2 121 2 138 2 357 2 893 2 805 0.5 753 929 628 495 357 D06AX07 gentamicin 0 0 <5 <5 1 D06AX09 mupirocin 97 98 47 43 39 0.0 12 16 8 <5 22 D06AX13 retapamulin 1 387 1 552 1 813 640 0 0.0 0 0 0 0 0 D06B CHEMOTHERAPEUTICS FOR TOPICAL USE 58 373 58 986 57 534 56 248 54 554 10.3 1 713 22 868 18 648 11 325 27 432 D06BA Sulfonamides 3 577 3 313 3 124 2 866 2 893 0.5 428 978 927 560 394 D06BA01 silver sulfadiazine 3 577 3 313 3 124 2 866 2 893 0.5 428 978 927 560 394 D06BB Antivirals 38 267 36 191 35 673 35 270 34 585 6.5 1 046 16 826 10 564 6 149 17 722 D06BB03 aciclovir 16 329 15 254 14 818 15 101 15 302 2.9 841 6 384 5 996 2 081 2 752 D06BB04 podophyllotoxin 13 286 12 623 12 096 10 834 10 353 2.0 72 8 704 1 486 91 2 910 D06BB06 penciclovir 1 385 1 087 958 871 691 0.1 25 252 300 114 150 D06BB10 imiquimod 8 079 7 993 8 494 9 299 8 973 1.7 108 2 074 2 897 3 894 11 902 D06BB12 sinecatechins 102 169 75 0 0 0.0 0 0 0 0 0 D06BB53 aciclovir, combinations 0 0 0 0 32 0.0 <5 13 13 <5 8 D06BX Other chemotherapeutics 17 174 20 174 19 386 18 720 17 664 3.3 240 5 193 7 371 4 860 9 316 D06BX01 metronidazole 14 089 14 666 14 082 13 311 12 426 2.3 239 5 094 5 133 1 960 2 540 D06BX02 ingenol mebutate 3 132 5 571 5 363 5 459 5 275 1.0 <5 101 2 254 2 919 6 776 D07 CORTICOSTEROIDS, DERMA - TOLOGICAL PREPARATIONS 383 757 390 663 406 760 420 091 424 136 79.9 66 068 129 203 145 312 83 553 100 254 D07A CORTICOSTEROIDS, PLAIN 326 739 336 817 349 112 360 719 361 928 68.1 59 969 109 243 122 439 70 277 76 866 D07AA Corticosteroids, weak (group I) 31 278 32 883 34 121 36 466 36 146 6.8 17 768 9 168 5 863 3 347 4 354 D07AA02 hydrocortisone 31 278 32 883 34 121 36 466 36 146 6.8 17 768 9 168 5 863 3 347 4 354 D07AB Corticosteroids, moderately potent (group II) 108 829 114 463 117 426 124 714 125 571 23.6 33 077 37 421 34 107 20 966 18 189 D07AB02 hydrocortisone butyrate 86 711 90 268 92 705 98 183 99 175 18.7 27 056 29 854 26 094 16 171 14 292 D07AB08 desonide 23 447 25 654 26 249 28 161 27 855 5.2 6 549 7 925 8 332 5 049 3 897 D07AC Corticosteroids, potent (group III) 169 282 169 883 176 406 176 748 173 574 32.7 17 944 56 299 62 508 36 823 37 564ATC group D ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales betamethasone 61 411 50 585 58 525 55 767 54 129 10.2 3 550 17 357 20 768 12 454 8 201 D07AC03 desoximetasone 11 620 14 876 12 571 11 848 10 660 2.0 421 2 668 4 568 3 003 4 534 D07AC04 fluocinolone acetonide 5 246 7 312 5 773 5 634 5 132 1.0 161 1 039 2 229 1 703 903 D07AC08 fluocinonide 498 477 446 376 362 0.1 <5 60 176 122 70 D07AC13 mometasone 86 651 100 745 98 164 102 116 102 281 19.3 13 080 34 714 34 657 19 830 21 765 D07AC17 fluticasone 11 447 5 704 8 791 8 661 7 759 1.5 1 297 2 542 2 520 1 400 2 090 D07AD Corticosteroids, very potent (group IV) 64 294 69 390 71 624 74 810 76 790 14.5 2 646 21 934 34 795 17 415 16 759 D07AD01 clobetasol 64 294 69 390 71 624 74 810 76 790 14.5 2 646 21 934 34 795 17 415 16 759 D07B CORTICOSTEROIDS, COMBI - NATIONS WITH ANTISEPTICS 32 142 26 806 32 087 32 979 37 187 7.0 5 248 10 823 12 746 8 370 5 754 D07BB Corticosteroids, moderately potent, combinations with antiseptics 6 059 10 013 9 621 4 673 6 995 1.3 2 111 1 739 1 866 1 279 1 108 D07BB02 desonide and antiseptics 6 059 10 013 9 621 4 673 6 995 1.3 2 111 1 739 1 866 1 279 1 108 D07BC Corticosteroids, potent, combinations with anti - septics 26 519 17 796 23 369 28 949 30 910 5.8 3 404 9 266 11 040 7 200 4 646 D07BC01 betamethasone and anti - septics 23 822 12 283 19 354 26 980 28 898 5.4 3 258 8 755 10 203 6 682 4 421 D07BC02 fluocinolone acetonide and antiseptics 3 030 6 371 4 786 2 260 2 135 0.4 156 536 887 556 225 D07C CORTICOSTEROIDS, COMBI - NATIONS WITH ANTIBIOTICS 25 863 26 063 26 192 26 831 25 974 4.9 4 531 7 731 8 558 5 154 3 596 D07CA Corticosteroids, weak, combinations with antibiotics 25 856 25 992 25 707 26 181 25 437 4.8 4 437 7 545 8 409 5 046 3 481 D07CA01 hydrocortisone and anti - biotics 25 856 25 992 25 707 26 181 25 437 4.8 4 437 7 545 8 409 5 046 3 481 D07CB Corticosteroids, moderately potent, combinations with antibiotics <5 <5 0 0 0 0.0 0 0 0 0 0 D07CB01 triamcinolone and antibi - otics <5 <5 0 0 0 0.0 0 0 0 0 0 D07CC Corticosteroids, potent, combinations with antibiotics 6 77 514 687 563 0.1 102 198 154 109 115 D07CC01 betamethasone and anti - biotics 5 76 513 684 562 0.1 102 197 154 109 114 D07CC05 fluocinonide and antibiotics <5 <5 0 0 1 D07X CORTICOSTEROIDS, OTHER COMBINATIONS 28 040 29 011 30 276 31 931 32 026 6.0 990 11 310 13 097 6 629 14 039 D07XA Corticosteroids, weak, other combinations 12 10 5 11 <5 - <5 0 <5 0 3 D07XA01 hydrocortisone 12 10 5 <5 - <5 0 <5 0 3 D07XC Corticosteroids, potent, other combinations 28 028 29 001 30 271 31 920 32 022 6.0 988 11 310 13 095 6 629 14 036ATC group D ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales betamethasone 29 001 30 271 31 920 32 022 6.0 988 11 310 13 095 6 629 14 036 D08 ANTISEPTICS AND DISINFECTANTS 20 798 20 487 20 934 22 159 22 094 4.2 3 802 8 321 6 570 3 401 4 639 D08A ANTISEPTICS AND DISINFECTANTS 20 798 20 487 20 934 22 159 22 094 4.2 3 802 8 321 6 570 3 401 4 639 D08AB Aluminium agents 462 526 570 753 794 0.2 224 248 209 113 118 D08AC Biguanides and amidines 17 537 17 157 17 667 18 699 18 749 3.5 2 908 7 405 5 719 2 717 3 930 D08AC01 dibrompropamidine 6 341 6 356 6 234 6 662 6 837 1.3 2 263 2 070 1 390 1 114 1 284 D08AC02 chlorhexidine 11 595 11 223 11 815 12 426 12 332 2.3 779 5 471 4 430 1 652 2 646 D08AG Iodine products 111 118 93 111 138 0.0 13 32 38 55 39 D08AG02 povidone-iodine 78 76 66 83 109 0.0 6 21 33 49 34 D08AG03 iodine 33 42 27 28 29 0.0 7 11 5 6 5 D08AJ Quaternary ammonium compounds 156 139 180 198 165 0.0 21 45 54 45 36 D08AJ03 cetylpyridinium 156 139 180 198 165 0.0 21 45 54 45 36 D08AL Silver compounds 26 22 16 12 13 0.0 0 <5 7 <5 16 D08AL01 silver nitrate 26 22 16 12 13 0.0 0 <5 7 <5 16 D08AX Other antiseptics and disinfectants 2 683 2 686 2 570 2 596 2 436 0.5 700 641 594 501 501 D08AX01 hydrogen peroxide 1 442 1 453 1 188 1 166 1 114 0.2 295 308 276 235 142 D08AX06 potassium permanganate 1 260 1 239 1 391 1 436 1 320 0.3 408 335 318 259 342 D09 MEDICATED DRESSINGS 1 670 1 427 1 330 1 144 1 129 0.2 84 224 374 447 308 D09A MEDICATED DRESSINGS 1 670 1 427 1 330 1 144 1 129 0.2 84 224 374 447 308 D09AA Medicated dressings with antiinfectives 1 539 1 324 1 238 1 067 1 060 0.2 83 216 356 405 145 D09AA02 fusidic acid 1 539 1 324 1 238 1 067 1 060 0.2 83 216 356 405 145 D09AB Zinc bandages 135 103 92 77 69 0.0 <5 8 18 42 163 D09AB01 zinc bandage without supplements 135 103 92 77 69 0.0 <5 8 18 42 163 D10 ANTI-ACNE PREPARATIONS 73 127 75 653 78 061 82 095 83 202 15.7 5 234 64 069 11 214 2 685 70 052 D10A ANTI-ACNE PREPARATIONS FOR TOPICAL USE 66 073 67 313 68 595 71 573 70 960 13.4 4 977 52 999 10 371 2 613 26 461 D10AD Retinoids for topical use in acne 38 278 40 391 43 437 46 115 47 702 9.0 3 980 39 326 3 467 929 20 078 D10AD01 tretinoin 2 728 3 113 3 253 3 483 3 608 0.7 23 1 554 1 551 480 1 192 D10AD03 adapalene 8 037 7 719 7 161 6 883 6 789 1.3 477 5 235 741 336 1 451 D10AD51 tretinoin, combinations 741 4 942 9 127 10 042 10 111 1.9 902 8 680 477 52 2 969 D10AD53 adapalene, combinations 27 931 26 587 26 519 28 445 29 909 5.6 2 866 26 202 772 69 14 466 D10AE Peroxides 2 886 2 736 2 630 3 390 3 939 0.7 476 3 294 149 20 934 D10AE01 benzoyl peroxide 2 886 2 736 2 630 3 390 3 939 0.7 476 3 294 149 20 934ATC group D ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales of acne 17 315 16 533 15 651 14 791 11 270 2.1 679 7 445 2 644 502 2 109 D10AF01 clindamycin 17 279 16 503 15 619 14 758 11 245 2.1 676 7 430 2 638 501 2 096 D10AF02 erythromycin 38 31 33 35 26 0.0 <5 15 7 <5 13 D10AX Other anti-acne prepara - tions for topical use 16 600 15 938 14 338 14 562 15 006 2.8 539 8 719 4 534 1 214 3 340 D10AX03 azelaic acid 16 593 15 934 14 334 14 554 15 003 2.8 539 8 718 4 533 1 213 3 339 D10AX30 various combinations <5 <5 ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE 10 676 12 523 14 285 15 925 17 959 3.4 529 16 287 1 055 88 43 592 D10BA Retinoids for treatment of acne 10 676 12 523 14 285 15 925 17 959 3.4 529 16 287 1 055 88 43 592 D10BA01 isotretinoin 10 676 12 523 14 285 15 925 17 959 3.4 529 16 287 1 055 88 43 592 D11 OTHER DERMATOLOGICAL PREPARATIONS 23 400 27 571 32 631 38 672 41 048 7.7 3 982 18 294 14 491 4 281 39 067 D11A OTHER DERMATOLOGICAL PREPARATIONS 23 400 27 571 32 631 38 672 41 048 7.7 3 982 18 294 14 491 4 281 39 067 D11AC Medicated shampoos 1 721 1 809 2 134 2 237 1 921 0.4 160 1 206 444 111 251 D11AC03 selenium compounds 1 721 1 809 2 134 2 237 1 921 0.4 160 1 206 444 111 251 D11AF Wart and anti-corn prepara - tions 2 701 2 857 2 884 3 214 3 010 0.6 1 301 1 116 454 139 762 D11AH Agents for dermatitis, excluding corticosteroids 14 358 16 458 17 758 19 667 20 505 3.9 2 489 9 444 6 635 1 937 27 566 D11AH01 tacrolimus 9 659 10 394 10 859 11 229 11 511 2.2 1 401 5 175 3 775 1 160 5 169 D11AH02 pimecrolimus 4 571 5 747 6 543 8 054 8 630 1.6 1 169 4 255 2 479 727 3 956 D11AH04 alitretinoin 364 733 853 967 973 0.2 0 326 559 88 17 836 D11AH05 dupilumab 0 0 0 0 6 0.0 0 <5 5 0 605 D11AX Other dermatologicals 4 777 6 705 10 323 14 238 16 363 3.1 46 6 898 7 268 2 151 10 489 D11AX01 minoxidil 325 358 397 469 597 0.1 6 349 169 73 302 D11AX10 finasteride 582 541 515 519 511 0.1 0 358 149 <5 2 720 D11AX16 eflornithine 560 685 790 934 1 019 0.2 6 595 329 89 770 D11AX18 diclofenac 339 249 368 406 304 0.1 0 8 107 189 332 D11AX21 brimonidine 1 572 2 489 1 954 1 805 1 405 0.3 <5 604 627 172 980 D11AX22 ivermectin 0 840 4 655 8 311 10 395 2.0 23 3 755 5 179 1 438 4 285 D11AX24 deoxycholic acid 0 0 0 <5 0 0.0 0 0 0 0 0ATC group D ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales HORMONES 814 987 835 159 859 381 876 623 889 096 167.4 4 102 443 058 285 681 156 255 1 147 178 G01 GYNECOLOGICAL ANTIIN - FECTIVES AND ANTISEPTICS 37 665 38 586 40 070 42 519 41 124 7.7 124 29 880 9 283 1 837 9 921 G01A ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS 37 665 38 586 40 070 42 519 41 124 7.7 124 29 880 9 283 1 837 9 921 G01AA Antibiotics 22 764 23 983 24 308 23 450 22 820 4.3 67 16 771 5 174 808 5 661 G01AA10 clindamycin 22 764 23 983 24 308 23 450 22 820 4.3 67 16 771 5 174 808 5 661 G01AC Quinoline derivatives 0 11 1 928 6 558 7 965 1.5 6 5 877 1 878 204 1 897 G01AC05 dequalinium 0 11 1 928 6 558 7 965 1.5 6 5 877 1 878 204 1 897 G01AD Organic acids 11 16 12 10 11 0.0 <5 <5 <5 5 17 G01AD02 acetic acid 11 16 12 10 11 0.0 <5 <5 <5 5 17 G01AF Imidazole derivatives 16 475 16 267 15 785 15 115 13 005 2.5 53 9 323 2 739 890 2 334 G01AF01 metronidazole 7 559 7 378 6 968 6 303 6 261 1.2 10 4 519 1 473 259 867 G01AF02 clotrimazole 7 953 8 021 7 976 7 989 5 936 1.1 36 4 244 1 094 562 1 267 G01AF05 econazole 1 268 1 168 1 127 1 127 1 034 0.2 7 734 209 84 200 G01AX Other antiinfectives and antiseptics 8 9 10 8 7 0.0 0 <5 <5 <5 11 G01AX03 policresulen 8 9 <5 <5 <5 11 G02 OTHER GYNECOLOGICALS 48 836 49 301 50 823 52 144 55 340 10.4 9 47 541 7 523 267 64 548 G02A UTEROTONICS 9 10 7 11 <5 - 0 <5 0 0 0 G02AB Ergot alkaloids 9 10 7 11 <5 - 0 <5 0 0 0 G02AB01 methylergometrine 9 10 7 11 <5 - 0 <5 0 0 0 G02B CONTRACEPTIVES FOR TOPICAL USE 46 545 46 915 48 551 49 912 53 116 10.0 8 46 322 6 773 13 61 600 G02BA Intrauterine contraceptives 27 849 28 972 31 358 34 139 38 443 7.2 6 32 310 6 115 12 47 696 G02BA03 plastic IUD with progestogen 27 849 28 972 31 358 34 139 38 443 7.2 6 32 310 6 115 12 47 696 G02BB Intravaginal contraceptives 19 002 18 259 17 547 16 170 15 083 2.8 <5 14 407 673 <5 13 904 G02BB01 vaginal ring with progestogen and estrogen 19 002 18 259 17 547 16 170 15 083 2.8 <5 14 407 673 <5 13 904 G02C OTHER GYNECOLOGICALS 2 374 2 444 2 331 2 296 2 295 0.4 <5 1 282 758 254 2 947 G02CB Prolactine inhibitors 2 310 2 279 2 315 2 293 2 295 0.4 <5 1 282 758 254 2 947 G02CB01 bromocriptine 936 797 728 654 595 0.1 <5 396 135 63 427 G02CB03 cabergoline 1 196 1 320 1 424 1 503 1 579 0.3 0 856 545 178 1 903 G02CB04 quinagolide 215 200 206 175 162 0.0 0 60 87 15 618 G02CX Other gynecologicals 64 165 16 <5 0 0.0 0 0 0 0 0 G02CX04 Cimicifugae rhizoma 64 165 16 <5 0 0.0 0 0 0 0 02.9 ATC group G - Genito urinary system and sex hormones ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM 575 031 583 927 593 953 594 870 594 129 111.9 3 160 369 166 55 488 530 391 G03A HORMONAL CONTRACEP - TIVES FOR SYSTEMIC USE 344 874 350 607 353 941 351 197 345 926 65.1 1 834 324 013 20 063 16 185 421 G03AA Progestogens and estro - gens, fixed combinations 237 366 238 577 236 034 230 419 222 612 41.9 1 354 214 635 6 617 6 111 167 G03AA07 levonorgestrel and ethinylestradiol 138 553 145 951 150 143 152 705 149 303 28.1 1 078 145 102 3 119 <5 53 260 G03AA09 desogestrel and ethinylestradiol 45 974 41 679 37 097 31 982 28 788 5.4 114 27 355 1 318 <5 12 906 G03AA12 drospirenone and ethinylestradiol 51 713 48 906 46 233 43 520 41 128 7.7 199 39 161 1 768 0 37 996 G03AA13 norelgestromin and ethinylestradiol 9 061 8 751 8 394 7 926 7 630 1.4 12 7 262 356 0 5 867 G03AA14 nomegestrol and estradiol 1 140 1 152 1 095 1 068 1 080 0.2 <5 984 93 <5 1 095 G03AA16 dienogest and ethinylestradiol 0 0 0 0 102 0.0 0 98 <5 0 42 G03AB Progestogens and estrogens, sequential preparations 12 601 11 539 10 426 9 293 8 116 1.5 28 7 145 942 <5 3 942 G03AB04 norethisterone and ethinylestradiol 10 762 9 765 8 750 7 727 6 684 1.3 19 5 891 773 <5 2 344 G03AB08 dienogest and estradiol 1 860 1 796 1 694 1 577 1 441 0.3 9 1 263 169 0 1 598 G03AC Progestogens 112 335 119 628 128 200 132 116 134 848 25.4 572 121 502 12 763 11 70 280 G03AC01 norethisterone 5 326 4 909 4 625 4 256 3 823 0.7 <5 3 072 746 <5 977 G03AC06 medroxyprogesterone 18 607 18 083 17 296 16 340 15 329 2.9 36 11 243 4 047 <5 4 381 G03AC08 etonogestrel 8 044 12 689 19 677 23 778 27 216 5.1 146 26 644 421 5 31 352 G03AC09 desogestrel 83 077 87 457 90 935 92 421 92 912 17.5 410 84 849 7 649 <5 33 570 G03AD Emergency contraceptives 1 091 285 151 141 115 0.0 <5 104 9 0 33 G03AD01 levonorgestrel 131 71 64 56 56 0.0 <5 52 <5 0 14 G03AD02 ulipristal 962 216 88 85 60 0.0 <5 53 6 0 19 G03B ANDROGENS 10 714 12 268 14 554 15 427 15 997 3.0 31 4 047 9 477 2 442 61 939 G03BA 3-oxoandrosten (4) deriva - tives 10 706 12 264 14 550 15 422 15 997 3.0 31 4 047 9 477 2 442 61 900 G03BA03 testosterone 10 706 12 264 14 550 15 422 15 997 3.0 31 4 047 9 477 2 442 61 900 G03BB 5-androstanon (3) derivatives 11 5 8 9 6 0.0 0 5 <5 0 39 G03BB01 mesterolone 11 5 8 9 6 0.0 0 5 <5 0 39 G03C ESTROGENS 134 122 138 256 144 129 150 015 156 072 29.4 164 7 540 99 292 49 076 117 603 G03CA Natural and semisynthetic estrogens, plain 127 204 131 613 137 669 143 976 150 342 28.3 164 7 434 94 622 48 122 109 052 G03CA01 ethinylestradiol 35 22 13 17 12 0.0 <5 5 <5 <5 349 G03CA03 estradiol 118 044 123 120 129 932 136 672 142 825 26.9 31 7 132 91 978 43 684 104 947ATC group G ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales estriol 10 657 9 956 9 242 8 853 9 411 1.8 131 339 3 674 5 267 3 754 G03CA57 conjugated estrogens <5 <5 2 G03CX Other estrogens 7 896 7 504 7 301 6 897 6 528 1.2 0 139 5 327 1 062 8 551 G03CX01 tibolone 7 896 7 504 7 301 6 897 6 528 1.2 0 139 5 327 1 062 8 551 G03D PROGESTOGENS 40 263 38 822 38 079 39 183 39 586 7.5 1 130 28 178 10 083 195 26 725 G03DA Pregnen (4) derivatives 15 007 15 507 15 875 16 568 17 737 3.3 41 12 275 5 236 185 23 894 G03DA02 medroxyprogesterone 6 557 6 510 6 469 6 869 7 303 1.4 41 3 867 3 283 112 1 415 G03DA04 progesterone 8 612 9 174 9 584 9 934 10 675 2.0 0 8 586 2 015 74 22 479 G03DB Pregnadien derivatives 169 172 191 241 388 0.1 0 354 34 0 690 G03DB01 dydrogesterone 0 0 0 64 221 0.0 0 217 <5 0 202 G03DB06 chlormadinone 0 <5 <5 0 0 0.0 0 0 0 0 0 G03DB08 dienogest 169 171 190 177 167 0.0 0 137 30 0 488 G03DC Estren derivatives 25 847 23 943 22 767 23 274 22 376 4.2 1 094 16 328 4 943 11 2 140 G03DC02 norethisterone 25 847 23 943 22 767 23 274 22 376 4.2 1 094 16 328 4 943 11 2 140 G03F PROGESTOGENS AND ESTROGENS IN COMBINATION 43 978 42 974 42 769 41 514 42 210 8.0 <5 2 720 35 416 4 073 36 063 G03FA Progestogens and estro - gens, fixed combinations 34 657 33 672 33 661 32 749 33 086 6.2 0 748 28 412 3 926 29 756 G03FA01 norethisterone and estrogen 33 829 32 779 32 742 31 823 32 146 6.1 0 686 27 617 3 843 28 631 G03FA12 medroxyprogesterone and estrogen 954 997 1 014 1 027 1 053 0.2 0 65 904 84 1 126 G03FB Progestogens and estrogens, sequential preparations 10 426 10 359 196 9 801 10 129 1.9 <5 2 7 922 154 6 307 G03FB05 norethisterone estrogen 10 426 10 359 10 196 801 10 129 1.9 <5 2 052 7 922 154 6 307 G03G GONADOTROPINS AND OTHER OVULATION STIMULANTS 10 411 10 672 10 733 9 047 8 573 1.6 0 8 307 257 9 90 918 G03GA Gonadotropins 6 475 6 932 7 143 7 587 7 743 1.5 0 7 609 132 <5 89 821 G03GA01 chorionic gonadotrophin 990 655 639 736 91 0.0 0 58 31 <5 446 G03GA02 human menopausal gonado - trophin 2 220 2 494 2 832 2 849 2 782 0.5 0 2 745 37 0 26 889 G03GA04 urofollitropin 461 81 5 <5 225 0.0 0 222 <5 0 1 374 G03GA05 follitropin alfa 2 004 2 627 2 812 3 532 4 000 0.8 0 3 960 40 0 39 712 G03GA06 follitropin beta 2 039 2 000 2 086 1 324 851 0.2 0 844 7 0 7 141 G03GA07 lutropin alfa 8 <5 0 0 0 0.0 0 0 0 0 0 G03GA08 choriogonadotropin alfa 5 308 6 005 6 240 6 467 7 067 1.3 0 6 979 88 0 4 565 G03GA09 corifollitropin alfa 289 313 352 486 469 0.1 0 457 12 0 3 671 G03GA10 follitropin delta 0 0 0 98 220 0.0 0 220 0 0 2 598 G03GA30 combinations 28 69 34 96 215 0.0 0 214 <5 0 3 425ATC group G ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales Ovulation stimulants, synthetic 4 883 4 732 4 489 1 935 1 031 0.2 0 891 133 7 1 097 G03GB02 clomifene 4 883 4 732 4 489 1 935 1 031 0.2 0 891 133 7 1 097 G03H ANTIANDROGENS 15 961 15 321 14 968 14 553 13 982 2.6 117 13 342 456 67 6 471 G03HA Antiandrogens, plain 160 199 221 255 312 0.1 0 198 47 67 721 G03HA01 cyproterone 160 199 221 255 312 0.1 0 198 47 67 721 G03HB Antiandrogens and estro - gens 15 802 15 127 14 749 14 301 13 672 2.6 117 13 146 409 0 5 750 G03HB01 cyproterone and estrogen 15 802 15 127 14 749 14 301 13 672 2.6 117 13 146 409 0 5 750 G03X OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM 838 1 346 1 903 2 062 1 155 0.2 <5 316 660 178 5 250 G03XA Antigonadotropins and similar agents 57 42 46 46 44 0.0 <5 12 23 8 196 G03XA01 danazol 57 42 46 46 44 0.0 <5 12 23 8 196 G03XB Progesterone receptor modulators 255 965 1 559 1 766 894 0.2 0 304 589 <5 4 425 G03XB01 mifepristone 0 <5 ulipristal 255 961 1 557 1 765 893 0.2 0 303 589 <5 4 424 G03XC Selective estrogen receptor modulators 526 339 298 250 217 0.0 0 0 48 169 629 G03XC01 raloxifene 526 339 298 250 217 0.0 0 0 48 169 629 G04 UROLOGICALS 198 315 210 612 253 063 47.6 834 26 771 117 667 107 791 542 318 G04B UROLOGICALS 136 908 144 609 154 301 165 551 174 799 32.9 831 23 151 91 G04BD Drugs for urinary frequency and incontinence 56 111 59 257 62 109 65 824 69 472 13.1 789 6 621 26 122 35 940 224 116 G04BD04 oxybutynin 1 624 1 882 2 364 2 839 3 499 0.7 158 1 995 895 451 15 126 G04BD07 tolterodine 9 815 8 622 7 939 7 389 6 550 1.2 362 338 2 061 3 789 16 409 G04BD08 solifenacin 18 606 17 576 17 047 16 400 16 145 3.0 279 1 121 6 127 8 618 41 729 G04BD10 darifenacin 2 862 2 454 2 187 2 011 1 803 0.3 0 80 627 1 096 5 423 G04BD11 fesoterodine 11 256 10 029 9 437 8 942 8 483 1.6 7 516 3 349 4 611 27 273 G04BD12 mirabegron 17 823 24 299 28 867 34 219 39 629 7.5 37 3 080 15 614 20 898 118 155 G04BE Drugs used in erectile dysfunction 82 779 87 401 94 327 101 982 107 704 20.3 38 16 466 66 818 24 382 192 458 G04BE01 alprostadil 3 165 3 134 3 169 3 091 3 280 0.6 0 143 1 817 1 320 5 985 G04BE03 sildenafil 36 589 39 750 44 279 49 803 54 309 10.2 37 8 317 33 301 12 654 68 882 G04BE04 yohimbine 11 <5 0 0 0 0.0 0 0 0 0 0 G04BE08 tadalafil 43 262 45 287 48 390 50 838 53 660 10.1 <5 8 612 34 101 10 946 104 090 G04BE09 vardenafil 8 321 8 096 8 256 8 188 6 931 1.3 <5 769 4 431 1 730 10 708 G04BE10 avanafil 0 0 0 286 1 224 0.2 0 191 770 263 845ATC group G ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales 403 636 727 0.1 0 34 461 232 1 948 G04BX Other urologicals 74 113 229 378 491 0.1 <5 294 160 34 4 977 G04BX01 magnesium hydroxide 20 14 23 17 20 0.0 27 G04BX13 dimethyl sulfoxide 0 <5 0.0 0 0 0 0 0 G04BX14 dapoxetine 13 37 139 294 394 0.1 0 272 119 <5 231 G04BX15 pentosan polysulfate sodium 37 58 60 61 72 0.0 0 14 37 21 4 678 G04BX16 tiopronin G04C DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY 72 725 78 579 83 917 89 368 94 665 17.8 <5 3 966 32 619 58 077 120 676 G04CA Alpha-adrenoreceptor antagonists 60 216 66 025 71 252 76 632 81 729 15.4 <5 2 031 30 057 49 638 102 120 G04CA01 alfuzosin 16 27 28 23 18 0.0 0 <5 <5 13 52 G04CA02 tamsulosin 47 791 50 322 52 615 55 027 57 370 10.8 <5 1 933 23 060 32 374 43 035 G04CA03 terazosin 547 502 509 421 395 0.1 0 45 159 191 373 G04CA52 tamsulosin and dutasteride 14 946 18 364 21 617 24 463 27 008 5.1 0 44 7 869 19 095 55 584 G04CA53 tamsulosin and solifenacin 0 25 348 703 1 134 0.2 0 22 521 591 3 076 G04CB Testosterone-5-alpha reductase inhibitors 17 815 17 549 17 492 17 414 17 467 3.3 0 1 945 3 613 11 909 18 556 G04CB01 finasteride 16 774 16 641 16 687 16 763 16 869 3.2 0 1 900 3 517 11 452 16 863 G04CB02 dutasteride 1 098 962 846 686 637 0.1 0 59 102 476 1 692ATC group G ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS 437 511 445 610 452 531 463 794 469 293 88.4 18 156 759 548 811 H01 PITUITARY AND HYPOTHA - LAMIC HORMONES AND ANALOGUES 26 356 26 947 26 687 27 881 27 529 5.2 9 836 14 090 2 007 1 596 293 191 H01A ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES 2 027 2 079 2 091 2 133 2 178 0.4 1 179 634 303 62 93 267 H01AA ACTH 0 <5 <5 23 H01AB Thyrotropin 0 0 <5 0 0 0.0 0 0 0 0 0 H01AB01 thyrotropin alfa 0 0 <5 0 0 0.0 0 0 0 0 0 H01AC Somatropin and somatropin agonists 1 995 2 042 2 048 2 087 2 133 0.4 1 175 625 281 52 80 626 H01AC01 somatropin 1 995 2 042 2 046 2 083 2 130 0.4 1 175 622 281 52 80 500 H01AC03 mecasermin 0 0 <5 6 5 0.0 0 5 0 0 126 H01AX Other anterior pituitary lobe hormones and analogues 32 35 40 42 41 0.0 0 9 22 10 12 617 H01AX01 pegvisomant 32 35 40 42 41 0.0 0 9 22 10 12 617 H01B POSTERIOR PITUITARY LOBE HORMONES 18 980 18 930 18 399 19 303 18 602 3.5 8 695 7 564 1 220 1 123 48 236 H01BA Vasopressin and analogues 11 736 11 854 11 662 11 983 11 997 2.3 8 635 1 089 1 153 1 120 46 260 H01BA02 desmopressin 11 736 11 854 11 662 11 982 11 996 2.3 8 635 1 089 1 153 1 119 46 241 H01BA04 terlipressin 0 0 0 <5 <5 - 0 0 0 <5 19 H01BB Oxytocin and analogues 7 249 7 078 6 737 7 320 6 607 1.2 60 6 477 67 <5 1 976 H01BB02 oxytocin 7 249 7 078 6 737 7 320 6 607 1.2 60 6 477 67 <5 1 976 H01C HYPOTHALAMIC HORMONES 5 608 6 196 6 487 6 745 7 042 1.3 10 6 049 558 425 151 688 H01CA Gonadotropin-releasing hormones 2 833 3 031 2 954 2 632 2 483 0.5 <5 2 466 15 <5 5 774 H01CA02 nafarelin 2 833 3 031 2 954 2 632 2 483 0.5 <5 2 466 15 <5 5 774 H01CB Somatostatin and analogues 830 895 927 944 987 0.2 9 63 491 424 132 796 H01CB02 octreotide 603 638 616 617 607 0.1 0 43 301 263 71 724 H01CB03 lanreotide 248 291 329 351 397 0.1 9 17 198 173 57 286 H01CB05 pasireotide <5 5 5 11 11 0.0 0 <5 6 <5 3 786 H01CC Anti-gonadotropin-releasing hormones 2 304 2 685 3 082 3 650 4 053 0.8 0 3 999 54 0 13 117 H01CC01 ganirelix 2 075 2 607 3 011 3 071 3 495 0.7 0 3 449 46 0 11 073 H01CC02 cetrorelix 286 109 143 753 640 0.1 0 632 8 0 2 044 H02 CORTICOSTEROIDS FOR SYSTEMIC USE 227 420 231 293 233 848 240 224 242 825 45.7 6 043 60 390 101 961 74 431 84 1382.10 ATC group H - Systemic hormonal preparations, excl. sex hormones and insulins ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales USE, PLAIN 227 187 231 055 233 616 240 195 242 824 45.7 6 043 60 390 101 961 74 430 84 137 H02AA Mineralocorticoids 1 403 1 442 1 490 1 546 1 563 0.3 88 462 652 361 497 H02AA02 fludrocortisone 1 403 1 442 1 490 1 546 1 563 0.3 88 462 652 361 497 H02AB Glucocorticoids 227 005 230 866 233 414 239 986 242 602 45.7 6 038 60 347 101 908 74 309 83 640 H02AB01 betamethasone 2 307 2 669 2 982 3 476 3 984 0.8 2 487 518 746 233 875 H02AB02 dexamethasone 5 508 7 268 8 837 10 446 11 688 2.2 439 1 088 5 748 4 413 16 647 H02AB04 methylprednisolone 10 306 9 769 9 093 7 919 6 941 1.3 33 1 444 3 307 2 157 2 625 H02AB06 prednisolone 174 044 177 416 181 260 187 335 191 453 36.0 2 699 41 808 80 621 66 325 34 389 H02AB07 prednisone 330 303 294 268 114 0.0 0 15 42 57 643 H02AB08 triamcinolone 38 537 37 521 35 086 34 710 32 421 6.1 282 16 055 13 367 2 717 5 274 H02AB09 hydrocortisone 683 700 827 948 989 0.2 84 342 473 90 16 030 H02AB10 cortisone 2 905 3 006 3 130 3 254 3 351 0.6 103 827 1 538 883 6 795 H02AB13 deflazacort 36 45 51 55 59 0.0 30 20 6 <5 361 H02B CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS 416 418 <5 - 0 0 <5 <5 1 H02BX Corticosteroids for systemic use, combinations 416 418 402 107 - 0 0 <5 <5 1 combi - nations <5 - 0 0 <5 <5 1 H03 THYROID THERAPY 202 576 207 068 212 089 216 620 220 398 41.5 1 417 40 676 104 204 74 101 103 541 H03A THYROID PREPARATIONS 197 828 202 215 207 170 211 335 214 677 40.4 1 374 39 006 101 789 72 508 95 349 H03AA Thyroid hormones 197 828 202 215 207 170 211 335 214 677 40.4 1 374 39 006 101 789 72 508 95 349 H03AA01 levothyroxine sodium 196 793 200 938 205 630 209 382 212 354 40.0 1 369 38 320 100 325 72 340 67 846 H03AA02 liothyronine sodium 5 361 6 206 7 273 8 412 9 883 1.9 18 2 840 5 960 1 065 7 030 H03AA03 combinations of 0 0 0 <5 - 0 <5 0 0 1 H03AA05 thyroid gland preparations 1 828 2 662 3 407 4 144 4 885 0.9 6 1 488 3 078 313 20 466 H03B ANTITHYROID PREPARATIONS 6 713 6 924 7 103 7 525 8 175 1.5 59 2 654 3 548 1 914 8 188 H03BA Thiouracils 733 629 557 552 733 629 557 64 807 H03BB Sulfur-containing imidazole derivatives 6 239 6 484 6 729 7 157 7 814 1.5 57 2 497 3 393 1 867 7 381 H03BB01 carbimazole 6 239 6 484 6 729 7 157 7 814 1.5 57 2 497 3 393 1 867 7 381 H03C IODINE THERAPY 6 12 7 <5 5 0.0 0 <5 <5 0 4 H03CA Iodine therapy 6 12 7 <5 5 0.0 0 <5 <5 0 4 H04 PANCREATIC HORMONES 5 495 5 398 5 588 5 427 5 353 1.0 1 169 2 282 1 460 442 2 180ATC group H ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales 5 398 5 588 5 427 5 353 1.0 1 169 2 282 1 460 442 2 180 H04AA Glycogenolytic hormones 5 495 5 398 5 588 5 427 5 353 1.0 1 169 2 282 1 460 442 2 180 H04AA01 glucagon 5 495 5 398 5 588 5 427 5 353 1.0 1 169 2 282 1 460 442 2 180 H05 CALCIUM HOMEOSTASIS 1 375 1 559 1 827 2 096 2 139 0.4 0 146 988 1 005 65 757 H05A PARATHYROID HORMONES AND ANALOGUES 608 720 931 1 151 1 133 0.2 0 65 597 471 52 003 H05AA Parathyroid hormones and analogues 608 720 931 1 151 1 133 0.2 0 65 597 471 52 003 H05AA02 teriparatide 608 720 931 1 151 1 123 0.2 0 61 592 470 35 199 H05AA03 parathyroid hormone 0 0 0 <5 22 0.0 0 7 14 <5 16 804 H05B ANTI-PARATHYROID AGENTS 767 839 896 945 1 006 0.2 0 81 391 534 13 755 H05BA Calcitonin preparations 16 8 7 8 6 0.0 0 <5 0 <5 57 H05BA01 calcitonin (salmon synthetic) 16 8 7 8 6 0.0 0 <5 0 <5 57 H05BX Other anti-parathyroid agents 751 831 889 937 1 001 0.2 0 78 391 532 13 698 H05BX01 cinacalcet 520 569 615 674 734 0.1 0 43 264 427 9 333 H05BX02 paricalcitol 289 309 341 333 336 0.1 0 42 160 134 4 364ATC group H ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales Antiinfectives for systemic use ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales in 1000 NOK<15 15-44 45-69 70 J ANTIINFECTIVES FOR SYSTEMIC USE 1 252 912 1 239 430 1 209 403 1 177 724 1 167 183 219.7 117 077 451 075 380 772 218 259 1 284 841 J01 ANTIBACTERIALS FOR SYSTEMIC USE 1 172 061 1 151 008 1 109 722 1 063 315 1 026 325 193.2 109 935 390 234 331 479 194 677 297 864 J01A TETRACYCLINES 179 821 181 380 168 809 159 385 152 173 28.7 2 433 79 325 47 780 22 635 31 310 J01AA Tetracyclines 179 821 181 380 168 809 159 385 152 173 28.7 2 433 79 325 47 780 22 635 31 310 J01AA02 doxycycline 138 206 141 617 131 272 122 266 115 433 21.7 1 035 52 799 40 408 21 191 18 899 J01AA04 lymecycline 24 963 24 561 23 337 24 396 24 801 4.7 1 037 18 642 4 354 768 8 973 J01AA06 oxytetracycline 32 21 30 26 29 0.0 0 13 11 5 9 J01AA07 tetracycline 19 709 18 062 16 804 15 267 14 239 2.7 400 9 510 3 530 799 3 398 J01AA08 minocycline 95 56 35 28 23 0.0 0 9 8 6 32 J01AA12 tigecycline <5 <5 <5 0 0 0.0 0 0 0 0 0 J01B AMPHENICOLS 0 0 <5 0 0 0.0 0 0 0 0 0 J01BA Amphenicols 0 0 <5 0 0 0.0 0 0 0 0 0 J01BA01 chloramphenicol 0 0 <5 0 0 0.0 0 0 0 0 0 J01C BETA-LACTAM ANTIBACTERIALS, PENICILLINS 774 578 769 281 750 891 730 187 713 965 134.4 83 728 263 956 226 979 139 302 134 101 J01CA Penicillins with extended spectrum 323 045 319 429 311 008 298 397 299 130 56.3 22 217 93 443 100 035 83 435 57 574 J01CA01 ampicillin 46 50 62 54 66 0.0 0 5 14 47 203 J01CA04 amoxicillin 133 023 132 447 125 992 119 990 117 650 22.2 18 346 26 852 40 800 31 652 18 008 J01CA08 pivmecillinam 203 727 200 847 198 004 190 781 194 098 36.5 4 088 69 117 63 416 57 477 39 355 J01CA11 mecillinam 11 10 16 18 6 0.0 <5 8 J01CE Beta-lactamase sensitive penicillins 421 779 417 025 404 417 394 483 373 320 70.3 61 531 149 233 111 417 51 139 51 761 J01CE01 benzylpenicillin 127 120 149 166 209 0.0 <5 281 J01CE02 416 404 289 394 163 70.3 61 529 149 188 111 371 51 075 51 161 J01CE08 benzathine benzylpenicillin 82 87 60 57 51 0.0 0 30 17 <5 319 J01CF Beta-lactamase resistant penicillins 104 462 105 990 105 128 103 589 105 680 19.9 5 274 42 485 36 399 21 522 22 904 J01CF01 dicloxacillin 101 196 104 241 103 820 103 272 105 556 19.9 5 211 42 473 36 377 21 495 22 454 J01CF02 cloxacillin 3 964 2 211 1 624 379 105 0.0 0 15 40 50 195 J01CF05 flucloxacillin 22 29 47 66 78 0.0 69 8 0 <5 256 J01CR Combinations of penicillins, incl. 1 1 652 0.5 891 386 729 amoxicillin beta-lacta - mase inhibitor 599 695 916 1 588 2 762 0.5 889 379 703 791 1 452 J01CR05 piperacillin and beta-lacta - mase inhibitor 53 79 104 0.0 34 410Legemiddelstatistikk 2019:2 Folkehelseinstituttet 62J01D OTHER BETA-LACTAM ANTIBACTERIALS 19 475 17 366 14 827 13 449 12 545 2.4 1 838 4 598 4 031 2 078 6 028 J01DB First-generation cephalosporins 18 026 16 071 13 968 12 546 11 728 2.2 1 791 4 284 3 795 1 858 1 887 J01DB01 cefalexin 18 012 16 055 13 951 12 529 11 708 2.2 1 791 4 282 3 784 1 851 1 853 J01DB03 cefalotin 15 16 19 17 22 0.0 <5 <5 12 7 33 J01DC Second-generation cephalosporins 78 93 97 72 75 0.0 0 9 19 47 96 J01DC02 cefuroxime 78 93 97 72 75 0.0 0 9 19 47 96 J01DD Third-generation cephalosporins 1 373 1 171 740 785 717 0.1 47 304 202 164 1 663 J01DD01 cefotaxime 1 054 789 363 305 169 0.0 <5 23 65 77 276 J01DD02 ceftazidime 77 69 68 75 55 0.0 <5 23 15 15 238 J01DD04 ceftriaxone 244 313 312 412 494 0.1 41 258 124 71 1 148 J01DD08 cefixime 0 0 0 0 <5 - 0 0 0 <5 1 J01DF Monobactams 13 14 13 16 18 0.0 <5 8 <5 <5 819 J01DF01 aztreonam 13 14 <5 8 <5 <5 819 J01DH Carbapenems 65 86 73 86 71 0.0 <5 16 29 24 1 446 J01DH02 meropenem 49 49 58 63 53 0.0 <5 12 22 17 1 021 J01DH03 ertapenem 16 32 10 21 18 0.0 0 <5 7 8 415 J01DH51 imipenem and cilastatin <5 9 <5 0 0 11 J01DI Other cephalosporins and penems 0 0 0 <5 <5 0 0 117 inhibitor 0 0 0 <5 0 0 117 J01E SULFONAMIDES AND TRIMETHOPRIM 121 251 121 066 121 722 121 434 125 601 23.7 12 478 30 893 42 652 39 578 15 421 J01EA Trimethoprim and derivatives 76 472 72 140 69 823 68 123 66 833 12.6 7 374 17 586 21 008 20 865 6 188 J01EA01 trimethoprim 76 472 72 140 69 823 68 123 66 833 12.6 7 374 17 586 21 008 20 865 6 188 J01EC Intermediate-acting sulfonamides 0 0 <5 - 0 2 J01EC02 sulfadiazine 0 0 <5 9 <5 - 0 0 2 J01EE Combinations of sulfon- amides and trimethoprim, incl. derivatives 49 930 54 153 57 183 58 807 64 637 12.2 5 529 14 307 23 514 21 287 9 231 J01EE01 sulfamethoxazole and trimethoprim 49 930 54 153 57 183 58 807 64 637 12.2 5 529 14 307 23 514 21 287 9 231 J01F MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS 267 602 242 351 217 006 187 736 163 664 30.8 21 286 67 258 55 173 19 947 29 571 J01FA Macrolides 212 200 190 236 168 977 145 999 123 066 23.2 17 734 51 656 40 262 13 414 20 242 J01FA01 erythromycin 110 826 101 160 92 247 82 929 67 900 12.8 14 576 24 098 21 296 7 930 10 417ATC group J ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales 1 652 1 307 1 065 884 0.2 13 292 443 136 139 J01FA06 roxithromycin 5 <5 10 <5 9 0.0 0 <5 6 0 7 J01FA09 clarithromycin 29 173 24 078 18 856 15 730 13 280 2.5 1 260 5 018 5 042 1 960 2 539 J01FA10 azithromycin 77 639 69 382 61 238 49 933 43 852 8.3 2 198 23 465 14 505 3 684 7 141 J01FA15 telithromycin <5 <5 0 0 0 0.0 0 0 0 0 0 J01FF Lincosamides 63 250 59 149 53 932 46 587 44 856 8.4 3 977 17 412 16 340 7 127 9 329 J01FF01 clindamycin 63 250 59 149 53 932 46 587 44 856 8.4 3 977 17 412 16 340 7 127 9 329 J01G AMINOGLYCOSIDE ANTIBACTERIALS 258 214 216 222 185 0.0 42 71 45 27 7 829 J01GA Streptomycins <5 0 <5 0 0 0.0 0 0 0 J01GA01 streptomycin <5 0 <5 0 0 0.0 0 0 0 0 0 J01GB Other aminoglycosides 257 214 215 222 185 0.0 42 71 45 27 7 829 J01GB01 tobramycin 213 177 168 172 140 0.0 35 59 28 18 6 265 J01GB03 gentamicin 34 24 32 32 33 0.0 7 7 11 8 989 J01GB06 amikacin 11 13 15 20 13 0.0 0 6 6 <5 575 J01M QUINOLONE ANTIBACTERIALS 65 117 58 859 53 197 45 649 42 077 7.9 312 10 442 16 882 14 441 11 045 J01MA Fluoroquinolones 65 117 58 859 53 197 45 649 42 077 7.9 312 10 442 16 882 14 441 11 045 J01MA01 ofloxacin 1 496 1 312 1 083 941 832 0.2 0 217 370 245 268 J01MA02 ciprofloxacin 63 320 56 847 51 047 43 221 39 387 7.4 312 8 369 16 482 14 224 9 044 J01MA12 levofloxacin 29 21 24 60 83 0.0 0 46 28 9 512 J01MA14 moxifloxacin 547 940 1 247 1 600 1 939 0.4 0 1 858 73 8 1 221 J01X OTHER ANTIBACTERIALS 63 139 64 278 65 539 66 806 62 147 11.7 1 020 10 119 21 307 29 701 62 558 J01XA Glycopeptide antibacterials 31 44 47 43 43 0.0 <5 7 21 13 522 J01XA01 vancomycin 30 44 47 42 43 0.0 <5 7 21 13 522 J01XA02 teicoplanin <5 0 0 <5 0 0.0 0 0 0 0 0 J01XB Polymyxins 88 94 111 111 104 0.0 9 45 36 14 3 877 J01XB01 colistin 88 94 111 111 104 0.0 9 45 36 14 3 877 J01XC Steroid antibacterials 481 411 346 326 326 0.1 24 105 109 88 252 J01XC01 fusidic acid 481 411 346 326 326 0.1 24 105 109 88 252 J01XD Imidazole derivatives 30 34 30 27 31 0.0 0 <5 19 9 94 J01XD01 metronidazole 30 34 30 27 31 0.0 0 <5 19 9 94 J01XE Nitrofuran derivatives 36 895 36 527 36 830 37 003 30 853 5.8 882 6 686 10 923 12 362 9 077 J01XE01 nitrofurantoin 36 895 36 527 36 830 37 003 30 853 5.8 882 6 686 10 923 12 362 9 077 J01XX Other antibacterials 31 554 33 306 34 356 35 522 36 348 6.8 137 3 921 12 073 20 217 48 735 J01XX01 fosfomycin 7 19 19 30 53 0.0 0 9 28 16 130 J01XX05 methenamine 31 313 33 030 34 039 35 183 35 980 6.8 137 3 859 11 904 20 080 43 134 J01XX08 linezolid 250 275 305 314 339 0.1 0 54 153 132 4 639ATC group J ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales 0 <5 0 28 J01XX11 tedizolid 0 0 9 0 <5 <5 804 J02 ANTIMYCOTICS FOR SYSTEMIC USE 47 208 43 725 41 387 40 492 7.6 439 24 839 11 861 3 353 38 666 J02A ANTIMYCOTICS FOR SYSTEMIC USE 48 649 47 208 43 725 41 387 40 492 7.6 439 24 839 11 861 3 353 38 666 J02AA Antibiotics <5 5 <5 <5 <5 5 <5 0 972 J02AB Imidazole derivatives 0 25 11 8 8 0.0 0 <5 <5 <5 259 J02AB02 ketoconazole 0 25 <5 <5 <5 259 J02AC Triazole derivatives 48 646 47 185 43 708 41 371 40 471 7.6 439 24 833 11 851 3 348 30 962 J02AC01 fluconazole 48 145 46 748 43 304 41 008 40 091 7.6 429 24 679 11 698 3 285 16 928 J02AC02 itraconazole 703 530 401 365 348 0.1 <5 213 105 28 581 J02AC03 voriconazole 85 103 105 97 96 0.0 <5 10 43 39 4 052 J02AC04 posaconazole 85 101 120 106 111 0.0 14 29 58 10 8 180 J02AC05 isavuconazole 0 0 0 <5 16 0.0 0 <5 9 <5 1 222 J02AX Other antimycotics for systemic use 5 8 10 10 20 0.0 0 <5 12 784 J02AX06 anidulafungin 0 <5 5 5 0 <5 6 <5 5 601 J04 ANTIMYCOBACTERIALS 2 105 1 794 1 971 1 998 1 938 0.4 160 759 591 428 7 925 J04A DRUGS FOR TREATMENT OF TUBERCULOSIS 1 636 1 349 1 496 1 517 1 471 0.3 149 666 390 266 7 474 J04AA Aminosalicylic acid and derivatives 0 <5 <5 0 0 0.0 0 0 0 0 0 J04AA01 4-aminosalicylic acid 0 <5 <5 0 0 0.0 0 0 0 0 0 J04AB Antibiotics 656 636 940 1 031 1 044 0.2 132 401 278 233 3 872 J04AB01 cycloserine 0 12 13 12 10 0.0 0 9 <5 0 437 J04AB02 rifampicin 644 583 651 696 706 0.1 76 171 237 222 1 125 J04AB04 rifabutin 12 5 6 11 9 0.0 0 <5 5 <5 309 J04AB05 rifapentine 0 36 272 319 322 0.1 57 221 35 9 2 001 J04AB30 capreomycin 0 0 <5 0 0 0.0 0 0 0 0 0 J04AC Hydrazides 78 115 336 378 377 0.1 55 251 54 17 208 J04AC01 isoniazid 78 115 336 378 377 0.1 55 251 54 17 208 J04AD Thiocarbamide derivatives 0 6 6 11 9 0.0 0 8 <5 0 88 J04AD01 protionamide 0 6 6 11 9 0.0 0 8 <5 0 88 J04AK Other drugs for treatment of tuberculosis 291 233 204 177 160 0.0 10 74 48 28 1 731 J04AK01 pyrazinamide 58 41 46 40 40 0.0 7 27 <5 <5 80ATC group J ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales ethambutol 273 219 181 162 145 0.0 6 66 46 27 668 J04AK05 bedaquiline <5 0 0 <5 <5 - 0 <5 <5 0 983 J04AM Combinations of drugs for treatment of tuberculosis 976 680 529 471 407 0.1 18 263 98 28 1 575 J04AM02 rifampicin and isoniazid 915 638 466 420 370 0.1 17 241 92 20 1 077 J04AM05 rifampicin, pyrazinamide and isoniazid 178 129 126 95 76 <5 52 17 6 171 J04AM06 rifampicin, pyrazinamide, ethambutol and isoniazid 53 68 101 128 126 0.0 <5 88 28 9 326 J04B DRUGS FOR TREATMENT OF LEPRA 470 448 475 485 473 0.1 11 95 203 164 451 J04BA Drugs for treatment of lepra 470 448 475 485 473 0.1 11 95 203 164 451 J04BA01 clofazimine 0 <5 5 <5 <5 36 J04BA02 dapsone 470 445 470 476 467 0.1 11 93 200 163 415 J05 ANTIVIRALS FOR SYSTEMIC USE 39 587 43 666 48 150 53 194 59 797 11.3 973 29 293 22 309 7 222 763 176 J05A DIRECT ACTING ANTIVIRALS 39 587 43 666 48 150 53 194 59 797 11.3 973 29 293 22 309 7 222 763 176 J05AB Nucleosides and nucleotides excl. reverse transcriptase inhibitors 33 914 37 006 40 201 43 852 47 025 8.9 786 23 444 16 512 6 283 48 364 J05AB01 aciclovir 12 720 13 191 13 449 13 519 14 000 2.6 525 7 387 4 696 1 105 J05AB11 valaciclovir 21 583 24 259 27 263 30 907 33 684 6.3 251 16 633 11 875 4 925 33 176 J05AB14 valganciclovir 379 371 377 439 409 0.1 25 102 219 63 9 264 J05AD Phosphonic acid derivatives <5 <5 0 0 0 0.0 0 0 0 0 0 J05AD01 foscarnet <5 <5 0 0 0 0.0 0 0 0 0 0 J05AE Protease inhibitors 1 339 1 064 772 508 349 0.1 <5 166 172 10 14 870 J05AE01 saquinavir 5 <5 <5 <5 0 0.0 0 0 0 0 0 J05AE03 ritonavir 1 004 811 605 399 269 0.1 <5 132 128 8 959 J05AE08 atazanavir 1 121 850 573 353 228 0.0 <5 103 120 <5 8 992 J05AE10 darunavir 228 218 200 148 124 0.0 0 65 53 6 4 919 J05AF Nucleoside and nucleotide reverse transcriptase inhibitors 663 778 941 1 095 1 300 0.2 24 585 639 52 18 820 J05AF01 zidovudine 21 15 14 19 15 0.0 6 <5 7 0 61 J05AF02 didanosine 11 5 0 0 0 0.0 0 0 0 0 0 J05AF05 lamivudine 89 94 84 75 103 0.0 16 23 57 7 785 J05AF06 abacavir 58 67 67 58 52 0.0 15 11 23 <5 1 439 J05AF07 tenofovir disoproxil 355 421 514 557 333 23 3 238 J05AF08 adefovir dipivoxil 10 9 6 5 <5 - 0 <5 <5 0 128ATC group J ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales <5 0 42 J05AF10 entecavir 210 271 343 410 410 0.1 <5 154 237 17 8 064 J05AF11 telbivudine <5 <5 <5 0 0 0.0 0 0 0 0 0 J05AF13 tenofovir alafenamide 0 0 0 121 130 0.0 0 59 63 8 5 061 J05AG Non-nucleoside reverse transcriptase inhibitors 346 307 246 197 230 0.0 <5 73 141 14 5 320 J05AG01 nevirapine 158 147 126 99 89 0.0 0 27 55 7 2 047 J05AG03 efavirenz 147 119 76 46 38 0.0 <5 12 19 5 947 J05AG04 etravirine 31 29 28 24 18 0.0 0 7 11 0 778 J05AG05 rilpivirine 15 14 19 31 85 0.0 0 27 56 <5 1 548 J05AH Neuraminidase inhibitors 1 098 1 528 2 153 1 923 3 571 0.7 156 1 369 1 332 714 870 J05AH01 zanamivir 18 52 25 0 0 0.0 0 0 0 0 0 J05AH02 oseltamivir 1 080 1 477 2 129 1 923 3 571 0.7 156 1 369 1 332 714 870 J05AP Antivirals for treatment of HCV infections 799 1 037 1 175 1 955 3 189 0.6 <5 1 437 1 707 42 255 185 J05AP01 ribavirin 696 561 754 380 88 0.0 0 17 67 <5 863 J05AP02 telaprevir 25 0 0 0 0 0.0 0 0 0 0 0 J05AP03 boceprevir 61 <5 0 0 0 0.0 0 0 0 0 0 J05AP05 simeprevir 94 69 5 <5 0 0.0 0 0 0 0 0 J05AP07 daclatasvir 32 129 235 47 0 0.0 0 0 0 0 0 J05AP08 sofosbuvir 450 360 384 101 <5 - 0 0 <5 0 1 109 J05AP09 dasabuvir 0 12 299 105 54 0.0 0 36 18 0 210 J05AP51 sofosbuvir and ledipasvir 0 534 312 29 98 0.0 <5 34 58 <5 7 216 J05AP53 ombitasvir, paritaprevir and ritonavir 0 13 312 107 55 0.0 0 36 19 0 2 418 J05AP54 elbasvir and grazoprevir 0 0 0 1 152 990 0.2 0 424 554 12 57 310 J05AP55 sofosbuvir and velpatasvir 0 0 51 504 1 988 0.4 0 930 1 036 22 172 910 J05AP56 sofosbuvir, velpatasvir and voxilaprevir 0 0 0 11 30 <5 7 624 J05AP57 glecaprevir and pibrentasvir 0 0 0 <5 30 0.0 0 6 20 <5 5 525 J05AR Antivirals for treatment of HIV infections, combinations 3 369 3 638 4 082 4 821 5 322 1.0 17 2 698 2 451 156 381 539 J05AR01 zidovudine and lamivudine 181 130 104 64 46 0.0 0 12 31 <5 1 289 J05AR02 lamivudine and abacavir 424 307 195 131 262 0.1 <5 94 151 13 2 343 J05AR03 tenofovir disoproxil and emtricitabine 1 589 1 536 1 454 1 627 2 130 0.4 <5 1 667 21 24 693 J05AR04 zidovudine, lamivudine and abacavir 732 649 467 317 0.1 0 140 165 12 20 251ATC group J ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales 76 12 862 J05AR09 emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat 135 265 259 104 52 0.0 0 25 26 <5 5 127 J05AR10 lopinavir and ritonavir 298 212 145 89 62 0.0 6 21 33 <5 1 933 J05AR13 lamivudine, abacavir and dolutegravir 91 610 968 1 200 1 230 0.2 <5 469 709 49 123 283 J05AR14 darunavir and cobicistat 0 17 48 83 383 0.1 0 175 199 9 8 926 J05AR15 atazanavir and cobicistat 0 <5 6 7 29 0.0 0 10 19 0 595 J05AR17 emtricitabine and tenofovir alafenamide 0 0 95 329 338 0.1 0 118 198 22 19 355 J05AR18 emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat 0 0 482 891 945 0.2 <5 397 510 37 108 687 J05AR19 emtricitabine, tenofovir alafenamide and rilpivirine 0 0 155 548 577 0.1 0 235 320 22 50 966 J05AR22 emtricitabine, tenofovir alafenamide, darunavir and cobicistat 0 0 0 14 0.0 0 <5 10 <5 1 056 J05AX Other antivirals 601 743 836 839 1 056 0.2 11 566 447 32 38 208 J05AX05 inosine pranobex 40 25 18 13 9 0.0 0 7 <5 0 98 J05AX08 raltegravir 470 580 638 583 643 0.1 9 415 207 12 16 638 J05AX09 maraviroc 8 8 7 6 7 0.0 0 <5 5 0 586 J05AX12 dolutegravir 105 143 194 246 413 0.1 <5 151 239 20 20 887ATC group J ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales 442 105 983 112 500 116 797 22.0 1 602 26 431 53 640 35 124 4 277 921 L02 ENDOCRINE THERAPY 26 977 27 821 28 869 31 639 32 537 6.1 186 5 899 10 888 15 564 412 703 L02A HORMONES AND RELATED AGENTS 10 472 10 398 10 452 10 640 10 832 2.0 182 1 720 1 904 7 026 106 048 L02AA Estrogens 0 <5 <5 0 0 0.0 0 0 0 0 L02AA02 polyestradiol phosphate 0 <5 <5 0 0 0.0 0 0 0 0 0 L02AB Progestogens 142 138 138 130 162 0.0 0 7 56 99 397 L02AB01 megestrol 142 138 138 130 162 0.0 0 7 56 99 397 L02AE Gonadotropin releasing hormone analogues 10 335 10 260 10 315 10 513 10 671 2.0 182 1 713 1 849 6 927 105 651 L02AE01 buserelin 724 495 387 335 252 0.1 0 248 <5 0 361 L02AE02 leuprorelin 3 477 3 139 2 786 2 467 2 236 0.4 182 491 251 1 312 22 301 L02AE03 goserelin 6 218 6 599 7 001 7 312 7 689 1.5 0 456 1 586 5 647 82 650 L02AE04 triptorelin 23 131 241 479 573 0.1 0 560 13 0 339 L02AE05 histrelin 6 0 0 0 0 0.0 0 0 0 0 0 L02B HORMONE ANTAGONISTS AND RELATED AGENTS 20 708 21 821 22 834 25 548 26 485 5.0 <5 4 590 10 066 11 825 306 654 L02BA Anti-estrogens 4 417 4 609 4 958 5 439 5 544 1.0 <5 849 3 634 1 059 25 824 L02BA01 tamoxifen 4 181 4 338 4 612 4 963 5 062 1.0 <5 835 3 390 835 4 798 L02BA03 fulvestrant 263 292 376 522 521 0.1 0 14 255 252 21 026 L02BB Anti-androgens 7 078 7 081 6 985 7 007 7 020 1.3 0 5 1 232 5 783 174 367 L02BB01 flutamide 136 108 85 82 64 0.0 0 <5 <5 60 492 L02BB03 bicalutamide 6 480 6 313 6 116 6 041 5 945 1.1 0 <5 1 026 4 915 20 970 L02BB04 enzalutamide 517 826 938 1 093 1 188 0.2 0 0 240 948 152 905 L02BG Aromatase inhibitors 8 902 9 813 10 626 12 995 13 880 2.6 <5 3 793 5 509 4 575 38 813 L02BG03 anastrozole 1 280 1 028 843 757 652 0.1 0 25 339 288 2 600 L02BG04 letrozole 6 999 8 128 9 079 11 537 12 524 2.4 <5 3 749 4 814 3 958 32 050 L02BG06 exemestane 910 983 1 015 974 1 041 0.2 0 30 553 458 4 163 L02BX Other hormone antagonists and related agents 1 380 1 415 1 401 1 273 1 180 0.2 0 0 241 939 67 651 L02BX02 degarelix 642 806 872 837 786 0.2 0 606 8 653 L02BX03 abiraterone 804 660 581 473 430 0.1 0 0 76 354 58 998 L03 IMMUNOSTIMULANTS 6 485 6 306 6 819 6 431 6 432 1.2 54 1 209 3 807 1 362 139 986 L03A IMMUNOSTIMULANTS 6 485 6 306 6 819 6 431 6 432 1.2 54 1 209 3 807 1 362 139 986 L03AA Colony stimulating factors 3 313 4 159 4 909 4 775 4 932 0.9 52 710 2 901 1 269 53 134 L03AA02 filgrastim 611 593 583 588 46 121 313 114 6 171 L03AA13 pegfilgrastim 2 734 3 138 3 605 3 947 1 811 0.3 <5 240 1 089 481 19 811 L03AA14 lipegfilgrastim 109 676 956 370 3 086 0.6 6 428 1 841 811 27 1522.12 ATC group L - Antineoplastic and immunomodulating agents ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales 375 1 210 952 763 0.1 <5 216 474 71 51 267 L03AB01 interferon alfa natural 8 8 0 0 0 0.0 0 0 0 0 0 L03AB03 interferon gamma 11 10 13 10 9 0.0 0 9 0 0 1 796 L03AB04 interferon alfa-2a 19 19 19 21 0 0.0 0 0 0 0 0 L03AB05 interferon alfa-2b 47 34 36 40 27 0.0 0 <5 12 12 703 L03AB07 interferon beta-1a 872 592 461 372 323 0.1 <5 75 230 16 26 310 L03AB08 interferon beta-1b 489 321 211 134 95 0.0 0 25 66 <5 5 871 L03AB10 peginterferon alfa-2b 171 71 51 50 40 0.0 0 9 26 5 1 369 L03AB11 peginterferon alfa-2a 550 319 315 214 184 0.0 0 52 99 33 8 338 L03AB13 peginterferon beta-1a <5 11 149 135 100 0.0 0 51 48 <5 6 881 L03AX Other immunostimulants 1 058 789 723 722 761 0.1 0 289 449 23 35 585 L03AX03 BCG vaccine 13 14 13 5 8 0.0 0 0 <5 5 64 L03AX13 glatiramer acetate 1 045 775 710 289 446 18 35 521 L04 IMMUNOSUPPRESSANTS 57 355 61 188 64 946 68 190 71 244 13.4 1 226 18 800 36 434 14 784 2 901 871 L04A IMMUNOSUPPRESSANTS 57 355 61 188 64 946 68 190 71 244 13.4 1 226 18 800 36 434 14 784 2 901 871 L04AA Selective immunosuppressants 8 528 9 551 10 333 10 851 11 856 2.2 143 2 982 6 743 1 988 650 746 L04AA06 mycophenolic acid 4 425 4 668 4 925 5 164 5 375 1.0 110 1 181 3 032 1 052 46 925 L04AA10 sirolimus 215 242 272 295 297 0.1 25 34 179 59 7 824 L04AA13 leflunomide 2 006 2 142 2 225 2 256 2 238 0.4 0 218 1 401 619 12 912 L04AA18 everolimus 474 484 487 481 508 0.1 13 85 278 132 38 669 L04AA23 natalizumab 0 0 0 <5 <5 - 0 0 <5 0 17 L04AA24 abatacept 144 222 258 283 268 0.1 0 42 159 67 19 340 L04AA25 eculizumab 11 17 18 18 18 0.0 0 9 7 <5 68 700 L04AA27 fingolimod 1 110 1 238 1 329 1 411 1 380 0.3 <5 672 699 8 254 382 L04AA28 belatacept 0 0 <5 0 <5 - 0 <5 0 0 19 L04AA29 tofacitinib 0 0 0 87 835 0.2 0 166 494 175 16 931 L04AA31 teriflunomide 638 1 069 1 362 1 427 1 465 0.3 <5 602 833 29 121 182 L04AA32 apremilast 0 9 35 27 15 0.0 0 5 10 0 772 L04AA33 vedolizumab <5 <5 0 0 0 0.0 0 0 0 0 0 L04AA37 baricitinib 0 0 0 28 56 0.0 0 15 30 11 2 562 L04AA40 cladribine 0 0 0 0 182 0.0 0 109 73 0 60 510 L04AB Tumor necrosis factor alpha (TNF-) inhibitors 15 154 15 163 15 647 16 505 16 764 3.2 276 5 874 8 681 1 933 1 151 897 L04AB01 etanercept 5 968 5 551 5 737 7 350 8 196 1.5 159 2 592 4 337 1 108 300 676 L04AB02 infliximab 0 <5 46 L04AB04 adalimumab 5 075 4 699 4 448 4 376 4 430 0.8 120 1 757 2 141 412 445 418 L04AB05 certolizumab pegol 3 024 3 506 4 262 3 646 2 990 0.6 0 1 140 1 542 308 237 619ATC group L ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales golimumab 1 848 1 684 1 514 0.3 <5 561 822 128 168 137 L04AC Interleukin inhibitors 820 1 408 1 848 2 673 3 062 0.6 21 985 1 731 325 286 850 L04AC01 daclizumab 0 0 0 14 5 0.0 0 <5 <5 0 245 L04AC03 anakinra 148 170 189 197 208 0.0 <5 94 83 28 14 342 L04AC05 ustekinumab 555 764 830 814 805 0.2 5 283 461 56 93 276 L04AC07 tocilizumab 112 455 521 608 618 0.1 <5 150 309 157 43 030 L04AC08 canakinumab 11 13 23 24 37 0.0 12 17 7 <5 42 565 L04AC10 secukinumab 0 22 371 1 102 1 430 0.3 0 448 895 87 92 926 L04AC12 brodalumab 0 0 0 0 15 0.0 0 7 6 <5 466 L04AD Calcineurin inhibitors 5 733 5 979 6 203 6 274 6 449 1.2 194 1 584 3 514 1 157 140 186 L04AD01 ciclosporin 3 156 3 156 3 130 2 954 2 893 0.5 81 660 1 513 639 42 238 L04AD02 tacrolimus 2 644 2 889 3 132 3 383 3 628 0.7 117 947 2 044 520 97 949 L04AX Other immunosuppressants 39 190 41 473 43 579 45 478 47 018 8.9 911 10 936 23 589 11 582 672 192 L04AX01 azathioprine 7 650 7 896 8 280 8 280 8 214 1.6 220 3 840 3 277 877 7 566 L04AX02 thalidomide 246 238 200 90 63 0.0 <5 5 24 30 2 099 L04AX03 methotrexate 30 026 31 709 33 357 35 139 36 511 6.9 695 6 596 19 237 9 983 107 478 L04AX04 lenalidomide 308 434 612 810 987 0.2 0 11 440 536 314 566 L04AX05 pirfenidone 58 65 69 78 98 0.0 0 <5 35 62 19 277 L04AX06 pomalidomide 74 99 130 178 191 0.0 0 <5 74 115 89 752 L04AX07 dimethyl fumarate 1 054 1 273 1 235 1 160 1 213 0.2 0 565 630 18 131 454ATC group L ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales MUSCULO-SKELETAL SYSTEM 928 438 942 110 946 467 963 353 954 846 179.8 15 248 318 251 441 641 179 706 495 981 M01 ANTIINFLAMMATORY 834 679 819 425 154.3 13 546 305 114 392 543 108 222 258 480 M01A ANTIINFLAMMATORY AND 154.3 13 112 392 536 108 218 256 790 M01AB Acetic acid derivatives and related substances 391 876 376 889 349 105 341 369 324 883 61.2 4 718 137 343 151 836 30 986 44 743 M01AB01 indometacin 1 232 1 179 1 220 1 282 1 302 0.3 15 519 630 138 1 452 M01AB02 sulindac 0 <5 5 5 <5 - 0 0 <5 <5 8 M01AB05 diclofenac 372 039 357 614 330 952 323 120 307 370 57.9 4 690 133 353 142 352 26 975 35 766 M01AB15 ketorolac 27 20 18 25 48 0.0 0 15 23 10 15 M01AB16 aceclofenac 0 0 <5 <5 <5 - 0 0 <5 0 6 M01AB55 diclofenac, combinations 22 213 21 482 19 774 19 896 18 773 3.5 16 4 322 10 256 4 179 7 496 M01AC Oxicams 48 308 40 897 35 293 31 649 27 443 5.2 91 7 816 15 290 4 246 8 805 M01AC01 piroxicam 36 954 32 479 28 375 25 189 21 552 4.1 84 6 626 12 066 2 776 7 120 M01AC06 meloxicam 11 551 8 740 7 051 6 577 5 991 1.1 7 1 230 3 279 1 475 1 685 M01AE Propionic acid derivatives 373 687 398 840 429 125 448 361 445 727 83.9 8 883 164 723 215 195 56 926 136 087 M01AE01 ibuprofen 224 042 222 341 222 755 230 829 221 288 41.7 7 447 93 013 100 027 20 801 36 978 M01AE02 naproxen 86 217 95 355 105 672 99 739 94 126 17.7 1 343 37 883 42 219 12 681 22 311 M01AE03 ketoprofen 4 975 4 492 4 252 3 766 3 559 0.7 11 788 1 967 793 2 106 M01AE14 dexibuprofen 539 200 30 24 12 0.0 0 <5 8 <5 21 M01AE17 dexketoprofen 11 9 9 17 24 0.0 0 10 11 <5 5 M01AE52 naproxen and esomeprazole 77 488 99 701 123 511 142 741 154 154 29.0 183 42 805 85 662 25 504 74 666 M01AG Fenamates 366 417 454 494 484 0.1 <5 292 17 393 M01AG02 tolfenamic acid 366 417 454 494 484 0.1 <5 292 173 17 393 M01AH Coxibs 92 056 97 949 96 791 101 372 104 773 19.7 120 30 946 56 408 17 299 50 793 M01AH01 celecoxib 15 175 14 873 14 296 14 719 14 942 2.8 18 3 930 7 797 3 14 512 1 M01AH05 etoricoxib 77 854 84 192 83 452 87 661 90 827 17.1 102 27 297 49 159 14 269 36 279 M01AX Other antiinflammatory and antirheumatic agents, non-steroids 32 661 32 466 31 596 30 244 28 000 5.3 <5 1 380 14 134 12 484 15 969 M01AX01 nabumetone 3 177 2 886 2 427 2 175 1 935 0.4 <5 325 1 048 561 1 051 M01AX05 glucosamine 28 822 28 918 28 405 27 221 25 322 4.8 <5 1 022 12 751 11 548 13 105 M01C SPECIFIC ANTIRHEUMATIC AGENTS 77 66 64 49 35 0.0 0 <5 20 12 1 690 M01CB Gold preparations 61 61 59 42 29 0.0 0 <5 16 12 1 652 M01CB01 sodium aurothiomalate 17 19 24 13 11 0.0 0 0 <5 8 63 M01CB03 auranofin 44 42 35 29 18 0.0 0 <5 13 <5 1 5882.13 ATC group M - Musculo-skeletal system ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales Penicillamine and 9 5 5 7 6 0.0 0 <5 <5 0 38 M01CC01 penicillamine 9 5 5 7 6 0.0 0 <5 <5 0 38 M01CX Other specific antirheumatic agents 7 0 0 0 0 0.0 0 0 0 0 0 M02 TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN 64 758 72 651 73 834 77 616 80 805 15.2 1 967 21 743 34 020 23 075 17 224 M02A TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN 64 751 72 643 73 830 77 611 80 800 15.2 1 967 21 742 34 017 23 074 17 223 M02AA Antiinflammatory preparations, non-steroids for topical use 64 683 72 631 73 826 77 607 80 797 15.2 1 966 21 742 34 017 23 072 17 222 M02AA10 ketoprofen 51 400 50 447 48 193 46 996 43 249 8.1 1 085 12 431 18 616 11 117 5 695 M02AA13 ibuprofen 5 790 4 995 4 420 3 930 2 689 0.5 168 797 925 799 602 M02AA15 diclofenac 8 030 18 015 22 059 27 659 35 931 6.8 718 8 739 14 878 11 and similar agents <5 <5 <5 0 0 0 0 0 M02AB01 capsaicin <5 <5 <5 0 0 0.0 0 0 0 0 0 M02AC Preparations with salicylic acid derivatives 73 0 0 0 0 0.0 0 0 0 0 0 M02AX Other topical products for joint and muscular pain 5 8 <5 5 <5 - <5 0 0 <5 1 M02AX10 various 5 8 <5 5 <5 - <5 0 0 <5 1 M03 MUSCLE RELAXANTS 6 869 7 501 8 272 8 991 10 310 1.9 154 3 504 5 341 1 311 63 378 M03B MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS 5 779 5 749 5 868 5 883 6 164 1.2 151 1 362 3 517 1 134 10 116 M03BA Carbamic acid esters 635 588 495 421 401 0.1 0 46 307 48 1 353 M03BA02 carisoprodol 635 588 495 421 401 0.1 0 46 307 48 1 353 M03BB Oxazol, thiazine, and triazine derivatives 20 21 41 44 57 0.0 0 22 24 11 97 M03BB03 chlorzoxazone 20 21 41 44 57 0.0 0 22 24 11 97 M03BX Other centrally acting agents 5 146 5 159 5 347 5 430 5 716 1.1 151 1 294 3 196 1 075 8 666 M03BX01 baclofen 5 080 5 075 5 269 5 357 5 637 1.1 151 1 270 3 149 1 067 8 103 M03BX02 tizanidine 93 107 105 103 108 0.0 0 31 66 11 563 M03C MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS 0 0 0 <5 0 0.0 0 0 0 0 0 M03CA Dantrolene and derivatives 0 0 0 <5 0 0.0 0 0 0 0 0 M03CA01 dantrolene 0 0 0 <5 0 0.0 0 0 0 0 0 M04 ANTIGOUT PREPARATIONS 50 836 53 499 56 374 59 343 61 965 11.7 24 3 974 25 508 32 459 53 326 M04A ANTIGOUT PREPARATIONS 50 836 53 499 56 374 59 343 61 965 11.7 24 3 974 25 508 32 459 53 326 M04AA Preparations inhibiting uric acid production 46 073 48 333 50 525 53 155 55 688 10.5 8 3 224 22 849 29 607 39 182 M04AA01 allopurinol 45 944 48 141 50 261 52 795 55 177 10.4 8 3 169 22 634 29 366 20 444ATC group M ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales 648 0.1 0 75 274 299 18 738 M04AB Preparations increasing uric acid excretion 1 942 1 924 1 878 1 788 1 752 0.3 0 91 691 970 2 512 M04AB01 probenecid 1 942 1 924 1 878 1 788 1 748 0.3 0 89 689 970 2 506 M04AB05 lesinurad 0 0 0 0 <5 - 0 <5 <5 0 6 M04AC Preparations with no effect on uric acid metabolism 6 207 7 054 8 293 9 200 9 575 1.8 16 1 123 4 217 4 219 11 632 M04AC01 colchicine 6 207 7 054 8 293 9 200 9 575 1.8 16 1 123 4 217 4 219 11 632 M05 DRUGS FOR TREATMENT OF BONE DISEASES 61 688 62 023 63 305 64 868 66 175 12.5 <5 678 24 504 40 992 87 429 M05B DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION 61 688 62 023 63 305 64 868 66 175 12.5 <5 678 24 504 40 992 87 429 M05BA Bisphosphonates 57 770 57 321 57 490 57 746 57 407 10.8 <5 626 23 103 33 677 48 590 M05BA02 clodronic acid 13 10 7 <5 0 0.0 0 0 0 0 0 M05BA03 pamidronic acid 16 17 9 5 5 0.0 0 0 <5 <5 18 M05BA04 alendronic acid 53 144 52 364 52 152 51 864 50 714 9.6 0 476 20 022 30 216 25 399 M05BA06 ibandronic acid 658 659 618 597 556 0.1 0 6 230 320 1 680 M05BA07 risedronic acid 481 403 327 309 280 0.1 0 <5 99 178 722 M05BA08 zoledronic acid 3 965 4 345 4 921 5 613 6 475 1.2 <5 154 3 054 3 266 20 772 M05BB Bisphosphonates, combinations <5 0 0 0 0 0.0 0 0 0 0 0 M05BB01 etidronic acid and calcium, sequential <5 0 0 0 0 0.0 0 0 0 0 0 M05BX Other drugs affecting bone structure and mineralization 4 412 5 198 6 410 7 906 9 608 1.8 0 55 1 582 7 971 38 839 M05BX04 denosumab 4 412 5 198 6 410 7 906 9 608 1.8 0 55 1 582 7 971 38 839 M09 OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM 40 60 166 295 120 0.0 <5 5 95 19 16 137 M09A OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM 40 60 166 295 120 0.0 <5 5 95 19 16 137 M09AB Enzymes 40 58 164 292 117 0.0 0 <5 94 19 2 045 M09AB02 collagenase clostridium histolyticum 40 58 164 292 117 0.0 0 <5 94 19 2 045 M09AX Other drugs for disorders of the M ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales 70 Legemiddelstatistikk 2019:2 Folkehelseinstituttet 74N NERVOUS SYSTEM 1 353 896 1 380 464 1 411 698 1 450 416 1 473 116 277.3 33 128 465 180 625 750 349 058 3 168 219 N02 ANALGESICS 818 063 847 882 913 571 176.1 8 653 285 423 415 653 225 842 819 563 N02A OPIOIDS 538 389 550 473 559 406 563 551 560 703 105.6 1 699 178 795 249 739 130 470 468 891 N02AA Natural opium alkaloids 37 640 42 022 48 789 57 193 62 111 11.7 147 10 789 26 896 24 279 108 877 N02AA01 morphine 7 145 7 572 7 951 8 200 8 068 1.5 95 836 3 457 3 680 20 418 N02AA03 hydromorphone 130 127 137 123 60 0.0 0 8 28 24 2 938 N02AA05 oxycodone 30 548 34 405 40 730 48 755 53 411 10.1 54 9 855 23 468 20 034 62 076 N02AA08 dihydrocodeine 45 35 42 37 34 0.0 0 <5 29 <5 250 N02AA51 morphine, combinations 0 0 0 <5 0 0.0 0 0 0 0 0 N02AA55 oxycodone and naloxone 5 037 5 713 6 521 7 246 7 726 1.5 <5 881 2 911 3 932 23 195 N02AB Phenylpiperidine derivatives 12 610 12 732 12 920 12 405 11 975 2.3 10 1 748 4 961 5 256 53 696 N02AB01 ketobemidone 4 342 4 252 4 146 3 604 3 241 0.6 <5 915 1 685 640 2 950 N02AB02 pethidine 1 247 1 180 1 112 948 976 0.2 <5 251 558 166 4 193 N02AB03 fentanyl 7 490 7 753 8 058 8 180 8 036 1.5 8 641 2 870 4 517 46 553 N02AC Diphenylpropylamine derivatives 7 12 0 0 0 0.0 0 0 0 0 0 N02AC04 dextropropoxyphene 7 12 0 0 0 0.0 0 0 0 0 0 N02AD Benzomorphan derivatives 24 20 15 10 10 0.0 0 <5 7 <5 668 N02AD01 pentazocine 24 20 15 10 10 0.0 0 <5 7 <5 668 N02AE Oripavine derivatives 16 731 17 814 18 354 18 403 17 999 3.4 7 1 381 4 701 11 910 52 134 N02AE01 buprenorphine 16 731 17 814 18 354 18 403 17 999 3.4 7 1 381 4 701 11 910 52 134 N02AG Opioids in combination with antispasmodics 1 812 1 766 1 719 1 688 1 546 0.3 0 509 775 262 2 104 N02AG01 morphine and antispasmodics 134 <5 0 0 0 0.0 0 0 0 0 0 N02AG02 ketobemidone and antispasmodics 1 681 1 765 1 719 1 688 1 546 0.3 0 509 775 262 2 104 N02AJ Opioids in combination with non-opioid analgesics 378 124 374 911 369 279 356 278 345 227 65.0 1 203 119 138 153 462 71 424 146 891 N02AJ06 codeine and paracetamol 373 346 367 454 361 371 351 291 339 932 64.0 1 186 117 354 151 170 70 222 144 559 N02AJ07 codeine and acetylsalicylic acid 20 23 20 18 21 0.0 0 <5 13 <5 44 N02AJ13 tramadol and paracetamol 6 826 10 499 10 761 6 698 6 878 1.3 17 2 365 2 924 1 572 2 289 N02AX Other opioids 188 983 204 523 217 509 228 155 229 799 43.3 400 71 906 106 286 51 207 104 521 N02AX02 tramadol 188 470 203 294 215 712 225 070 226 103 42.6 400 71 128 104 373 50 202 87 297 N02AX06 tapentadol 851 2 006 2 822 4 613 5 304 1.0 0 1 191 2 692 1 421 17 224 N02B OTHER ANALGESICS AND ANTIPYRETICS 416 641 446 694 481 088 527 266 562 351 105.9 5 141 130 195 254 641 172 374 138 412 N02BA Salicylic acid and derivatives 1 019 1 074 1 086 1 261 1 195 0.2 213 512 331 139 584 N02BA01 acetylsalicylic acid 1 017 1 071 1 082 1 257 1 191 0.2 213 512 328 138 5372.14 ATC group N - Nervous system ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales <5 0 0.0 0 0 0 0 0 N02BB Pyrazolones 1 031 1 144 1 318 1 550 1 551 0.3 11 776 540 224 492 N02BB02 metamizole sodium 41 41 49 65 59 0.0 0 6 27 26 107 N02BB51 phenazone, combinations excl. psycholeptics 990 1 103 1 269 1 485 1 492 0.3 11 770 513 198 385 N02BE Anilides 414 896 444 981 479 273 525 156 560 287 105.5 4 924 129 244 253 956 172 163 126 930 N02BE01 paracetamol 414 754 444 764 479 030 524 901 559 985 105.4 4 915 129 063 253 880 172 127 126 832 N02BE51 paracetamol, combinations excl. psycholeptics 240 322 355 392 446 0.1 10 244 130 62 98 N02BG Other analgesics and antipyretics 366 344 326 472 541 0.1 <5 130 360 48 10 406 N02BG07 flupirtine <5 <5 0 0 0 0.0 0 0 0 0 0 N02BG09 methoxyflurane 0 0 0 0 <5 - 0 <5 0 0 2 N02BG10 cannabinoids 365 340 326 472 540 0.1 <5 129 360 48 10 405 N02C ANTIMIGRAINE PREPARATIONS 101 231 105 206 107 882 115 514 119 333 22.5 2 546 57 282 53 642 5 863 212 260 N02CA Ergot alkaloids 454 373 292 246 59 21 104 N02CA52 ergotamine, combinations excl. psycholeptics 8 9 7 7 35 0.0 0 <5 19 14 82 N02CA72 ergotamine, combinations with psycholeptics 446 366 287 240 31 0.0 0 <5 19 10 22 N02CC Selective serotonin (5HT1) agonists 97 102 101 029 103 715 111 321 114 869 21.6 2 468 56 144 50 862 5 395 201 168 N02CC01 sumatriptan 50 676 52 591 51 695 58 093 59 989 11.3 2 072 32 457 22 986 2 474 90 769 N02CC02 naratriptan 1 941 2 109 2 242 2 485 2 847 0.5 8 1 377 1 338 124 7 391 N02CC03 zolmitriptan 15 840 16 229 20 268 19 321 19 236 3.6 325 8 705 9 226 980 43 367 N02CC04 rizatriptan 26 829 27 936 30 355 31 217 32 744 6.2 288 16 475 14 610 1 371 31 488 N02CC05 almotriptan 3 056 2 889 2 916 2 934 3 022 0.6 5 1 371 1 508 138 6 245 N02CC06 eletriptan 11 871 12 332 12 796 13 275 13 650 2.6 38 5 837 7 142 633 21 612 N02CC07 frovatriptan 20 180 223 192 <5 149 76 <5 297 N02CX Other antimigraine preparations 4 524 4 622 4 762 4 844 5 722 1.1 84 1 628 3 509 501 10 988 N02CX01 pizotifen 62 58 50 45 35 0.0 0 8 22 5 121 N02CX02 clonidine 4 463 4 567 4 714 4 802 5 308 1.0 82 1 423 3 322 481 3 671 N02CX07 erenumab 0 0 0 0 399 0.1 <5 204 177 16 7 196 N03 ANTIEPILEPTICS 118 788 122 561 127 262 131 955 136 190 25.6 3 650 38 977 62 574 30 989 467 840 N03A ANTIEPILEPTICS 118 788 122 561 127 262 131 955 136 190 25.6 3 650 38 977 62 574 30 989 467 840 N03AA Barbiturates and derivatives 2 246 2 175 2 087 2 006 1 901 0.4 52 176 933 740 4 451 N03AA02 phenobarbital 1 920 1 829 1 744 1 630 1 519 0.3 51 126 780 562 3 480ATC group N ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales 51 155 184 971 N03AB Hydantoin derivatives 1 541 1 436 1 281 1 118 1 022 0.2 19 112 516 375 2 223 N03AB02 phenytoin 1 541 1 436 1 281 1 118 1 022 0.2 19 112 516 375 2 223 N03AB05 fosphenytoin <5 <5 0 0 0 0.0 0 0 0 0 0 N03AD Succinimide derivatives 227 224 266 289 294 0.1 148 122 20 <5 3 366 N03AD01 ethosuximide 227 224 266 289 294 0.1 148 122 20 <5 3 366 N03AE Benzodiazepine derivatives 10 909 9 856 8 702 7 198 6 416 1.2 136 1 387 3 254 1 639 3 619 N03AE01 clonazepam 10 909 9 856 8 702 7 198 6 416 1.2 136 1 387 3 254 1 639 3 619 N03AF Carboxamide derivatives 16 205 15 671 15 310 14 894 14 432 2.7 730 3 563 7 082 3 057 42 961 N03AF01 carbamazepine 13 396 12 723 12 256 11 495 10 461 2.0 143 2 153 5 682 2 483 11 758 N03AF02 oxcarbazepine 2 518 2 635 2 703 2 968 3 387 0.6 579 1 054 1 220 534 12 030 N03AF03 rufinamide 98 96 94 90 83 0.0 19 49 14 <5 2 227 N03AF04 eslicarbazepine 332 383 461 590 783 0.2 9 406 286 82 16 946 N03AG Fatty acid derivatives 15 285 15 211 15 249 15 197 15 072 2.8 1 463 5 634 6 247 1 728 51 048 N03AG01 valproic acid 15 200 15 137 15 167 15 118 15 014 2.8 1 443 5 622 6 226 1 723 50 340 N03AG03 aminobutyric acid 20 8 16 14 8 0.0 0 <5 5 0 11 N03AG04 vigabatrin 90 85 85 87 78 0.0 40 16 17 5 536 N03AG06 tiagabine 9 9 9 9 7 0.0 0 <5 <5 <5 161 N03AX Other antiepileptics 85 807 91 243 97 526 104 042 109 602 20.6 2 198 32 332 49 865 25 207 360 173 N03AX03 sultiame 239 238 277 323 343 0.1 264 77 <5 0 3 090 N03AX09 lamotrigine 27 569 28 531 29 235 30 145 30 746 5.8 917 14 093 12 209 3 527 112 569 N03AX10 felbamate 17 22 18 19 21 0.0 <5 13 5 <5 428 N03AX11 topiramate 3 649 3 954 4 174 4 617 4 814 0.9 198 2 580 1 830 206 12 648 N03AX12 gabapentin 32 203 35 539 39 417 42 711 46 051 8.7 138 9 207 23 037 13 669 71 260 N03AX14 levetiracetam 7 934 8 529 9 244 9 761 10 306 1.9 895 3 356 3 614 2 441 49 032 N03AX15 zonisamide 633 638 639 623 611 0.1 53 320 187 51 8 892 N03AX16 pregabalin 20 230 20 712 21 852 23 571 24 468 4.6 18 5 317 12 329 6 804 77 522 N03AX17 stiripentol 25 27 30 33 34 0.0 17 17 0 0 2 602 N03AX18 lacosamide 500 555 625 703 770 0.1 53 370 271 76 11 194 N03AX21 retigabine 36 20 17 <5 <5 - 0 <5 0 0 13 N03AX22 perampanel 220 254 303 360 361 0.1 22 193 118 28 5 535 N03AX23 brivaracetam 0 0 89 201 289 0.1 10 168 92 19 5 387 N04 ANTI-PARKINSON DRUGS 20 072 20 745 21 511 22 269 23 072 4.3 37 1 690 9 299 12 046 156 713 N04A ANTICHOLINERGIC AGENTS 2 348 2 252 2 119 2 071 1 990 0.4 20 413 1 235 322 1 495 N04AA Tertiary amines 2 322 2 236 2 103 2 055 1 979 0.4 20 413 1 226 320 1 474 N04AA01 trihexyphenidyl 41 44 52 54 39 0.0 17 9 10 <5 253 N04AA02 biperiden 2 279 2 189 2 049 2 000 1 939 0.4 <5 404 1 215 317 1 220ATC group N ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales N04AB Ethers chemically close to antihistamines 32 17 17 17 11 0.0 0 0 9 <5 21 N04AB02 orphenadrine (chloride) 32 17 17 17 11 0.0 0 0 9 <5 21 N04B DOPAMINERGIC AGENTS 17 785 18 546 19 443 20 262 21 150 4.0 18 1 280 8 090 11 762 155 218 N04BA Dopa and dopa derivatives 9 033 9 331 9 663 10 093 10 586 2.0 15 132 2 938 7 501 99 361 N04BA02 levodopa and decarboxylase inhibitor 8 339 8 701 9 055 9 513 10 003 1.9 15 129 2 736 7 123 85 877 N04BA03 levodopa, decarboxylase inhibitor and inhibitor 1 391 1 350 1 392 1 387 1 380 0.3 0 8 529 843 13 484 N04BB Adamantane derivatives 158 166 191 207 178 0.0 <5 38 97 42 716 N04BB01 amantadine 158 166 191 207 178 0.0 <5 38 97 42 716 N04BC Dopamine agonists 11 676 12 154 12 849 13 281 13 773 2.6 <5 1 147 6 467 18 N04BC04 ropinirole 2 869 2 930 2 957 2 923 2 914 0.6 0 152 1 385 1 377 13 557 N04BC05 pramipexole 8 469 8 906 9 577 10 013 10 581 2.0 <5 987 4 994 4 598 15 216 N04BC06 cabergoline 109 88 91 80 61 0.0 0 5 27 29 108 N04BC07 apomorphine 26 30 45 62 60 0.0 0 0 29 31 3 557 N04BC09 rotigotine 560 533 537 552 521 218 271 6 102 N04BD Monoamine oxidase B inhibitors 3 868 4 011 4 134 4 304 4 302 0.8 0 47 1 858 2 397 15 264 N04BD01 selegiline 2 257 2 318 2 400 2 439 2 465 0.5 0 26 1 078 1 361 4 273 N04BD02 rasagiline 1 648 1 739 1 778 1 887 1 807 0.3 0 21 777 1 009 9 890 N04BD03 safinamide 0 0 10 101 86 0.0 0 0 36 50 1 102 N04BX Other dopaminergic agents 111 105 127 142 157 0.0 0 0 61 96 1 319 N04BX01 tolcapone 6 8 9 8 6 0.0 0 0 <5 <5 247 N04BX02 entacapone 105 98 118 134 151 0.0 0 0 57 94 1 072 N05 PSYCHOLEPTICS 630 363 631 424 638 090 645 060 647 068 121.8 14 320 158 342 273 027 201 379 684 161 N05A ANTIPSYCHOTICS 109 198 113 430 118 840 124 611 129 459 24.4 1 097 48 737 56 801 22 824 320 172 N05AA Phenothiazines with aliphatic side-chain 18 907 17 572 16 472 15 331 13 921 2.6 9 3 280 7 357 3 275 5 529 N05AA01 chlorpromazine 201 167 168 202 202 0.0 0 123 57 22 507 N05AA02 levomepromazine 18 724 17 418 16 313 15 135 13 727 2.6 9 3 160 7 304 3 254 5 022 N05AB Phenothiazines with piperazine structure 11 104 10 514 9 382 9 108 8 690 1.6 13 1 979 3 636 3 062 7 617 N05AB02 fluphenazine 17 17 14 9 7 0.0 0 0 <5 <5 26 N05AB03 perphenazine 1 758 1 707 1 659 1 577 1 507 0.3 0 233 952 322 6 064 N05AB04 prochlorperazine 9 346 8 803 7 715 7 529 7 185 1.4 13 1 750 2 683 2 739 1 527 N05AB06 trifluoperazine <5 <5 0 <5 0 0.0 0 0 0 0 0ATC group N ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales 46 44 38 35 31 0.0 0 <5 14 94 N05AC01 3 N05AC02 thioridazine 43 41 36 33 30 0.0 0 14 92 N05AC04 pipotiazine <5 <5 <5 0.0 0 0 0 0 0 N05AD Butyrophenone derivatives 4 030 3 878 3 998 3 835 3 628 0.7 5 264 1 250 2 109 1 176 N05AD01 haloperidol 4 023 3 871 3 987 3 822 3 608 0.7 5 262 1 245 2 096 1 149 N05AD03 melperone 6 7 11 11 18 0.0 24 N05AD08 4 N05AE Indole derivatives 870 963 1 013 1 006 1 091 0.2 <5 549 478 62 9 075 N05AE03 sertindole 100 110 96 79 72 0.0 0 23 45 <5 817 N05AE04 ziprasidone 766 677 639 586 550 0.1 <5 193 309 47 4 010 N05AE05 lurasidone 5 189 291 347 476 0.1 <5 337 127 11 4 247 N05AF Thioxanthene derivatives 21 600 20 893 20 308 19 329 17 745 3.3 12 5 696 8 810 3 227 13 889 N05AF01 flupentixol 4 185 3 902 3 744 3 486 3 171 0.6 0 757 1 546 868 2 701 N05AF03 chlorprothixene 15 115 14 811 14 499 13 822 12 619 2.4 12 4 530 6 063 2 014 8 308 N05AF05 zuclopenthixol 2 914 2 729 2 561 2 470 2 314 0.4 0 522 1 408 384 2 880 N05AG Diphenylbutylpiperidine derivatives 114 112 112 104 101 0.0 0 43 44 14 342 N05AG01 fluspirilene 0 <5 <5 <5 0 0.0 0 0 0 0 0 N05AG02 pimozide 114 111 109 101 97 0.0 0 43 41 13 309 N05AG03 penfluridol 0 0 <5 and oxepines 50 56 873 64 650 72 723 80 292 15.1 145 35 545 34 747 9 855 151 437 N05AH01 loxapine 0 <5 0 0 0 0.0 0 0 0 0 0 N05AH02 clozapine 2 571 2 576 2 610 2 651 2 700 0.5 0 1 078 1 469 153 9 679 N05AH03 olanzapine 16 701 16 920 16 990 17 421 17 673 3.3 41 6 595 8 158 2 879 53 863 N05AH04 quetiapine 33 528 39 948 47 818 55 638 63 125 11.9 106 29 476 26 431 7 112 87 886 N05AH05 asenapine 50 28 29 29 <5 - 0 <5 0 0 9 N05AL Benzamides 600 657 608 629 641 0.1 0 290 324 27 4 139 N05AL01 sulpiride 0 0 0 <5 <5 - 597 650 604 624 637 0.1 0 288 322 27 4 113 N05AN Lithium 7 559 7 580 7 570 7 628 7 639 1.4 0 2 287 3 964 1 388 17 025 N05AN01 lithium 7 559 7 580 7 570 7 628 7 639 1.4 0 2 287 3 964 1 388 17 025 N05AX Other antipsychotics 14 019 14 345 14 612 14 943 14 999 2.8 960 6 610 5 322 2 107 109 849 N05AX07 prothipendyl <5 <5 <5 <5 0 0.0 0 0 0 0 0 N05AX08 risperidone 8 329 8 264 8 305 8 141 8 040 1.5 821 2 751 2 727 1 741 26 125 N05AX12 aripiprazole 5 399 5 731 5 910 6 375 6 530 1.2 192 3 669 2 323 346 45 457ATC group N ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales paliperidone 832 860 887 936 973 0.2 0 530 407 36 38 267 N05B ANXIOLYTICS 267 746 262 535 258 101 252 789 247 153 46.5 2 520 58 022 109 820 76 791 107 313 N05BA Benzodiazepine derivatives 241 318 236 275 233 577 229 065 223 638 42.1 2 201 49 046 100 499 71 892 95 724 N05BA01 diazepam 116 561 109 998 105 594 100 854 95 870 18.1 1 897 21 236 43 437 29 300 40 633 3 N05BA04 oxazepam 134 599 135 729 137 340 136 950 135 934 25.6 78 30 046 60 807 45 003 49 065 N05BA06 lorazepam 54 70 98 142 148 0.0 <5 51 77 19 445 N05BA08 bromazepam 6 7 7 11 N05BA09 clobazam 752 779 836 896 329 416 177 14 2 688 N05BA12 alprazolam 3 535 3 206 2 895 2 587 2 409 0.5 0 886 1 201 322 2 878 N05BB Diphenylmethane derivatives 34 711 34 044 31 107 29 716 29 178 5.5 326 10 638 11 977 6 237 7 871 N05BB01 hydroxyzine 34 711 34 044 31 107 29 716 29 178 5.5 326 10 638 11 977 6 237 7 871 N05BE Azaspirodecanedione derivatives 2 230 2 273 2 248 2 119 2 053 0.4 0 758 903 392 3 717 N05BE01 buspirone 2 230 2 273 2 248 2 119 2 053 0.4 0 758 903 392 3 717 N05C HYPNOTICS AND SEDATIVES 423 732 424 789 431 014 435 943 437 472 82.4 11 998 91 108 181 336 153 030 256 677 N05CA Barbiturates, plain <5 0 0 0 0 0.0 0 0 0 0 0 N05CA04 barbital <5 0 0 0 0 0.0 0 0 0 0 0 N05CC Aldehydes and derivatives 6 10 7 13 12 0.0 <5 6 <5 <5 73 N05CC01 chloral hydrate <5 6 <5 <5 73 N05CD Benzodiazepine derivatives 28 276 27 282 26 877 26 433 25 703 4.8 2 831 5 334 9 176 8 362 32 305 N05CD01 flurazepam 17 15 11 9 8 0.0 0 0 <5 6 25 N05CD02 nitrazepam 23 303 21 518 20 328 19 139 17 915 3.4 305 3 103 7 630 6 877 10 946 N05CD03 flunitrazepam 1 119 961 790 645 559 0.1 <5 103 277 178 1 468 N05CD05 triazolam 74 67 62 49 49 0.0 0 8 20 21 123 N05CD08 midazolam 4 255 5 220 6 217 7 125 7 702 1.5 2 745 2 291 1 327 1 339 19 743 N05CF Benzodiazepine related drugs 358 302 354 753 355 844 350 093 345 210 65.0 43 52 358 154 033 138 776 137 547 N05CF01 zopiclone 304 071 298 583 296 755 290 210 283 705 53.4 34 38 955 125 133 119 583 111 807 N05CF02 zolpidem 65 751 67 382 70 628 70 841 72 357 13.6 10 15 833 33 650 22 864 25 740 N05CH Melatonin receptor agonists 68 793 76 032 82 748 94 753 101 659 19.1 9 585 42 806 34 102 15 166 83 786 N05CH01 melatonin 68 793 76 032 82 748 94 753 101 659 19.1 9 585 42 806 34 102 15 166 83 786 N05CM Other hypnotics and sedatives 2 150 2 145 2 122 1 961 1 948 0.4 <5 148 483 1 316 2 965 N05CM02 clomethiazole 1 939 1 971 1 945 1 835 1 824 0.3 0 115 429 1 280 2 826 N05CM05 scopolamine 110 61 65 41 25 0.0 0 <5 <5 22 42 N05CM06 propiomazine 100 108 105 77 97 0.0 0 32 52 13 96 N05CM09 Valerianae radix 5 5 9 9 <5 - 0 0 0 <5 0ATC group N ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales 0 0 1 N06 PSYCHOANALEPTICS 359 882 367 511 376 408 382 158 385 557 72.6 12 161 133 612 155 582 84 202 735 595 N06A ANTIDEPRESSANTS 317 158 322 941 329 608 332 397 333 229 62.7 616 108 705 149 779 74 129 309 943 N06AA Non-selective monoamine reuptake inhibitors 67 286 68 350 69 403 70 267 71 207 13.4 77 18 731 37 464 14 935 30 013 N06AA02 imipramine 16 16 16 13 10 0.0 0 <5 5 <5 34 N06AA04 clomipramine 2 488 2 342 2 216 2 122 1 953 0.4 <5 305 1 031 614 1 698 N06AA05 opipramol 9 7 8 7 8 0.0 0 <5 <5 <5 17 N06AA06 trimipramine 9 406 8 837 8 128 7 521 7 105 1.3 <5 1 205 3 334 2 564 5 157 N06AA07 lofepramine 6 6 5 5 6 0.0 0 <5 <5 <5 29 N06AA09 amitriptyline 51 933 53 891 55 869 57 811 59 416 11.2 69 16 691 32 024 10 632 20 845 N06AA10 nortriptyline 2 178 2 192 2 251 2 143 2 422 0.5 5 730 1 107 580 1 313 N06AA12 doxepin 2 016 1 846 1 641 1 454 1 133 0.2 0 77 362 694 921 N06AA21 maprotiline <5 0 0 0 0 0.0 0 0 0 0 0 N06AB Selective serotonin reup - take inhibitors 185 867 186 025 186 321 183 597 180 025 33.9 516 66 061 76 179 37 269 124 764 N06AB03 fluoxetine 11 117 12 142 12 232 12 055 11 817 2.2 125 7 000 3 908 784 16 197 N06AB04 citalopram 23 517 22 312 20 210 18 571 17 008 3.2 0 3 302 8 602 5 104 9 759 N06AB05 paroxetine 14 246 13 797 13 122 12 510 12 050 2.3 0 2 241 6 354 3 455 10 596 N06AB06 sertraline 30 840 30 095 32 444 34 076 35 157 6.6 377 15 677 13 106 5 997 33 977 N06AB08 fluvoxamine 543 554 542 505 488 0.1 <5 176 237 74 882 N06AB10 escitalopram 110 767 113 703 112 762 110 559 107 723 20.3 29 39 763 45 387 22 Monoamine oxidase inhibi - tors, non-selective 89 88 89 93 97 0.0 0 24 47 26 1 427 N06AF01 isocarboxazid 0 <5 <5 <5 0 0.0 0 0 0 0 0 N06AF03 phenelzine 83 83 85 88 89 0.0 0 20 43 26 650 N06AF04 tranylcypromine 7 6 <5 8 9 0.0 0 <5 5 0 777 N06AG Monoamine oxidase A inhibitors 707 721 668 634 569 0.1 0 143 269 157 1 349 N06AG02 moclobemide 707 721 668 634 569 0.1 0 143 269 157 1 349 N06AX Other antidepressants 103 291 107 779 112 616 115 819 118 415 22.3 33 35 423 52 312 30 647 152 389 N06AX01 oxitriptan 280 203 95 90 78 0.0 <5 31 36 8 155 N06AX02 tryptophan 18 9 32 17 18 0.0 0 <5 12 <5 22 N06AX03 mianserin 26 388 25 419 24 219 23 176 22 033 4.2 5 4 526 10 317 7 185 10 954 N06AX05 trazodone 17 19 18 24 16 0.0 0 7 8 <5 43 N06AX06 nefazodone 30 31 28 26 25 0.0 0 <5 21 <5 390 N06AX11 mirtazapine 38 608 40 915 43 265 45 123 46 334 8.7 15 11 479 18 005 16 835 42 317 N06AX12 bupropion 11 691 12 123 12 100 11 958 11 934 2.3 <5 5 636 5 308 989 26 291 N06AX14 tianeptine 0 7 6 9 10 0.0 0 6 <5 0 156ATC group N ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales venlafaxine 31 307 32 625 32 903 32 906 32 734 6.2 8 10 785 15 720 6 221 27 818 N06AX18 reboxetine 338 329 286 263 262 0.1 0 95 142 25 534 N06AX21 duloxetine 3 958 4 664 5 361 6 119 7 206 1.4 0 2 232 3 867 1 107 18 234 N06AX22 agomelatine 17 12 19 16 13 0.0 0 7 <5 <5 191 N06AX26 vortioxetine 25 1 381 5 041 7 126 8 703 1.6 <5 3 970 3 808 924 25 284 N06B PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS 37 098 39 627 42 365 45 899 48 609 9.2 11 694 30 052 6 641 222 377 163 N06BA Centrally acting sympathomimetics 36 710 39 231 41 988 45 520 48 281 9.1 11 692 29 896 6 525 168 369 845 N06BA01 amfetamine 419 378 315 348 327 0.1 <5 189 122 15 15 695 N06BA02 dexamfetamine 1 886 2 009 2 282 2 589 2 861 0.5 192 1 814 828 27 53 958 N06BA04 methylphenidate 32 335 34 062 35 618 37 698 38 784 7.3 9 986 23 926 4 780 92 184 114 N06BA07 modafinil 486 548 582 678 704 0.1 9 444 220 31 7 795 N06BA09 atomoxetine 3 635 3 630 3 669 3 707 3 621 0.7 1 253 2 082 284 <5 33 357 N06BA12 lisdexamfetamine 388 2 115 3 908 5 884 8 217 1.6 2 225 5 026 960 6 74 925 N06BC Xanthine derivatives 311 321 304 300 269 0.1 <5 130 96 42 204 N06BC01 caffeine 311 321 304 300 269 0.1 <5 130 96 42 204 N06BX Other psychostimulants and nootropics 89 93 92 98 78 0.0 <5 40 25 12 7 113 N06BX03 piracetam 73 72 75 81 64 0.0 0 28 24 12 293 N06BX13 idebenone 16 21 17 17 14 0.0 <5 12 <5 0 6 820 N06C PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION 0 0 <5 0 <5 - 0 0 <5 0 1 N06CA Antidepressants in combination with psycholeptics 0 0 <5 0 <5 - 0 0 <5 0 1 N06CA02 melitracen and psycholeptics 0 0 <5 <5 - 0 0 <5 0 1 N06D ANTI-DEMENTIA DRUGS 15 427 15 170 15 233 15 281 15 356 2.9 <5 10 1 614 13 731 48 488 N06DA Anticholinesterases 12 805 12 597 12 572 12 630 12 729 2.4 0 5 1 394 11 330 38 657 N06DA02 donepezil 7 701 7 479 7 360 7 449 7 546 1.4 0 <5 834 6 711 19 589 N06DA03 rivastigmine 5 212 5 239 5 344 5 380 5 404 1.0 0 <5 617 4 783 18 006 N06DA04 galantamine 257 224 193 172 139 0.0 0 0 15 124 1 063 N06DX Other anti-dementia drugs 3 729 3 646 3 821 3 818 3 685 0.7 <5 5 430 3 249 9 831 N06DX01 memantine 3 729 3 646 3 821 3 818 3 685 0.7 <5 5 430 3 249 9 831 N07 OTHER NERVOUS SYSTEM DRUGS 44 934 41 860 40 271 38 745 37 137 7.0 37 10 823 22 561 3 716 286 130 N07A PARASYMPATHOMIMETICS 784 781 837 874 928 0.2 8 166 371 383 4 933 N07AA Anticholinesterases 619 621 692 737 770 0.1 8 155 291 316 3 163 N07AA01 neostigmine 0 0 0 <5 0 0.0 0 0 0 0 0ATC group N ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales 688 733 767 3 147 0 0 0 0 0 0 N07AB Choline esters 32 21 9 0 0 0.0 0 0 0 0 0 N07AB01 carbachol 32 21 9 0 0 0.0 0 0 0 0 0 N07AX Other parasympathomimetics 134 140 139 137 158 0.0 0 11 80 67 1 769 N07AX01 pilocarpine 134 140 135 130 152 0.0 0 11 76 65 1 033 N07AX03 cevimeline 0 0 <5 7 6 0.0 0 0 <5 <5 736 N07B DRUGS USED IN ADDICTIVE DISORDERS 41 853 38 602 36 830 35 133 33 381 6.3 13 10 198 20 466 2 704 215 774 N07BA Drugs used in nicotine dependence 17 794 17 104 16 961 16 000 14 701 2.8 <5 3 305 9 708 1 686 24 433 N07BA01 nicotine 931 993 1 191 1 168 1 284 0.2 <5 143 719 420 992 N07BA03 varenicline 16 911 16 175 15 833 14 902 13 506 2.5 0 3 175 9 048 1 283 23 441 N07BB Drugs used in alcohol dependence 16 397 13 682 12 143 11 498 11 158 2.1 10 3 537 6 675 936 12 995 N07BB01 disulfiram 4 233 4 225 4 247 4 146 4 003 0.8 0 1 251 2 415 337 2 619 N07BB03 acamprosate 469 465 472 435 384 0.1 0 120 237 27 725 N07BB04 naltrexone 10 488 8 189 6 840 6 483 6 407 1.2 10 2 057 3 807 533 8 965 N07BB05 nalmefene 1 615 1 162 921 695 583 0.1 0 192 344 47 687 N07BC Drugs used in opioid dependence 8 017 8 117 8 010 7 933 7 791 1.5 <5 3 431 4 271 88 178 346 N07BC01 buprenorphine 2 894 3 037 3 168 3 321 3 485 0.7 0 1 819 1 658 8 63 815 N07BC02 methadone 3 604 3 548 3 424 3 346 3 295 0.6 <5 1 037 2 179 78 85 937 N07BC05 levomethadone <5 6 14 16 16 0.0 0 <5 1 421 N07BC51 buprenorphine, combina - tions 2 265 2 198 2 018 1 774 1 455 0.3 0 851 602 <5 27 172 N07C ANTIVERTIGO PREPARATIONS 682 708 732 719 704 0.1 <5 156 368 177 1 661 N07CA Antivertigo preparations 682 708 732 719 704 0.1 649 674 698 673 176 1 576 N07CA03 flunarizine 33 34 34 44 48 0.0 <5 25 19 <5 80 N07CA52 cinnarizine, combinations 0 0 0 <5 6 0.0 0 <5 <5 0 5 N07X OTHER NERVOUS SYSTEM DRUGS 2 076 2 153 2 210 2 300 2 388 0.5 14 323 1 559 492 63 762 N07XX Other nervous system drugs 2 076 2 153 2 210 2 300 2 388 0.5 14 323 1 559 492 63 762 N07XX02 riluzole 290 301 336 353 359 0.1 0 15 194 150 4 321 N07XX04 sodium oxybate 96 103 116 142 141 0.0 10 100 28 <5 12 639 N07XX05 amifampridine 7 11 14 8 13 0.0 <5 <5 7 <5 4 172 N07XX06 tetrabenazine 52 48 41 44 57 0.0 <5 11 25 18 725ATC group N ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales 1 690 1 703 1 751 1 796 0.3 0 184 1 297 315 37 093 N07XX08 tafamidis 0 0 0 0 <5 - 0 0 0 <5 1 262 N07XX11 pitolisant 0 0 0 6 29 0.0 <5 20 6 <5 2 126 N07XX59 dextromethorphan, combinations 0 0 0 8 9 0.0 0 <5 8 0 1 422ATC group N ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales REPELLENTS 97 581 94 700 93 310 93 329 94 332 17.8 4 509 41 622 35 657 12 544 30 006 P01 ANTIPROTOZOALS 92 914 89 211 87 278 86 800 87 630 16.5 2 865 37 875 34 643 12 247 24 757 P01A AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES 59 261 57 467 55 655 53 658 52 535 9.9 686 20 939 21 502 9 408 6 434 P01AB Nitroimidazole derivatives 59 259 57 467 55 655 53 655 52 529 9.9 685 20 938 21 499 9 407 6 278 P01AB01 metronidazole 59 238 57 451 55 641 53 649 52 508 9.9 685 20 930 21 488 9 405 6 181 P01AB02 tinidazole 27 22 26 16 27 0.0 <5 <5 19 P01AB03 ornidazole 0 <5 <5 0 77 P01AC Dichloroacetamide derivatives 5 0 0 0 0 0.0 0 0 0 0 0 P01AC01 diloxanide 5 0 0 0 0 0.0 0 0 0 0 0 P01AX Other agents against amoebiasis and other protozoal diseases 0 0 0 <5 <5 156 0 <5 0 40 P01AX06 88 P01AX11 0 0 <5 - 0 0 <5 0 27 P01B ANTIMALARIALS 34 230 32 306 32 165 33 624 35 594 6.7 2 183 17 165 13 349 2 897 18 267 P01BA Aminoquinolines 6 041 6 216 6 288 6 280 6 298 1.2 38 1 662 3 343 1 255 4 031 P01BA01 chloroquine 13 12 11 11 9 0.0 0 <5 5 <5 15 P01BA02 hydroxychloroquine 6 020 6 199 6 258 6 260 6 279 1.2 38 1 658 3 331 1 252 4 000 P01BA03 primaquine 9 11 22 10 10 0.0 0 <5 7 <5 16 P01BB Biguanides 25 262 23 467 23 563 25 145 27 088 5.1 1 833 14 579 9 267 1 409 13 149 P01BB01 proguanil <5 <5 0 <5 0 0.0 0 0 0 0 0 P01BB51 proguanil, combinations 25 260 23 465 23 563 25 144 27 088 5.1 1 833 14 579 9 267 1 409 13 149 P01BC Methanolquinolines 3 086 2 769 2 436 2 323 2 336 0.4 319 989 786 242 1 072 P01BC01 quinine 350 368 331 286 253 0.1 0 14 89 150 268 P01BC02 mefloquine 2 737 2 401 2 105 2 037 2 083 0.4 319 975 1 P01BE Artemisinin and derivatives, plain 0 <5 0 0 0 0.0 0 0 0 0 0 P01BE03 artesunate 0 <5 0 0 0 0.0 0 0 0 0 0 P01BF Artemisinin and derivatives, combinations 5 <5 6 13 16 0.0 0 10 6 0 16 P01BF01 artemether and lumefantrine 5 <5 6 13 16 0.0 0 10 6 0 162.15 ATC group P - Antiparasitic products, insecticides and repellents ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales P01CX Other trypanoso - 55 P02 ANTHELMINTICS 2 775 2 960 3 066 3 231 3 438 0.7 1 289 1 550 467 132 2 531 P02B ANTITREMATODALS 52 66 65 56 63 0.0 8 48 7 0 125 P02BA Quinoline derivatives and related substances 52 66 65 56 63 0.0 8 48 7 0 125 P02BA01 praziquantel 52 66 65 56 63 0.0 8 48 7 0 125 P02C ANTINEMATODAL AGENTS 2 713 2 894 2 991 3 167 3 370 0.6 1 281 1 499 459 131 2 396 P02CA Benzimidazole derivatives 2 432 2 612 2 626 2 696 2 457 0.5 1 190 843 327 97 1 048 P02CA01 mebendazole 2 272 2 277 2 261 2 294 2 065 0.4 1 021 676 281 87 479 P02CA03 albendazole 172 345 376 415 405 0.1 174 171 48 12 569 P02CF Avermectines 125 124 217 324 769 0.1 25 593 124 27 1 322 P02CF01 ivermectin 125 124 217 324 769 0.1 25 593 124 27 1 322 P02CX Other antinematodals 176 186 174 177 167 0.0 74 72 13 8 27 P02CX01 pyrvinium 176 186 174 177 167 0.0 74 72 13 8 27 P02D ANTICESTODALS 20 10 22 22 16 0.0 5 8 <5 <5 9 P02DA Salicylic acid derivatives 20 10 22 22 16 0.0 5 8 <5 <5 9 P02DA01 niclosamide 20 10 22 22 8 <5 9 P03 ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS 2 157 2 779 3 211 3 561 3 681 0.7 376 2 494 624 187 2 719 P03A ECTOPARASITICIDES, INCL. SCABICIDES 2 157 2 779 3 211 3 561 3 681 0.7 376 2 494 624 187 2 719 P03AC Pyrethrines, incl. synthetic compounds 2 092 2 706 3 148 3 507 3 622 0.7 371 2 452 613 186 2 676 P03AC04 permethrin 2 092 2 706 3 148 3 507 3 622 0.7 371 2 452 613 186 2 676 P03AX Other ectoparasiticides, incl. scabicides 72 87 69 71 0.0 6 53 13 <5 42 P03AX01 benzyl benzoate 32 36 37 44 73 0.0 6 53 13 <5 42 P03AX03 malathion 41 51 32 27 0 0.0 0 0 0 0 0ATC group P ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales 70 Legemiddelstatistikk RESPIRATORY SYSTEM 1 259 843 1 296 996 1 330 147 1 374 981 1 397 861 263.2 159 019 507 225 508 602 223 015 1 779 464 R01 NASAL PREPARATIONS 405 387 416 923 428 436 460 559 470 847 88.6 39 071 212 624 170 655 AND OTHER NASAL PREPARA - TIONS FOR TOPICAL USE 349 590 357 048 366 599 395 123 405 551 76.4 37 534 178 401 145 406 44 210 143 119 R01AA Sympathomimetics, plain 3 606 3 691 3 702 3 300 3 983 0.8 1 408 1 356 844 375 437 R01AA05 oxymetazoline 2 000 2 101 2 047 1 563 2 241 0.4 1 115 628 376 122 268 R01AA07 xylometazoline 1 618 1 596 1 671 1 745 1 746 0.3 296 728 469 253 169 R01AB Sympathomimetics, combi - nations excl. corticosteroids 427 495 480 435 382 0.1 7 162 142 71 33 R01AB06 xylometazoline 427 495 480 435 382 0.1 7 162 142 71 33 R01AC Antiallergic agents, excl. corticosteroids 47 317 42 319 42 169 46 164 45 902 8.6 12 880 20 164 10 521 2 337 12 153 R01AC01 cromoglicic acid 8 651 7 724 7 457 7 607 4 927 0.9 1 132 1 910 1 514 371 1 093 R01AC02 levocabastine 38 754 34 707 34 878 38 774 41 371 7.8 11 864 18 361 9 135 2 011 11 060 R01AC03 azelastine 214 101 0 0 0 0.0 0 0 0 0 0 R01AD Corticosteroids 305 163 316 586 325 942 351 612 361 610 68.1 24 728 159 599 135 668 41 615 129 329 R01AD04 flunisolide 12 12 12 12 11 0.0 0 0 8 <5 25 R01AD05 budesonide 28 577 26 320 25 023 25 004 20 345 3.8 651 6 463 9 865 3 366 8 216 R01AD08 fluticasone 21 841 21 422 21 199 21 209 20 341 3.8 969 6 471 9 611 3 290 11 004 R01AD09 mometasone 160 714 160 156 161 114 171 090 176 300 33.2 11 705 73 262 68 734 22 599 42 342 R01AD11 triamcinolone 6 975 6 357 6 023 5 719 5 523 1.0 171 1 886 2 596 870 2 308 R01AD12 fluticasone furoate 92 012 88 454 87 374 92 014 91 495 17.2 8 855 43 992 30 546 8 102 18 629 R01AD58 fluticasone, combinations 7 848 31 102 42 588 55 895 67 751 12.8 3 262 36 540 22 333 5 616 46 805 R01AX Other nasal preparations 1 224 1 332 1 482 1 923 2 047 0.4 149 798 595 505 1 168 R01AX03 ipratropium bromide 615 600 585 791 910 0.2 <5 156 318 434 778 R01AX06 mupirocin 609 732 899 1 134 1 137 0.2 147 642 277 71 390 R01B NASAL DECONGESTANTS FOR SYSTEMIC USE 84 739 92 556 97 245 105 358 106 138 20.0 2 229 55 352 41 622 6 935 15 174 R01BA Sympathomimetics 84 739 92 556 97 245 105 358 106 138 20.0 2 229 55 352 41 622 6 935 15 174 R01BA01 phenylpropanolamine 84 735 92 554 97 241 105 358 106 138 20.0 2 229 55 352 41 622 6 935 15 174 R01BA51 phenylpropanolamine, combinations 0 <5 <5 0 0 0.0 0 0 0 R01BA52 pseudoephedrine, combina - tions <5 <5 0 0 0 0.0 0 0 0 0 0 R02 THROAT PREPARATIONS 231 601 860 959 718 0.1 41 405 200 72 79 R02A THROAT PREPARATIONS 231 601 860 959 718 0.1 41 405 200 72 79 R02AA Antiseptics 0 0 113 242 174 0.0 7 102 53 12 17 R02AA03 dichlorobenzyl alcohol 0 0 113 242 174 0.0 7 102 53 12 17 R02AX Other throat preparations 231 601 748 721 547 0.1 34 306 147 60 622.16 ATC group R - Respiratory system ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales 105 0.0 <5 63 29 11 15 R02AX03 benzydamine 231 601 735 639 456 0.1 32 254 121 49 47 R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES 430 210 437 223 448 102 457 872 462 106 87.0 67 331 114 893 174 656 105 226 1 201 084 R03A ADRENERGICS, INHALANTS 370 805 379 576 395 846 410 441 414 624 78.1 56 627 104 878 158 807 485 R03AA Alpha- and beta- adrenoreceptor agonists 157 122 68 52 55 0.0 38 11 6 0 161 R03AA01 epinephrine 157 122 68 52 55 0.0 38 11 6 0 161 R03AC Selective beta-2- adrenoreceptor agonists 278 642 283 525 297 047 308 927 310 331 58.4 54 562 83 583 111 647 60 539 149 011 R03AC02 salbutamol 231 841 239 798 255 957 270 499 274 663 51.7 53 974 74 919 95 446 50 324 97 383 R03AC03 terbutaline 29 663 28 386 27 455 25 686 23 882 4.5 557 7 636 10 993 4 696 9 356 R03AC04 fenoterol 17 16 11 11 13 0.0 0 0 12 <5 37 R03AC12 salmeterol 8 614 8 427 8 185 8 238 8 111 1.5 231 1 009 3 490 3 381 12 723 R03AC13 formoterol 12 919 12 162 11 282 10 731 9 958 1.9 132 1 678 4 718 3 430 15 697 R03AC18 indacaterol 9 391 7 525 6 114 5 163 4 402 0.8 0 47 1 869 2 486 11 716 R03AC19 olodaterol 131 817 927 1 029 1 070 0.2 0 27 512 531 2 098 R03AK Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics 183 306 187 960 192 942 196 252 196 886 37.1 7 893 463 081 R03AK06 salmeterol and fluticasone 92 173 88 214 83 967 78 843 73 827 13.9 6 053 16 856 29 856 21 062 145 449 R03AK07 formoterol and budesonide 83 643 82 839 80 791 78 736 75 825 14.3 759 18 176 36 374 20 516 168 540 R03AK08 formoterol and beclometa - sone 5 526 8 761 13 249 17 061 20 625 3.9 143 5 304 9 905 5 273 51 919 R03AK10 vilanterol and fluticasone furoate 5 049 12 816 20 372 26 166 30 321 5.7 949 7 591 13 808 7 973 84 904 R03AK11 formoterol and fluticasone 3 733 3 673 4 045 4 482 4 765 0.9 183 1 460 2 153 969 12 268 R03AL Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids 4 849 10 887 17 031 22 168 28 395 5.4 <5 385 12 013 15 995 127 233 R03AL02 salbutamol and ipratropium bromide 0 0 0 <5 0 0.0 0 0 0 0 0 R03AL03 vilanterol and umeclidinium bromide 137 2 442 4 546 6 634 8 310 1.6 <5 113 3 625 4 571 34 934 R03AL04 indacaterol and glycopyrro - nium bromide 4 720 7 447 7 618 7 435 6 766 1.3 0 47 2 742 3 977 31 325 R03AL05 formoterol and aclidinium bromide 0 919 2 538 2 823 2 679 0.5 0 44 1 195 1 440 10 718 R03AL06 olodaterol and tiotropium bromide 0 440 3 086 5 969 7 631 1.4 0 97 3 105 4 429 29 373 R03AL08 vilanterol, umeclidinium bromide and fluticasone furoate 0 0 0 0 1 802 0.3 0 26 756 1 020 5 476ATC group R ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales 0 337 3 221 0.6 <5 75 1 350 1 795 15 407 R03B OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS 159 015 159 605 162 051 165 633 164 441 31.0 40 903 26 535 52 825 44 178 261 574 R03BA Glucocorticoids 96 580 97 203 99 473 103 028 102 566 19.3 40 451 22 438 27 049 12 628 84 200 R03BA01 beclometasone 3 822 3 692 3 652 3 817 3 889 0.7 721 1 016 1 383 769 2 837 R03BA02 budesonide 18 785 17 790 17 063 16 579 15 784 3.0 1 761 3 885 6 443 3 695 21 066 R03BA05 fluticasone 64 166 63 633 64 979 67 460 67 034 12.6 38 079 12 434 11 504 5 017 35 008 R03BA07 mometasone 578 431 392 348 348 0.1 9 107 155 77 474 R03BA08 ciclesonide 11 093 13 598 15 260 16 702 17 330 3.3 659 5 390 8 015 3 266 24 815 R03BB Anticholinergics 68 515 68 644 69 233 69 975 69 276 13.0 1 068 5 607 28 775 33 826 177 317 R03BB01 ipratropium bromide 28 642 29 167 30 118 30 696 31 013 5.8 1 056 4 579 12 438 12 940 28 327 R03BB04 tiotropium bromide 40 771 40 059 38 667 37 851 36 257 6.8 28 1 137 15 151 19 941 124 385 R03BB05 aclidinium bromide 2 631 2 976 3 048 2 929 2 575 0.5 0 40 1 146 1 389 7 459 R03BB06 glycopyrronium bromide 2 874 2 251 1 905 1 705 1 506 0.3 0 17 666 823 5 213 R03BB07 umeclidinium bromide 0 214 1 854 3 072 3 589 0.7 0 64 1 673 1 852 11 933 R03BC Antiallergic agents, excl. corticosteroids 364 326 210 10 28 <5 9 11 7 56 R03BC01 cromoglicic acid 364 326 210 10 28 0.0 <5 9 11 7 56 R03C ADRENERGICS FOR SYSTEMIC USE 23 347 20 578 13 869 4 772 3 573 0.7 1 651 571 906 445 1 324 R03CA Alpha- and beta- adrenoreceptor agonists 8 918 7 538 4 389 3 636 2 745 0.5 1 358 485 663 239 846 R03CA02 ephedrine 8 918 7 538 4 389 3 636 2 745 0.5 1 358 485 663 239 846 R03CC Selective beta-2- adrenoreceptor agonists 14 831 13 283 9 634 1 161 845 0.2 301 88 249 207 478 R03CC02 salbutamol 3 141 2 693 3 741 483 377 0.1 279 41 38 19 194 R03CC03 terbutaline 11 582 10 517 6 105 536 342 0.1 22 38 156 126 152 R03CC12 bambuterol 218 172 145 150 145 0.0 0 11 68 66 127 R03CC13 clenbuterol 0 <5 <5 <5 <5 - 0 <5 0 0 6 R03D OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES 40 854 39 982 39 686 39 924 39 922 7.5 5 389 9 827 16 782 7 924 198 701 R03DA Xanthines 3 049 2 677 2 316 2 017 1 873 0.4 0 89 871 913 2 417 R03DA02 choline theophyllinate 6 5 0 0 0 0.0 0 0 0 0 0 R03DA04 theophylline 3 039 2 667 2 305 2 006 1 864 0.4 0 86 865 913 2 374 R03DA05 aminophylline 12 13 15 16 12 0.0 0 <5 8 0 44 R03DC Leukotriene receptor antagonists 37 473 36 610 36 321 36 373 36 185 6.8 5 340 9 000 15 292 6 553 28 556 R03DC01 zafirlukast 20 17 15 16 15 0.0 0 0 7 8 173ATC group R ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales 36 306 36 357 36 171 6.8 5 340 9 000 15 286 6 545 28 383 R03DX Other systemic drugs for obstructive airway diseases 1 452 1 764 2 147 2 691 3 066 0.6 69 966 1 277 754 167 727 R03DX05 omalizumab 413 752 1 122 1 519 1 812 0.3 69 911 716 116 129 128 R03DX07 roflumilast 1 039 1 012 977 997 981 0.2 0 <5 386 591 4 532 R03DX08 reslizumab 0 0 0 <5 17 0.0 0 <5 12 <5 1 163 R03DX09 mepolizumab 0 0 61 197 247 0.1 0 43 162 42 31 237 R03DX10 benralizumab 0 0 0 0 34 0.0 0 14 17 <5 1 667 R05 COUGH AND COLD PREPARATIONS 356 030 387 311 390 932 389 149 385 115 72.5 22 224 123 108 158 873 80 910 97 910 R05C EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS 104 508 106 877 103 679 101 730 98 295 18.5 4 546 18 295 38 621 36 833 45 442 R05CA Expectorants 5 185 5 302 6 010 5 064 4 035 0.8 819 1 209 1 230 777 383 R05CA03 guaifenesin 0 0 <5 0 0 0.0 0 0 0 0 0 R05CA10 combinations 5 185 5 302 6 007 5 064 4 035 0.8 819 1 209 1 230 777 383 R05CB Mucolytics 100 034 102 335 98 519 97 444 95 089 17.9 3 766 17 284 37 689 36 350 45 058 R05CB01 acetylcysteine 96 331 98 794 94 871 93 303 90 768 17.1 1 393 16 585 36 951 35 839 35 110 R05CB02 bromhexine 4 351 4 157 4 300 4 689 4 926 0.9 2 349 769 1 013 795 845 R05CB13 dornase alfa ( desoxyribonuclease) 145 155 156 165 182 0.0 58 101 18 5 9 103 R05D COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS 246 923 271 828 275 066 273 933 271 068 51.0 15 808 95 055 115 099 45 106 43 228 R05DA Opium alkaloids and derivatives 246 923 271 828 275 066 273 933 271 068 51.0 15 808 95 055 115 099 45 106 43 228 R05DA01 ethylmorphine 238 540 262 841 266 227 265 341 262 514 49.4 15 302 92 478 111 327 43 407 39 809 R05DA03 hydrocodone 441 493 395 364 284 0.1 <5 50 142 90 119 R05DA04 codeine 6 709 7 208 7 015 6 853 6 858 1.3 38 2 235 3 248 1 337 2 295 R05DA07 noscapine 1 771 1 818 2 177 2 270 2 102 0.4 493 672 626 311 248 R05DA09 dextromethorphan 0 0 0 0 <5 - 0 <5 <5 <5 3 R05DA20 combinations 2 619 2 746 2 532 2 369 2 265 0.4 24 541 1 204 496 754 R05F COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS 44 505 51 620 55 023 55 933 56 945 10.7 2 635 20 121 24 142 10 047 9 240 R05FA Opium derivatives and expectorants 44 505 51 620 55 023 55 933 56 945 10.7 2 635 20 121 24 142 10 047 9 240 R05FA02 opium derivatives and expectorants 44 505 51 620 55 023 55 933 56 945 10.7 2 635 20 121 24 142 10 047 9 240 R06 ANTIHISTAMINES FOR SYSTEMIC USE 615 581 618 418 642 752 683 165 706 540 133.0 86 467 287 541 249 338 83 194 248 197 R06A ANTIHISTAMINES FOR SYSTEMIC USE 615 581 618 418 642 752 683 165 706 540 133.0 86 467 287 541 249 338 83 194 248 197ATC group R ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales 2 581 8 784 9 372 1.8 17 4 178 3 981 1 196 4 468 R06AA02 diphenhydramine 5 8 11 10 28 0.0 <5 10 13 <5 13 R06AA04 clemastine 20 13 20 13 27 0.0 <5 7 9 7 38 R06AA09 doxylamine 0 0 2 535 8 741 9 303 1.8 12 4 158 3 953 1 180 4 297 R06AA52 diphenhydramine, combinations 19 29 17 20 14 0.0 0 <5 6 5 120 R06AB Substituted alkylamines 18 231 11 594 5 868 5 347 4 573 0.9 984 1 345 1 503 741 5 281 R06AB02 dexchlorpheniramine 18 231 11 594 5 868 5 347 4 573 0.9 984 1 345 1 503 741 5 281 R06AD Phenothiazine derivatives 69 771 71 388 72 539 72 702 74 509 14.0 3 317 28 174 31 499 11 519 59 943 R06AD01 alimemazine 63 783 65 271 66 312 66 923 68 852 13.0 3 282 25 550 29 363 10 657 57 455 R06AD02 promethazine 6 509 6 681 6 799 6 324 6 186 1.2 40 2 888 2 347 911 2 489 R06AD03 thiethylperazine 5 6 <5 0 0 0.0 0 0 0 0 0 R06AE Piperazine derivatives 297 671 285 596 285 951 291 357 288 008 54.2 32 385 107 006 107 098 41 519 67 103 R06AE03 cyclizine 837 947 1 076 1 098 475 0.1 9 103 235 128 613 R06AE05 meclozine 2 983 3 202 3 378 3 838 4 355 0.8 131 3 338 580 306 599 R06AE07 cetirizine 293 687 281 318 281 412 286 302 283 122 53.3 32 222 103 614 106 189 41 097 65 348 R06AE09 levocetirizine 619 597 600 612 602 0.1 32 253 255 62 544 R06AX Other antihistamines for systemic use 268 418 285 917 311 620 343 951 369 107 69.5 53 659 163 249 119 700 32 499 111 402 R06AX02 cyproheptadine 32 35 29 25 20 0.0 <5 5 5 6 44 R06AX13 loratadine 62 810 57 895 55 508 54 389 52 598 9.9 1 454 21 303 22 083 7 758 15 483 R06AX17 ketotifen 7 7 11 11 11 0.0 0 5 <5 <5 28 R06AX22 ebastine 9 554 11 024 11 836 12 808 13 182 2.5 229 5 541 5 880 1 532 7 969 R06AX26 fexofenadine 34 434 36 385 39 227 42 308 44 851 8.4 820 22 300 17 182 4 549 16 485 R06AX27 desloratadine 169 031 188 292 212 900 243 334 267 221 50.3 51 554 118 751 77 509 19 407 71 378 R06AX28 rupatadine 0 38 130 122 <5 - <5 <5 0 0 5 R06AX29 bilastine <5 10 12 23 25 0.0 0 14 7 <5 10 R07 OTHER RESPIRATORY SYSTEM PRODUCTS 15 18 39 49 57 0.0 18 32 7 0 73 853 R07A OTHER RESPIRATORY SYSTEM PRODUCTS 15 18 39 49 57 0.0 18 32 7 0 73 853 R07AX Other respiratory system products 8 10 26 41 45 0.0 10 31 <5 0 73 698 R07AX02 ivacaftor 8 10 11 13 15 0.0 <5 8 <5 0 29 542 R07AX30 ivacaftor and lumacaftor 0 0 15 28 30 0.0 6 23 <5 0 44 157ATC group R ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales 104 833 192 838 215 644 161 152 427 356 S01 OPHTHALMOLOGICALS 578 242 569 996 572 678 596 365 600 667 113.1 90 242 168 456 190 282 151 687 411 304 S01A ANTIINFECTIVES 252 458 246 271 240 135 243 441 238 050 44.8 55 309 70 713 73 727 38 301 50 751 S01AA Antibiotics 249 383 243 185 236 834 239 977 234 627 44.2 55 196 69 575 72 320 37 536 49 089 S01AA01 chloramphenicol 193 008 190 250 187 623 193 942 193 278 36.4 40 988 59 397 61 771 31 122 43 276 S01AA02 chlortetracycline 6 <5 0 2 S01AA11 gentamicin 42 37 31 17 24 0.0 <5 10 11 <5 4 S01AA12 tobramycin 1 629 1 0.2 153 358 442 307 125 S01AA13 fusidic acid 60 942 55 781 51 375 48 485 41 986 7.9 15 832 10 135 10 070 5 949 3 542 S01AA26 azithromycin 6 944 6 268 5 796 5 330 4 876 0.9 1 281 1 395 1 415 785 586 S01AA27 cefuroxime 0 <5 0 0 0 0.0 0 0 0 0 0 S01AA30 combinations of different antibiotics 5 579 5 758 6 263 6 446 8 651 1.6 485 2 152 3 355 2 659 1 435 S01AD Antivirals 3 287 2 915 3 300 3 375 3 300 0.6 114 891 1 338 957 835 S01AD02 trifluridine 0 0 0 <5 <5 - 0 <5 <5 0 7 S01AD03 aciclovir 3 287 2 915 3 300 3 374 3 299 0.6 114 890 1 338 957 828 S01AE Fluoroquinolones 2 669 2 844 2 926 3 082 3 016 0.6 116 1 100 1 227 573 767 S01AE03 ciprofloxacin 2 669 2 844 2 926 3 082 3 016 0.6 116 1 100 1 227 573 767 S01AX Other antiinfectives 8 8 <5 5 S01B ANTIINFLAMMATORY AGENTS 53 602 59 749 62 824 67 149 70 182 13.2 2 563 11 539 24 110 31 970 26 910 S01BA Corticosteroids, plain 35 407 37 698 42 473 48 920 53 707 10.1 2 518 10 664 19 365 21 160 15 940 S01BA01 dexamethasone 21 838 23 155 29 392 36 013 37 430 7.1 697 5 618 13 746 17 369 11 391 S01BA02 hydrocortisone 0 0 0 60 4 618 0.9 202 1 067 1 953 1 396 1 573 S01BA04 prednisolone 14 636 15 448 16 479 17 943 18 288 3.4 1 784 5 959 6 731 3 814 2 924 S01BA07 fluorometholone 9 9 25 17 16 0.0 0 <5 7 7 20 S01BA09 clobetasone 13 12 12 14 13 0.0 <5 <5 7 <5 31 S01BA13 rimexolone 4 105 4 322 2 440 83 0 0.0 0 0 0 0 0 S01BC Antiinflammatory agents, non-steroids 21 212 26 341 27 895 28 399 29 077 5.5 57 1 211 8 402 19 407 10 970 S01BC03 diclofenac 6 025 7 512 7 688 7 732 7 782 1.5 40 692 2 522 4 528 1 847 S01BC10 nepafenac 9 786 12 825 15 204 17 423 17 752 3.3 11 322 4 980 12 439 8 216 S01BC11 bromfenac 5 715 6 465 5 400 3 545 4 061 0.8 6 205 1 052 2 798 9072.17 ATC group S - Sensory organs ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales IN COMBINATION 58 553 55 148 49 893 43 762 43 173 8.1 1 153 7 509 15 491 19 020 8 785 S01CA Corticosteroids and antiinfectives in combination 58 553 55 148 49 893 43 762 43 173 8.1 1 153 7 509 15 491 19 020 8 785 S01CA01 dexamethasone and antiinfectives 58 553 55 148 49 893 43 762 43 173 8.1 1 153 7 509 15 491 19 020 8 785 S01E ANTIGLAUCOMA PREPARATIONS AND MIOTICS 72 872 73 682 74 978 76 099 76 868 14.5 285 2 398 21 121 53 064 155 029 S01EA Sympathomimetics in glaucoma therapy1)5 140 5 386 4 901 4 787 4 647 0.9 10 181 1 205 3 251 4 183 S01EA03 apraclonidine 193 238 169 205 178 0.0 <5 25 62 90 68 S01EA05 brimonidine 4 998 5 196 4 772 4 633 4 492 0.9 9 159 1 149 3 175 4 115 S01EB Parasympathomimetics 955 907 917 910 841 0.2 <5 64 528 1 308 S01EB01 pilocarpine 955 907 917 910 841 0.2 <5 64 528 1 308 S01EC Carbonic anhydrase inhibitors 11 093 11 520 12 539 13 374 13 984 2.6 156 855 3 433 9 540 22 456 S01EC01 acetazolamide 1 822 1 623 1 687 2 065 2 107 0.4 55 579 758 715 1 136 S01EC02 diclofenamide 0 0 0 0 7 0.0 0 6 <5 0 2 172 S01EC03 dorzolamide 2 430 2 567 2 840 3 152 3 443 0.7 28 103 875 2 437 5 303 S01EC04 brinzolamide 7 266 7 478 7 486 7 290 7 108 1.3 81 147 1 477 5 403 8 990 S01EC05 methazolamide <5 0 0 0 0 0.0 0 0 0 0 0 S01EC54 brinzolamide, combinations 0 614 1 554 2 062 2 594 0.5 <5 64 669 1 859 4 855 S01ED Beta blocking agents1)50 197 50 544 51 182 51 703 52 160 9.8 194 1 323 14 268 36 375 74 832 S01ED01 timolol 21 495 21 519 21 391 21 098 20 510 3.9 149 537 6 131 13 693 23 541 S01ED02 betaxolol 1 150 960 834 723 651 0.1 6 8 125 512 384 S01ED51 timolol, combinations 29 552 30 224 31 281 32 044 33 251 6.3 57 880 8 700 23 614 50 907 S01EE Prostaglandin analogues1)37 948 38 603 38 866 38 665 38 696 7.3 44 742 9 982 27 928 52 250 S01EE01 latanoprost 23 693 24 167 24 533 24 257 24 309 4.6 32 457 6 131 17 689 23 986 S01EE03 bimatoprost 2 344 2 584 2 380 2 444 2 425 0.5 0 80 601 1 744 4 337 S01EE04 travoprost 6 454 5 844 5 206 4 520 4 026 0.8 <5 46 839 3 140 6 846 S01EE05 tafluprost 6 577 7 156 7 675 8 197 8 698 1.6 11 173 2 601 5 913 17 081 S01F MYDRIATICS AND CYCLOPLEGICS 5 397 5 208 5 556 4 995 4 918 0.9 312 1 328 2 272 1 006 1 065 S01FA Anticholinergics 5 384 5 201 5 540 4 976 4 910 0.9 312 1 327 2 266 1 005 1 060 S01FA01 atropine 2 033 1 851 1 553 1 336 1 120 0.2 229 S01FA04 cyclopentolate 3 401 3 373 4 059 3 749 3 907 0.7 80 1 102 1 904 821 706ATC group S ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales tropicamide 168 162 128 86 93 0.0 7 29 48 9 25 S01FA54 cyclopentolate, combinations 0 <5 excl. antiglaucoma preparations 46 39 46 51 30 0.0 0 5 20 5 5 S01FB01 phenylephrine 46 39 46 51 30 0.0 0 5 20 5 5 S01G DECONGESTANTS AND ANTIALLERGICS 195 587 184 820 185 939 201 407 202 110 38.1 34 918 87 127 63 015 17 050 63 847 S01GA Sympathomimetics used as decongestants 21 906 20 455 19 535 20 161 19 732 3.7 1 851 8 582 7 512 1 787 5 712 S01GA01 naphazoline 0 0 5 12 11 0.0 0 <5 5 <5 2 S01GA52 tetryzoline, combinations 21 906 20 455 19 530 20 152 19 723 3.7 1 851 8 579 7 508 1 785 5 709 S01GX Other antiallergics 177 610 167 905 169 762 185 118 186 023 35.0 33 716 80 159 56 650 15 498 58 135 S01GX01 cromoglicic acid 25 240 23 575 23 034 23 718 22 328 4.2 3 304 8 586 8 115 2 323 8 027 S01GX02 levocabastine 91 780 86 161 87 921 97 537 98 785 18.6 19 357 43 161 28 705 7 562 24 759 S01GX04 nedocromil 1 168 0 0 0 0 0.0 0 0 0 0 0 S01GX06 emedastine 384 380 398 413 430 0.1 93 154 128 55 146 S01GX07 azelastine 615 118 0 0 0 0.0 0 0 0 0 0 S01GX08 ketotifen 21 010 20 747 21 391 23 557 24 107 4.5 4 211 10 151 7 595 2 150 9 580 S01GX09 olopatadine 43 210 41 899 41 694 45 550 45 755 8.6 8 179 20 009 13 670 3 897 15 624 S01X OTHER OPHTHALMOLOGICALS 52 955 61 071 69 033 79 807 88 992 16.8 779 9 194 34 699 44 320 104 678 S01XA Other ophthalmologicals 52 955 61 071 69 033 79 807 88 992 16.8 779 9 194 34 699 44 320 104 678 S01XA03 sodium chloride, hypertonic 23 24 34 39 63 0.0 0 <5 24 37 95 S01XA08 acetylcysteine 0 0 0 <5 <5 - 0 <5 0 0 32 S01XA18 ciclosporin 601 784 1 823 2 697 3 881 0.7 63 637 1 831 1 350 26 504 S01XA20 artificial tears and other indifferent preparations 52 768 60 852 68 604 79 216 87 932 16.6 735 8 974 34 245 43 978 74 200 S01XA21 mercaptamine 0 0 0 6 10 0.0 <5 7 0 0 3 439 S01XA25 lifitegrast 0 0 0 0 6 0.0 0 <5 <5 <5 180 S02 OTOLOGICALS 23 042 24 528 22 510 20 226 22 924 4.3 4 959 7 160 7 622 3 183 4 170 S02A ANTIINFECTIVES 7 549 6 437 5 536 5 224 4 986 0.9 1 690 1 479 1 321 496 859 S02AA Antiinfectives 7 549 6 437 5 536 5 224 4 986 0.9 1 690 1 479 1 321 496 859 S02AA01 chloramphenicol 11 13 11 0 0 0.0 0 0 0 0 0 S02AA03 boric acid <5 <5 8 20 5 0.0 0 0 <5 <5 8 S02AA15 ciprofloxacin 7 537 6 423 5 520 5 204 4 982 0.9 1 690 1 479 1 318 495 851 S02B CORTICOSTEROIDS 10 853 12 168 7 855 1 355 1 429 0.3 18 310 738 363 280 S02BA Corticosteroids 10 853 12 168 7 855 1 355 1 429 0.3 18 310 738 363 280 S02BA07 betamethasone 10 853 12 168 7 855 1 355 1 429 0.3 18 310 738 363 280ATC group S ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales COMBINATION 5 664 7 030 10 163 14 369 17 171 3.2 3 386 5 560 5 793 2 432 3 028 S02CA Corticosteroids and antiinfectives in combination 5 664 7 030 10 163 14 369 17 171 3.2 3 386 5 560 5 793 2 432 3 028 S02CA02 flumetasone and antiinfectives 101 74 62 59 <5 - 0 <5 0 1 S02CA05 fluocinolone acetonide and antiinfectives 5 565 6 964 10 104 14 314 17 169 3.2 3 386 5 560 5 791 2 432 3 027 S03 OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS 75 987 72 113 74 436 74 488 73 692 13.9 13 449 23 020 25 844 11 379 11 882 S03C CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION 75 987 72 113 74 436 74 488 73 692 13.9 13 449 23 020 25 844 11 379 11 882 S03CA Corticosteroids and antiinfectives in combination 75 987 72 113 74 436 74 488 73 692 13.9 13 449 23 020 25 844 11 379 11 882 S03CA01 dexamethasone and antiinfectives 12 881 10 738 10 956 10 854 9 588 1.8 717 2 571 4 224 2 076 1 387 S03CA04 hydrocortisone and antiinfectives 65 069 63 009 65 134 65 319 65 568 12.3 12 837 20 889 22 272 9 570 10 495ATC group S ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales VARIOUS 30 050 32 694 35 372 37 093 7.0 5 420 12 581 11 428 7 664 187 635 V01 ALLERGENS 10 346 11 619 12 876 14 582 16 203 3.1 2 847 10 393 2 858 105 125 642 V01A ALLERGENS 10 346 11 619 12 876 14 582 16 203 3.1 2 847 10 393 2 858 105 125 642 V01AA Allergen extracts 10 346 11 619 12 876 14 582 16 203 3.1 2 847 10 393 2 858 105 125 642 V01AA02 grass pollen 7 480 8 644 9 845 11 002 12 021 2.3 2 042 8 005 1 926 48 76 816 V01AA03 house dust mites 552 556 514 933 1 544 0.3 176 1 034 322 12 10 910 V01AA05 tree pollen 5 287 5 535 5 791 6 259 6 585 1.2 1 210 4 010 1 318 47 30 402 V01AA07 insects 148 165 149 144 136 0.0 19 36 70 11 1 095 V01AA10 flowers 120 96 43 <5 10 0.0 0 <5 5 <5 104 V01AA11 animals 526 570 555 513 581 0.1 98 369 112 <5 6 314 V03 ALL OTHER THERAPEUTIC PRODUCTS 3 015 3 294 3 530 3 868 4 210 0.8 95 491 1 643 1 981 51 302 V03A ALL OTHER THERAPEUTIC PRODUCTS 3 015 3 294 3 530 3 868 4 210 0.8 95 491 1 643 1 981 51 302 V03AB Antidotes 108 100 120 82 122 0.0 <5 45 55 18 223 V03AB01 ipecacuanha 8 <5 2 V03AB03 edetates 0 0 <5 0 0 0 0 V03AB06 thiosulfate <5 <5 <5 56 V03AB09 dimercaprol 8 12 6 6 <5 - 0 0 <5 0 10 V03AB14 protamine 0 0 <5 0 <5 - 0 0 0 <5 1 V03AB15 naloxone 14 12 20 11 27 0.0 <5 12 <5 18 V03AB16 0 0 <5 <5 <5 <5 amyl nitrite 0 0 5 V03AB32 glutathione 61 63 72 34 26 0.0 0 5 16 5 88 V03AB33 hydroxocobalamin 0 <5 0 0 <5 - 0 0 <5 0 6 V03AC Iron chelating agents 127 122 139 144 157 0.0 25 47 43 42 17 765 V03AC01 deferoxamine 36 31 30 31 26 0.0 10 9 <5 <5 530 V03AC02 deferiprone 26 23 22 21 23 0.0 <5 8 5 6 986 V03AC03 deferasirox 83 82 105 109 122 0.0 16 38 35 33 16 249 V03AE Drugs for treatment of hyperkalemia and hyperphosphatemia 2 486 2 699 2 813 2 965 3 072 0.6 8 263 1 218 1 583 29 611 V03AE01 polystyrene sulfonate 727 846 881 951 876 0.2 5 57 325 489 1 941 V03AE02 sevelamer 1 746 1 790 1 862 1 987 2 014 0.4 <5 191 856 964 13 2532.18 ATC-group V - Various ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales 603 644 562 590 0.1 0 62 253 275 9 339 V03AE04 calcium acetate and magnesium carbonate 96 94 19 12 5 0.0 0 <5 <5 <5 24 V03AE05 sucroferric oxyhydroxide 0 0 63 122 115 0.0 0 7 65 43 1 340 V03AE09 patiromer calcium 0 0 0 <5 257 0.1 <5 27 116 113 3 708 V03AE10 sodium zirconium cyclosilicate 0 0 0 0 <5 - 0 <5 0 0 7 V03AF Detoxifying agents for antineoplastic treatment 66 57 61 61 38 0.0 11 10 12 5 366 V03AF01 mesna 7 <5 9 10 12 0.0 0 <5 10 0 17 V03AF03 calcium folinate 59 55 52 51 26 0.0 11 8 <5 5 349 V03AG Drugs for treatment of hypercalcemia 163 280 371 579 736 0.1 34 113 277 312 853 V03AH Drugs for treatment of hypoglycemia 20 28 24 28 28 0.0 10 8 6 <5 2 222 V03AH01 diazoxide 20 28 24 28 28 0.0 10 8 6 <5 2 222 V03AX Other therapeutic products <5 15 6 16 63 0.0 0 <5 37 22 253 ATC group V ATC level2014 2015 2016 2017 2018 2018 2018 2018 Number of individuals Prevalence per 1 000Number of individuals per age groupSales (klassifikasjonssystem for legemidler)ATC Therapeutical Chemical (classification system for medicines) DDD Definert DDD Defined Daily Doses FHI Folkehelseinstituttet HELFO Helse\u00f8konomiforvaltningen HELFO The Norwegian Health Economics Administration MA Markedsf\u00f8ringstillatelse MA Marketing Authorisation NIPH Norwegian Institute of Public Health NOK Norske kroner NOK Norwegian kroner NorPD Reseptregisteret NorPD Norwegian Prescription Database OTC Reseptfritt OTC Over The Counter, non prescription SPC Preparatomtale SPC Summary of Product i det definerte befolkningsutvalget. Definitions Prevalence Users (individuals) are defined as persons who had at least one prescription dispensed at pharmacies in the period. Prevalence is defined as the number of users per 100 (%) or 1000 (promille) inhabitants in the defined population sample. Incidence (new users) Incidence is the number of users of a particular drug or drug group in a defined time period who were not users in a previous, defined time period. Incidence can be expressed as a percentage relative to the number of potential users in the defined population sample. Legemiddelstatistikk 2019:2 Folkehelseinstituttet 98Folkemengde i Norge 2014-2018 (per 1. juli) Population in Norway 2014-2018 (as of 1st July) Year 2014 2015 2016 2018 2018 Population 5 137 321 5 189 984 5 236 624 5 276 847 5 311 797 Folkemengde etter alder i 2018 (per 1. juli) Population by age in 2018 (as of 1st July) Age groups <15 15-44 45-69 70 Population 905 749 2 093 866 1 650 202 661 981 per 21.02.2019 List of publications based on data from the Norwegian Prescription Database (NorPD) as of 21.02.2019 2018: Andersson J, Hofsli M, Heegaard S, A. Use of topical ocular antibiotics in young children: a Scandinavian drug utilization study. Acta Ophthalmol (Oxf) LI, Engeland A, Fasmer OB, et al. Diabetes is associated with decreased migraine risk: A nationwide cohort study. Cephalalgia 2018;38(11):1759-64. Baftiu A, Feet SA, Larsson PG, Burns ML, Henning O, Saetre E, et al. Utilisa - tion and polypharmacy aspects of antiepileptic drugs in elderly versus younger patients with epilepsy: A pharmacoepidemiological study of CNS- active drugs in Norway, 2004-2015. Epilepsy Res 2018;139:35-42. Bateman BT, Heide-J\u00f8rgensen U, Einarsdottir M, Reutfors J, Selmer R, Zoega H. Beta-blocker use in pregnancy and the risk of congenital malformations: An international cohort study. Ann Intern Med 2018; 169: 665-73. Benko R, Matuz Furtado C, Fungie G, Bordas R, Blix HS. Cross-national comparison of paediatric antibiotic use in Norway, Portugal and Hungary.Basic Clin TB, Steinsbekk A. Register-based study showed that the age when children were prescribed antibiotic tablets and capsules instead of liquids increased from 2004 to 2016. Acta Paediatr 2018;22:22. Bergene EH, Nordeng for new oral antibi - otic prescriptions in children within 2 days: a Norwegian population-based study. Fam Pract 2018;35(6):690-7. Charlton V, Bos HJ, Engeland A, Garne E, Gini R, Hansen AV, de Jong-van den Berg LTW, Jordan S, Klungs\u00f8yr K, Neville AJ, Pierini A, Puccini A, Sinclair M, Thayer D, Dolk H.The limitations of some European healthcare databases for monitoring the effectiveness of pregnancy preven- tion programmes as risk minimisation measures. Eur J 74:513-20 Cohen JM, Wood ME, Hernandez-Diaz S, Nordeng H. Agreement between paternal self-reported medication use and records from a national prescrip- tion database. Pharmacoepidemiol Drug Saf 2018;27(4):413-21. Cortese Engeland A, Ascherio A, Bjornevik K. Urate and the risk of Parkinson's in and women. Parkinsonism Relat Disord 2018;52:76-82. Dalen DM, Locatelli M, Strom on Pharma- ceutical Data. Atl NE. Hypertensive preg - nancy complications in women with epilepsy and antiepileptic drugs: a population-based cohort study of first pregnancies in Norway. BMJ Open 2018;8(4):e020998. Diaz E, Omland G, Hannestad Y , Ruths S. Use of hormonal contraceptives among immigrant women and their daughters in Norway: Data from the Norwegian Prescription Database. Acta Obstetricia et Gynecologica Scandi - navica Staff Eide GE, Daltveit AK, Klungsoyr K, et al. Pregnancy-Related Risk Factors Are Associated With a Significant Burden of Treated Hypertension Within 10 Years of Delivery: Findings From a Population-Based Norwegian Cohort. J Am Heart Assoc 2018;7(10):13. Engeland T, Klungsoyr K, Hjellvik V, Skurtveit S, Furu K. Trends in prescription drug use during pregnancy and postpartum in Norway, 2005 to 2015. Pharmacoepidemiol Drug Saf GH, Gjelstad S, Kvaerner KJ, Lindbaek M. Prescribing antibiotics when the stakes are higher - do GPs prescribe less when patients are pregnant? A retrospective observational study. BJGP open Lindbaek M, Gjelstad S, Kvaerner KJ. Relationship between Maternal and First Year of Life Dispensations of Antibiotics and Antiasth- matics. Antibiotics (Basel) 2018;7(3):17. Frank AS, Lupattelli A, Matteson DS, Nordeng H. Maternal use of thyroid hormone replacement therapy before, during, and after pregnancy: agree -ment between self-report and prescription records and group-based tory of patterns. OM, Skurtveit S, Handal M, Hjellvik V. A complete national cohort study of prescriptions of analgesics and benzodiazepines to cancer survivors in Norway 10 years after diagnosis. Pain 2018;07:07. Gulati al. intracranial hemorrhage (RICH) in users of oral antithrombotic drugs: Nation Engeland A. Associations between attention-deficit/hyperactivity disorder and autoimmune diseases are modified by sex: a population-based cross-sectional study. Eur Child Adolesc Skurtveit S, Lobmaier PPK, Vederhus JK, Bramness JG. Use of drugs for alcohol use disorder in Norway 2004-16. Tidsskrift for Den Norske Laegeforening 2018;138(18):13. Hoff Meyer HE, Langhammer AJ, Syversen U, et al. Anti-osteoporosis drug use: too little, too much, or just right? The HUNT and Amphet - amine use in Pregnancy and Risk of Congenital Malformations: A cohort study from the International Pregnancy Safety Consortium. M, et al. Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications prescription rates of anxiolytics and hypnotics to survivors of cancer in child - hood, adolescence, and young adulthood-A population-based study. Pediatr Blood Cancer A, Sciupokas A, Petrikonis K, Kadusevicius E. Impact of the World Health Organization Pain Treatment Guidelines and the European Medicines Agency Safety Recommendations on Nonsteroidal Anti-Inflammatory Drug Use in Lithuania: An Observational Study. Kjerpeseth Selmer R, Ariansen I, Furu K, Skovlund E. Risk factors for stroke and choice of oral anticoagulant in atrial fibrillation. Eur J Thurston M, Hagquist C. Leisure-time physical activity among adolescents and subsequent use of antidepressant and hypnotic drugs: a prospective register linkage study. Eur Child NE, et al. Antiepileptic and psychiatric medication in a nationwide cohort of patients with glioma WHO grade II-IV. J Neurooncol 2018;140(3):739-48. prescribing Magnus MC, Lunde J, Stordal K. Prospective Cohort Study of Breast - feeding and the Risk of Childhood Asthma. J Pediatr SJ, Wilcox AJ, Nystad W, H\u00e5berg SE. Maternal history of miscarriages and measures of fertility in relation to childhood asthma. Thorax. SJ, Nystad W. Association of Maternal Psychosocial Stress With Increased Risk of Asthma Development in Offspring. Am J Epide - miol.2018;187(6):1199-209. Mauseth SA, Skurtveit S, Langhammer A, Spigset O. Incidence of and factors associated with anticholinergic drug use among Norwegian women with urinary incontinence. Medication use and association with urinary incontinence in women: Data from the Norwegian Prescription Database and the HUNT study. Neurourol Urodyn 2018;37(4):1448-57. Meijer E, Bolin K, Stavem K, Ersb\u00f8ll AK. Finasteride treatment and male breast cancer: a register-based cohort study in four Nordic countries. IB, Karlstad \u00d8, Furu children 2004-2015 [Forskrivning av legemidler astma . Incidence Trends of Atopic Dermatitis in Infancy and Early Childhood in a Nationwide Prescrip- tion Registry Study in Norway. JC, Tysnes OB, Holmoy T. Assessing amyotrophic lateral sclerosis prevalence in Norway from 2009 to 2015 from compulsory nation - wide health registers. Amyotroph Lateral Scler Frontotemporal Degener R, Engeland A, Handal M. Neonatal Outcomes after Fetal Exposure to Methadone and Buprenorphine: National Registry Studies from the Czech Republic and Norway. Addiction 2018. Nesvag R, Bramness JG, Handal M, Hartz I, inci - dence, psychiatric co-morbidity and pharmacological treatment of severe mental disorders in children and adolescents. Eur Psychiatry 2018;49:16-22. Parr Haugen M, et al. Vitamin A and D intake in pregnancy, infant supplementation, and asthma development: the Norwegian Mother and Child Cohort. Am J Clin Nutr 2018;107(5):789-98. Pasternak M, Stephansson O. Oral Fluconazole in Pregnancy and Risk of Stillbirth and Neonatal Death. JAMA 2018. Raknes G, Smabrekke L. The Effect of Low-Dose Naltrexone on Medication in Inflammatory Bowel Disease: A Quasi Experimental Before- and-After Prescription Database Study. J Crohns Colitis 2018;12(6):677-86. Raman K, Bahmanyar S, Bilder Boukhris T,Bushnell Kieler H, Kubota Lai EC, Martikainen JE, Maura G, Moore N, Montero D, Nakamura H, Neumann A, Pate V, Potteg\u00e5rd A, Pratt NL, Roughead DM, St\u00fcrmer CC, Zoega Sturkenbroom M, Chan EW, Coghill D, Ip P , Wong I. Regional and national trends in attention-deficit/hyperactivity disorder (ADHD) medication use: a multinational study in North America, Europe, Asia and Australia. Lancet Psychiatry 2018; 5(10):824-835. Reset A, Skurtveit S, Furu K, Skovlund E. Effect of the market withdrawal of dextropropoxyphene on use of other prescribed analgesics. Scand J Pain 2018;18(4):667-74. Roksvaag I, Skjeldestad FE. Decreasing trends in number of depot medroxy - progesterone acetate starters in Norway - a cross-sectional Acta Gulseth HL, et al. Pandemic influenza and subsequent risk of type 1 diabetes: a nationwide cohort study. Diabetologia Ghanima W, Holst R, Halvorsen S. New score for assessing bleeding risk in patients with atrial fibrillation treated with NOACs. Open Heart 2018;5(2):e000931. Skurtveit I, Nesvag R, Hauge LJ, et al. Increase in diagnosis of depressive disorders contributes to the increase in antidepressant use in adolescents. Acta Psychiatr Scand cardiovas- cular disease risk J, Klungs\u00f8yr K. Gender differences in Psychiatric Comorbidity in Diagnostikk av hyperki - forstyrrelse hos Svendsen K, Halvorsen KH, S, Samdal H, Garcia B. Adverse drug reaction reporting: how can drug consumption information add to analyses using spontaneous reports? Eur J HJ. Is self-rated health in adolescence a predictor of prescribed medication in adulthood? Findings from the Nord Trondelag Health Study and Popul Health 2018;4:144-52. Walle-Hansen MM, Hoye S. Geographic Variation in Antibiotic Consumption- Is It Due to Doctors' Prescribing or (Basel) Schmidt M, Karlstad \u00d8, Potteg\u00e5rd A. Trends in Use of Paracetamol Nordic Countries. Basic Clin Pharmacol AT, et al. by interferon-gamma release assay level Engeland A, Bernt Fasmer O, et al. Diabetes is associated with decreased migraine risk: A nationwide cohort study. Cephalalgia 2017:333102417748573. Baftiu A, Feet SA, Larsson PG, Burns ML, Henning O, Saetre E, et al. Utilisation and polypharmacy aspects of antiepileptic drugs in elderly versus younger patients with epilepsy: A pharmacoepidemiological study of CNS-active drugs \u00d6verland S, et al. General practice consultations and use of prescription drugs after changes to school absence policy. Tidsskr Nor Laegeforen 2017;137(16):1178-84. Beisland C, Johannesen TB, Klepp O, et al. Overall survival in renal cell carcinoma after introduction of targeted therapies: a Norwegian population- based study. S, et al. Does progestin-only contraceptive use after pregnancy affect recovery from pelvic girdle pain? A prospective population study. PLoS One 2017;12(9):14. Blandhol M, Tysland T, Blix HS, Hoye S. Antibiotic switch during treatment with antibiotics against respiratory tract infections in ambulatory care in Norway. Infect Dis (Lond) 2017;49(11-12):854-8. Brakedal B, Flones I, Reiter C, Assmus J, et al. Glitazone Use Associated With Reduced Risk of Parkinson's Disease. Mov Disord 2017;32(11):1594-9. But A, De Bruin ML, MT, Hjellvik M, Auvinen A, Starup- Linde F, Karlstad \u00d8, Ekstr\u00f8m, N, Haukka J. Cancer Risk among insulin users: comparing analogues with human insulin in the CARING Length in Users Acetylcholinesterase Dement Cogn Daltveit AK, Vikse BE, Haugen M. Low Calcium Intake in Midpregnancy Is Associated with Hypertension Development within 10 Years after Pregnancy: The Norwegian Mother and Child Cohort Study. Journal of Nutrition 2017;147(9):1757-63. Engeland A, Bjorge T, Klungsoyr K, Skurtveit S, Furu K. Preterm births and use of medication in early adulthood: a population-based registry study. Pharmacoepidemiology and Drug Safety , Schwarze PE, et al. Road traffic noise and registry based use of sleep medication. Environ Health 2017;16:12. Ezat B, Pihlstrom L, Aasly J, Tysnes OB, Egge A, Dietrichs E. Use of advanced therapies for Parkinson's disease in Norway. Tidsskr Nor Laegeforen 2017;137(9):619-23. Fadnes LT, Diaz E. Primary healthcare usage and use of medications among immigrant children according to age of arrival to Norway: a population- of analgesics during complete disease trajectories in patients who are diagnosed with and die from cancer within the five-year period 2005-2009. European Journal of Pain 2017;21(3):530-40. Fredheim OMS, Skurtveit S, Borchgrevink PC. Provision of analgesics to children before and after the new recommendations on Tidsskr of Stimulants and Atomoxetine for Attention-Deficit/ Hyperactivity Disorder among 5.4 million Children Using Population-based Longitudinal Data. Basic & Clin agent quetiapine is increasingly not used as such: dispensed in Norway 2004-2015. Eur J Clin Pharmacol Graner D, Pasternak B, Kieler H. Neuraminidase inhibitors during pregnancy, and the risk of adverse neonatal outcomes and congenital malformations-A population based European 2017. Mar 1;356:j629. http://www.bmj.com/content/356/bmj.j629.long Grinde B, Engdahl B. Prescription database analyses indicates that the asthma medicine montelukast might protect against dementia: a hypothesis to be verified. Association of Warfarin Use With Lower Overall Cancer Incidence Among Patients Older Than 50 Years. JAMA Intern Med 2017;177(12):1774-80. Halvorsen S, C, Falck P , Solli O, et al. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants. Eur Heart J-Cardiovasc Pharmacother 2017;3(1):28-36. Hoff M, Meyer HE, Skurtveit AJ, Syversen U, et al. Validation of FRAX and the impact of self-reported falls among elderly in a general population: the HUNT study, Norway. despite easy access to contraception and E, et al. Hypnotics use in children 0-18 months: moderate agreement between mother-reported survey data and prescription registry data. J 2017;10:28. Johannsdottir Karlstad O, Loge Skurtveit S. Prescriptions of Antidepressants to Survivors of Cancer in Childhood, Adolescence, and Young Adulthood: A Population-Based Study. J PA. Fecal carriage of extended spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae after urinary tract infection - A three year prospective cohort study. PLoS One 2017;12(3):16. and Treatment in Relation to Children's Birth Month: Nationwide Study from Norway. Scand J Public Health. 2017 Jun;45:343-9. Kaspersen F, Ose SO, JH. Employees' drug purchases before and after organizational downsizing: a natural experiment on the Norwegian working population (2004-2012). Scand J Work Environ Health 2017;43(4):307-15. Kjerpeseth Selmer R, Ariansen I, Furu K, Skovlund E. Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, to Kravdal \u00d8, Grundy E, Skirbekk V. Fertility history and use of antidepressant medication in late mid-life: a register-based analysis of Norwegian women and men. Aging Ment Health. 2017 May;21(5):477-486. doi: 10.1080/13607863.2015.1118010. Epub Gemzell-Danielsson K, Heikinheimo O, Hognert H, Milsom I, et al. Contraceptive use O. Incidence of and factors associated with anticholinergic drug use among Norwegian women with urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2017;04:04. Milenkovic M, Haavik S. Recording of pharmaceutical interventions of potential clinical importance in Norwegian pharmacies. Norsk Farmaceutisk Tidsskrift M, Forsmo S, et al. Psoriasis, fracture risk and bone mineral density: the HUNT Study, Norway. Br J Dermatol 2017;176(5):1162-9. Modalsli Asvold BO, Snekvik I, Romundstad PR, Naldi L, Saunes M. The association between the clinical diversity of psoriasis and depressive symptoms: the HUNT Study, Norway. J Dermatol Venereol 2017;31(12):2062-8. M\u00e5rild K, Blix HS, St\u00f6rdal K. Use of antibiotics in children during the period 2005 - 16. Tidsskr Nor Laegeforen 2017;137(18):1414-9. Nakken O, Lindstrom JC, Tysnes OB, Holmoy T. Assessing amyotrophic lateral sclerosis prevalence in Norway from 2009 to 2015 from compulsory nationwide health registers. Amyotrophic Lateral sclerosis & Frontotemporal Degeneration 2017:1-8. Odsbu I, Selmer R, Lundborg CS, Blix HS. Increased prescribing of systemic tetracyclines and PM, et al. Maternal Folate Intake during Pregnancy and Childhood Asthma in a Population-based Cohort. Am J Respir Norwegian dentists: a survey over 25 years (1990- 2015). Eur J Oral Sci 2017;125(4):280-7. Raknes G, Smabrekke L. Low dose naltrexone in multiple sclerosis: Effects on medication use. A quasi-experimental PLoS and opioid consumption: a drug utilization cohort study based on data from the Norwegian prescription database. Pharmacoepidemiology and Drug Safety 2017;26(6):685-93. Raknes G, Smabrekke L. A sudden and unprecedented increase in low dose naltrexone (LDN) prescribing in Norway. Patient and prescriber characteristics, and dispense patterns. A drug utilization cohort study. Pharmacoepidemiology and Drug Safety 2017;26(2):136-42. Rebnord, E.W., Strand, E., Midttun, \u00d8. et al. The kynurenine: tryptophan ratio as a predictor of incident type 2 diabetes mellitus in individuals with coronary artery disease. Diabetologia AK, Robsahm TE, et al. Cancer Risk in Women Treated with Fertility Drugs According to Parity Status-A Registry-based Cohort Study. Cancer Epidemiology Biomarkers & Prevention 2017;26(6):953-62. Sakshaug S, Handal M, Hjellvik V, Berg C, Ripel A, Gustavsen I, et al. Long- term Use of Z-Hypnotics and with Benzodiazepines J, Baz-Lomba JA, Bramness JG. Assessing prescription drug abuse using functional principal component analysis (FPCA) of wastewater data. Pharmacoepidemiology and Drug Safety 2017;26(3):320-6. Samuelsen PJ, Nielsen CS, Wilsgaard T, Stubhaug A, Svendsen K, Eggen AE. Pain sensitivity Jason LA, Kirkevold M. From good health to illness with post- infectious fatigue syndrome: a qualitative study of adults' experiences of the illness trajectory. BMC family practice 2017;18(1):49. Straiton ML, Reneflot A, Diaz E. Mental Health of Refugees and Non-refugees from War-Conflict Countries: Data from Primary Healthcare Services and the Norwegian Prescription Database. Journal of Immigrant and Minority Health 2017;19(3):582-9. Svendsen K, Halvorsen KH, Vorren S, Samdal H, Garcia B. Adverse drug reaction reporting: how can drug consumption information add to analyses using spontaneous reports? Eur J Clin Pharmacol 2017;18:18. Svendsen T, A, Burns Johannessen SI, Landmark CJ. Therapeutic Drug Monitoring of Lacosamide in Norway: Focus on - acetate-A national approach to the evalu - ation of therapeutic drug monitoring data and clinical outcome. Epilepsy Research 2017;129:125-31. Svendsen T, Brodtkorb E, Reimers A, variability, efficacy and tolerability of eslicarbazepine acetate-A national approach to the evaluation of therapeutic drug moni - toring data and clinical outcome. Length in Users Acetylcholinesterase Dement Cogn Seim A, Krokstad S, Helvik AS. Use of alcohol and drugs with addiction potential among older women and men in a population-based study. The Nord-Trondelag Health Study and users and disability pension: an eight-year nationwide observational follow-up study. Scand J Prim Health Care 2017;35(3):240-6. Urbaniak AM, Strom BO, Krontveit R, Svanqvist KH. Prescription Patterns of Non-Vitamin K Oral Anticoagulants Across Indications and Factors Associated with Their Increased Prescribing in Atrial Fibrillation Between 2012-2015: A Study from the Norwegian Prescription Database. Drugs Aging 2017;34(8):635-45. Vie TL, Hufthammer KO, Holmen TL, Meland E, Breidablik HJ. Is self-rated health in adolescence a predictor of prescribed medication in adulthood? Findings from the Nord Tr\u00f8ndelag Health Study and the D\u00edez-Domingo Ziv-Baran T, Kim SK. Anti- biotic Use in Children - A Cross-National Analysis of 6 Countries. J Pediatr 2017;182:239-44. L. Psycho social factors are strongly associated with insomnia in users and nonusers of prescribed sleep medication: Evidence from the HUNT3 study. J Multidisci - 2016;9:547-55. SI, Larsson PG. Changes in of antiepileptic drugs in epilepsy and non-epilepsy disorders-a pharmacoepidemiological Dorum LM, et al. Aspirin as secondary prevention in patients with colorectal cancer: An S. Antipsychotic Drugs and Risk of Hip Fracture in People Aged 60 and Older in Norway. J Am Geriatr Soc AH, al. Prescription trajectories and effect of total hip arthroplasty on the use of analgesics, hypnotics, antidepressants, and anxiolytics: Results from a popu total hip N, et al. Opioids for outpatients with cancer in their last year of life: A nation - wide pharmacoepidemiological study. Journal of Opioid Management 2016;12(1):25-36. Charlton RA, Klungs\u00f8yr K, Neville AJ, Jordan S, Pierini A, de Jong-van den Berg LTW, et al. Prescribing of Antidiabetic Medicines before, during and after Pregnancy: A Study in Seven European Regions. PLoS One 2016; 18;11(5): e0155737. doi: 10.1371/journal.pone.0155737. Charlton RA, A, Klungs\u00f8yr K, Neville AJ, Jordan S, de Jong-van den Berg LT, et al. Asthma medication prescribing before, during and after pregnancy: a study in seven European regions. BMJ Open 2016 Jan 19;6(1):e009237. leiner HF, Bjoro T, Midthjell K, Grill V, Asvold BO. Prevalence of thyroid dysfunction in autoimmune and type 2 diabetes: The population-based hunt study in Norway. S, Lund IO, Handal M. A Unique Opportunity to Study Short and Long Term Consequences in Children Prenatally Exposed to Illicit Drugs and Opioid Maintenance Treat - ment Using Czech and Scandinavian Registers. Cent Eur J Public Health 2016;24(3):248-51. Garne E, Vinkel Hansen A, Morris J, Jordan S, Klungs\u00f8yr K, Engeland A, et al. Risk of congenital anomalies after exposure to asthma medica- tion in the first trimester of pregnancy - a cohort linkage study. BJOG 2016;123(10):1609-18. Gimeno-Feliu LA, Calderon-Larranaga A, Prados-Torres A, Revilla-Lopez C, Diaz E. Patterns of pharmaceutical use for immigrants to Spain and Norway: a comparative study of prescription databases in two European countries. International Journal for Equity in Health 2016;15. Halvorsen S, Jortveit J, Hasvold P , Thuresson M, \u00d8ie E. Initiation of and long-term adherence to secondary preventive drugs after acute myocardial Nesv\u00e5g R, Handal M. Antidepressant drug use among adolescents during drug use among 0-17 year olds during 2004-2014: a nationwide prescription database S. Prescriptions of Antidepressants to Survivors of Cancer in Childhood, Adolescence, and Young Adulthood: A Population-Based Study. J Adolesc Young Adult Oncol 2016;14:14. Jordan S, Morris JK, Davies GI, Tucker D, Thayer DS, Luteijn JM, et al. Selective and Congenital Linked Databases in Wales, Martikainen Kieler H, et al. Use of drugs for ADHD among adults-a multinational study among 15.8 million adults in the Nordic countries. Eur J Clin Pharmacol 2016;72(12):1507-14. Kaspersen SL, Pape K, Ose Unemployment and initiation of psychotropic medication: a case-crossover study of 2 348 Occup Environ Med 2016;73(11):719-26. Kjaerulff TM, Ersboll AK, Green A, Emneus M, Pukkala E, Bolin K, et al. Patterns of finasteride use in the male populations of four Nordic countries: A cross-national drug utilization study. Scand J Urol 2016;50(3):220-7. KM, Engeland A, Gilhus AM, Owe JF. Does the choice of antiepileptic drug patients? J Neurooncol 2016;129(3):461-9. Kravdal \u00d8, Grundy E. Health effects of parental deaths among adults in Norway: Purchases of prescription medicine before and after bereavement. SSM - Population Nystad W. Prenatal and infant paracetamol exposure and development of asthma: The Norwegian Mother and Child Cohort Study. Int J 2016;45(2):512- al. Maternal plasma total neopterin and kynurenine/tryptophan levels during pregnancy in relation to asthma development in the offspring. J Allergy Clin Immunol 2016;138(5):1319-25.e4. M, M, Schreuder P , Tambs K, Vold L, Stoltenberg C. Cohort Profile Update: The Norwegian Mother and Child Cohort Study (MoBa). Int J Epidemiol. 2016;45(2):382-8. Mellbye A, Borchgrevink OMS. The duration and course of opioid therapy in patients with chronic non-malignant JW, Dalgard O. Hepatitis C Treatment Uptake among Patients Who Have Received Opioid Substitution Treatment: A Population-Based Study. Hjellvik V, Handal M, Skurtveit S. Mental disorder diagnoses among children and adolescents who use antipsychotic drugs. Eur Neuropsychopharmacol 2016;26:1412-8. Olah KS, Kim TH, Lee HH, Kim JM. Re: Use of hormonal contraceptives among immigrant and native women in Norway: data from the Norwegian Prescription Database The contraceptive situation in Korea. BJOG 2016;123(5):840. Roman M, Graff-Iversen S, Weiderpass E, Vangen S, Sakshaug S, Hofvind S, et al. Postmenopausal hormone therapy and breast cancer prognostic characteristics: A linkage between nationwide registries. Cancer Epidemiology Biomarkers Prevention 2016;25(11):1464-73. Roman M, Sakshaug S, Graff-Iversen S, Vangen S, Weiderpass E, Ursin G, et al. Postmenopausal hormone therapy and the risk of breast cancer in Norway. Int J Cancer 2016;138(3):584-93. Legemiddelstatistikk 2019:2 Folkehelseinstituttet 103Samuelsen Nielsen CS, Eggen AE. Persistent analgesic use and the association with chronic pain and other risk factors in the population-a longitudinal study from the Tromso Study and the Norwegian Prescription Database. Eur J Clin Pharmacol 2016;72:977-85. Selmer R, Haglund B, Furu K, Andersen M, Norgaard M, Zoega H, et al. Individual-based versus aggregate meta-analysis in multi-database studies of pregnancy outcomes: the Nordic example of selective serotonin reuptake inhibitors and venlafaxine in pregnancy. Pharmacoepidemiol Drug Saf 2016;25(10):1160-9. Skipenes VP , Skjeldestad FE. Prevalence of combined Acta Obstet Gynecol Scand 2016;95(9):1027-33. S\u00f8rensen M, Arneberg F, Line TM, Berg TJ. Cost of diabetes in Norway 2011. Diabetes Res Clin Pract 2016;122:124-32. Straiton ML, Reneflot A, Diaz E. Mental Health of Refugees and Non-refugees from War-Conflict Countries: Data from Primary Healthcare Services and the Norwegian Prescription Database. J Immigr Minor Health 2016;21:21. Tjagvad C, Skurtveit S, Bramness JG, Gjersing L, Gossop M, Clausen T. Misuse of prescription drugs and overdose deaths. Journal of Substance Use 2016;21(5):515-20. Tvete IF, Bj\u00f8rner T, Skomedal T. A 5-year follow-up study of users of benzodiazepine: Starting with diazepam versus oxazepam. Br J Gen Pract 2016;66(645):e241-e7. \u00d8vre-Eide V, Skjeldestad FE. Use pattern Acta Gynecol Handal M. Reduced Prescribing M. prescriptions and cycles of Mycoplasma pneumoniae infections in Norway: can a nationwide prescription register be used for surveillance? Epidemiology and Infection. 2015;143(9):1884-92. Skurtveit S, Clausen T, Kun\u00f8e N. The Norwegian Offender Mental Health and Addiction Study - Design and Implementation of a National Survey and Prospective Cohort Study. Subst Abuse. 2015;9(Suppl 2):59-66. doi: 10.4137/SaRt.S23546. eCollection 2015. Charlton R, Garne E, Wang H, Klungs\u00f8yr K, Jordan S, Neville A, Pierini A, Hansen A, Engeland A et al. Antiepileptic drug prescribing before, during and after pregnancy: a study in seven European regions. Pharmacoepidemiol Drug Saf. 2015 Nov;24(11):1144-54. doi: 10.1002/pds.3847. Dale Romundstad P , Skurtveit S. Prevalence of use of non-prescription analgesics in the Norwegian HUNT3 population: Impact of gender, age, exercise and prescription of opioids. BMC Public Health. 2015;15:461. doi: 10.1186/s12889-015-1774-6 Gini R, Jordan SE, Klungsoyr K, Loane M, et al. Improving Information on Maternal Medication Use by Linking Prescription Data to Congenital Anomaly Registers: A S, Furu K. Preeclampsia in pregnancy and later use of antihypertensive drugs. European Journal of Epidemiology. 2015;30(6):501-8. doi: Fredheim T. Risk factors for excessive benzodiazepine use in a working age population: a nationwide 5-year survey in Norway. Scand J Prim Care. 10.3109/02813432.2015. Furu M, H, N\u00f8rgaard M. Serotonin-Reuptake Inhibitors and Venlafaxine in early pregnancy and risk of birth defects - a population based cohort study and sibling design. BMJ 2015. Moger TA. Socio-economic inequality in the use of procedures and mortality among AMI patients: Quantifying the effects along different T, Martinussen PE. Benzodiazepine J Chron Obstruct Pulmon Dis 2015;10:1695-702. doi: 10.2147/COPD.S83107 Hansen Borchgrevink PC, Dale O, Romundstad PR, Mahic M, et al. Consumption of and satisfaction with health care among opioid users with Use of Melatonin - A Register Linkage Study between the Norwegian Prescription Database and Patient Register. Basic Clinl Pharmacol Toxicol 2015;117(4):267-73. doi: 10.1111/bcpt.12411 Hermann Monitoring of Selec - tive Serotonin Reuptake Inhibitors in Elderly Monitoring. doi: 10.1097/FTD.0000000000000169. Hoff M, Skurtveit S, Meyer HE, Langhammer S\u00f8gaard AJ, Syversen U, et al. Use of anti-osteoporotic drugs in central Norway after a forearm fracture. Archives of Osteoporosis. 2015;10:30. doi: 10.1007/s11657-015-0235-2. H\u00f8iseth G, Middelkoop G, M\u00f8rland Has Previous Abuse of Fluni - trazepam Been Replaced by Clonazepam? European Addiction GS, Espehaug B, Midthjell K, Graue M, et al. Anxiety, depression and timing of insulin treatment among people with type 2 diabetes: Nine-year follow-up of the Nord-Tr\u00f8ndelag Health Study, Norway. Journal of Psychosomatic Research. 2015;79(4):309-15. Jensen ET, Daniels JL, Sturmer T, Robinson WR, Williams CJ, Vejrup K, et al. Hormonal contraceptive use before and after conception in relation to preterm birth and small for gestational age: An observational cohort study. BJOG 2015;122(10):1349-61. DOI: 10.1111/1471-0528.13114 C, Beiske G, Baftiu A, Burns ML, Johannessen SI. Experience from therapeutic drug monitoring and gender aspects of gabapentin and pregabalin in clinical practice. Seizure. 2015;28:88-91. doi:10.1016/j.seizure.2015.02.017 Kann IC, Lundqvist C, Lur\u00e5s H. Polypharmacy Among the Elderly in a List-Patient System. Drugs - Real World Outcomes. 2015;2(3):193-8. doi: 10.1007/s40801-015-0036-3 Kelly E, Lu CY , Albertini S, Vitry A. Longitudinal trends in utilization of endocrine therapies for breast cancer: an international comparison. Journal of Clinical Pharmacy and K, Gissler M, et al. Use of antidepressants and association with elective termination of pregnancy: population based case-control study. BJOG-an International and use of anti- depressant medication in late mid-life: a register-based analysis of Norwegian women and men. Aging & mental health. 2015:1-10. doi: 10.1080/13607863.2015.1118010 Lund IO, Skurtveit S, Handal M. Commentary on Raitasalo et al: the great potential in nation-wide registers to study prescription drug use and abuse. Addiction (Abingdon, England). 2015;110(4):644-5. DOI: 10.1111/add.12856 Lund IO, Bukten Handal M, Nordfjaern T, Brunborg GS, Rossow I. A Cohort Study on Long-Term Adverse Effects of Parental Drinking: Background and Study Design. Subst Abuse. 2015 Use of prescribed opioids by children and adolescents: Differences between Denmark, Norway and Sweden. Eur J Pain. 2015 Sep;19(8):1095-100. doi: Nystad W. Grandmother's smoking when pregnant with the mother and asthma in the grandchild: the Norwegian Mother and Child Cohort Study. Thorax. 10.1136/thoraxjnl-2014-206438. Neutel 10.1007/s00228-015-1841-z. Rossow I, Bramness JG. The total sale of prescription drugs with an abuse potential predicts the number of excessive users: a national prescription database study. LB, Engeland A. Risk of hip fracture among older people using antihypertensive drugs: a Bramness JG. Incident Users of Antipsychotic Agents and Future Use of Cholesterol-Lowering Drugs: An Observational, Pharmacoepidemiologic Study. Journal 10.4088/JCP .14m08996. Suhrke P , Zahl PH. Breast cancer incidence and menopausal hormone therapy in Norway from 2004 to 2009: A register-based cohort study. Cancer Medicine. 2015;4(8):1303-8. doi: 10.1002/cam4.474 Tvete IF, Bj\u00f8rner T, Skomedal T. Risk factors for excessive benzodiaz - epine use in a working age population: a nationwide 5-year survey in Norway. Scand J Prescription patterns of inhaled corticosteroids for preschool children - A Norwegian register study. Pediatric Allergy and Immunology. 2015;26(7):655-61. L, al. of SSRI and SNRI Antidepressants during Pregnancy: A Population-Based Study from epide drug treatment and comorbidity in myasthenia gravis: a population-based cohort study. S, Ruths S. Risk of hip fracture among older people using anxiolytic and hypnotic drugs: a nationwide prospective cohort study. Eur Clin Berg-Hansen P , Moen S, Harbo H, Celius E. High prevalence and no latitude gradient of multiple sclerosis in Norway. Mult Scler 2014;20:1780-1782 Ferrer P , Rafaniello C, Sabate E, Coma A, Zara C, et al. Cross- national comparison of antiepileptic drug use: Catalonia, Denmark and Norway, 2007-2011. Epidemiology Public Health. 2014;11:e9405-1. Fredheim OM, Skurtveit S, Dale O, Romundstad P , Borchgrevink PC. Chronic pain and use of opioids: a population based pharmacoepidemio - logical study from the Norwegian prescription database and the Nord-Tr\u00f8n - delag health study (HUNT). Pain 2014;155:1213-1221 Gjelsvik B, Heyerdahl F, Lunn D, Hawton K. Change in access to prescribed medication following an episode of deliberate self-poisoning: a multilevel approach. of b-Blockers and Prostate Cancer-Specific Survival: A Cohort Study of 3561 Prostate Cancer Patients with High-Risk or Metastatic Disease. European Urology 2014;65:635-641. Halvorsen T, Martinussen PE. The geography of chronic obstructive pulmonary disease: A population-based study of Norway. Soc Sci Med 2014;21:25-34. Jensen ET, Daniels JL, Sturmer T, Robinson WR, Williams CJ, Moster D, et al. Maternal hormonal contraceptive use and offspring overweight or obesity. Int J Obes. 2014;38:1275-81. Kalseth J, Cross-country comparisons of health-care costs: The case of cancer treatment in the Nordic countries. Health Policy 2014:115;172-179. Kann IC, Lundqvist C, Luras H. Prescription of addictive and non-addictive drugs to home-dwelling elderly. Drugs Aging. 2014 Jun;31(6):453-9. Karlstad \u00d8, Furu K, Skurtveit S, Selmer R. Drugs for Attention- Deficit Hyperactivity Disorder in Opioid Maintenance Treatment Patients in Norway. Eur Addict Res 2014;20:59-65. Kieler H, Malm H, Artama M, Engeland A, Furu K, Gissler M, et al. Use of antidepressants and association with elective termination of pregnancy: population based case-control study. BJOG. 2014 Nov KB, Amundsen EJ, Dalgard O. HCV treatment uptake in people who have injected drugs - observations in a large cohort that received addiction treatment 1970-1984. Scand J Gastroenterol. 2014 Dec;49(12):1465-72. Langballe H, Ballard C, Aarsland D, Selbaek G. Short- and Long-Term Mortality Risk Associated with the Use of Antipsy -chotics Among 26,940 Dementia Outpatients: A Mahic M, Fredheim OM, Borchgrevink PC, Skurtveit S. Use of prescribed opioids by children and adolescents: Differences between Denmark, Norway and Sweden. Eur J Pain. 2014 Nov 20;[Epub ahead of print]: doi 10.1002/ Co-morbidity in persistent opioid users with chronic non-malignant pain in Norway. Eur J Pain. 2014;18:1083-1093 Neutel CI, Skurtveit S, Berg C, Sakshaug S. Trends in prescription of strong opioids for 41-80 year old Norwegians, 2005-2010. Eur J Pain. 2014 Mar;18(3):438-46. Nordfj\u00e6rn T, Bjerkeset G, Moylan S, R. demographic, lifestyle and psychological predictors of benzodiazepine and z-hypnotic use patterns. Nord J Psychiatry Norum J, Olsen AI, Nohr FI, Heyd A, Totth A. Medical treatment of children and youths with attention-deficit/hyperactivity disorder (ADHD): a Norwegian Prescription Registry Based Study. Glob J Health Sci. 2014 Jul;6(4):155-62. Omland G, Ruths S, Diaz E. Use of hormonal contraceptives among immi - grants and native women in Norway: data from the Norwegian Prescription Database. BJOG 2014;121:1221-1228 Riska BS, Skurtveit S, Furu Dispensing of benzodi - azepines and benzodiazepine-related drugs to pregnant women: a popula - cohort Stene LC, Drivvoll AK, Strom H, Joner G. Incidence of type 1 diabetes in Norway among children aged 0-14 years between 1989 and 2012: has the incidence stopped rising? Results from the Norwegian Child - hood Diabetes Registry. Diabetologia 2014;57:57-62. Skurtveit S, Selmer R, Odsbu I, Handal M. Self-reported data on medicine use in the Norwegian mother and child cohort study compared to data from the Norwegian prescription database. Norsk Epidemiologi. 2014;24(1-2). Str\u00f8m H, Selmer R, Birkeland KI, Schirmer H, Berg TJ, Jenum AK, et al. No increase in new users of blood glucose-lowering drugs in Norway 2006-2011: a nationwide prescription database study. BMC Public Health. 2014;14:520. K, Fredheim PA. High rate of per oral mecillinam treatment failure in community-acquired urinary tract infec S, Ruths S. Increased risk of hip fracture among older people using antidepressant drugs: data from the Norwegian Prescription Database and the Norwegian Hip Fracture Registry. Age Ageing 2013;42:514-20. Berge LI, Riise T, KJ, Midthjell K, et al. Does diabetes have a protective effect on migraine? Epidemiology 2013;24:129-34. Bjorner T, Tvete IF, Aursnes I, Skomedal T. [Dispensing benzodiazepines and S, et al. Antidepressants to cancer patients during the last year of life--a population- based study. Psychooncology A, Falch JA, Furu K, Meyer HE. Hip fracture and other predictors of anti-osteoporosis drug use in Norway. Osteoporos Int T, Daltveit AK, Skurtveit Vangen S, Vollset SE, et al. Effects of preconceptional paternal drug exposure on birth outcomes: Cohort study of 340000 pregnancies using Norwegian population-based databases. British Journal of Gjelstad S, Dalen KJ. Are children carrying the burden of broad-spectrum antibiotics in general practice? Prescription pattern for paediatric outpatients with respiratory tract infec - tions in Norway. Open 2013;3:e002285. M, Skurtveit S. A pharmacoepi - demiological cohort study nonma -Legemiddelstatistikk 2019:2 Folkehelseinstituttet 105lignant pain: Pain 201;154:2487-93. Hold\u00f8 I, Handal M, Skurtveit S, Bramness JG. Association between prescribing hypnotics for parents and children in Norway. Arch Dis Child 2013;98:732-6. Hoye S, Gjelstad S, Lindbaek M. Effects on antibiotic dispensing rates of interventions to promote delayed prescribing for respiratory tract infections in primary care. Br J GenPract. 2013;63:e777-86. Jonasson C, Tvete IF, Hatlebakk JG. Patterns of proton pump inhibitor utilization in gastroesophageal reflux disease and the effect of restrictions on reimbursement: a nationwide prescription database study. Scand J Gastroenterol H, Natas Systematic screening with infor - mation and home sampling for genital Chlamydia trachomatis infections in young men and women in Norway: a randomized controlled trial. BMC Infectious Diseases 2013;13:30. Kravdal O. The poorer cancer survival among the unmarried in Norway: Is much explained by comorbidities? Social Science and Medicine 2013;81:42-52. Kvaale MK, Grave K, Kristoffersen AB, Norstrom M. The prescription rate of antibacterial agents in dogs in Norway - geographical patterns and trends during the period 2004-2008. J Vet Pharmacol Fossa SD. A national study of adverse effects and global quality of life among candidates for curative treatment for prostate cancer. BJU Int 2013;111:221-32. Lillefjell M, Haugan T, Martinussen P , Halvorsen T. Treatment outcomes among individuals in a musculoskeletal pain rehabilitation program related to the prevalence and trends in the dispensing of prescribed medications. Journal of Musculoskeletal Pain 2013;21:311-319. Log T, Skurtveit S, Selmer R, Tverdal A, Furu K, Hartz I. The association between prescribed opioid use for mothers and children: a record-linkage study. Eur J Clin Pharmacol Engeland A, Furu K, Ravndal E, Handal M. Prescription drug use among pregnant women in opioid Maintenance Treatment. Addic - tion 2013;108:367-76. Mauseth SA, Skurtveit S, Spigset O. Adherence, persistence and switch rates for anticholinergic drugs used for overactive bladder in women: data from Norwegian Obstet 2013;92:1208-1215. prescribers in older safety during pregnancy: a Norwegian population registry study. Eur J Epidemiol 2013;28:759-69. Nordeng H, Lupattelli A, Rom\u00f8ren M, Koren G. Neonatal outcomes after gestational exposure to nitrofurantoin. Obstetrics and Gynecology 2013;121:306-13. Nordfjaern T, Bjerkeset O, Moylan Berk M, Grawe RW. Clusters of person - ality traits and psychological symptoms associated with later benzodiazepine prescriptions in the general population: The HUNT Cohort Study. Addict Behav 2013;38:2575-80. Nordfjaern T. Prospective associations between benzodiazepine use and later life satisfaction, somatic pain and psychological health among the elderly. Hum Psychopharmacol 2013;28:248-57. Persheim Tidsskrift for den Fetveit A, Dalen I, Straand J. Prescription peer academic detailing to reduce inappropriate prescribing for older patients: a cluster randomised controlled trial. Tornhage CJ, Lokk J. a way to manage treatment strategies in Parkinson's disease? Pharmaceutical prescribing patterns and patient experiences of symptom control and their impact on disease. J Multidiscip Healthc tive prescriptions to cancer outpatients receiving opioids: A study from the Norwegian prescription database. Supportive Care in Cancer 2013;21:67-73. Skurtveit S, Selmer R, Tverdal A, Furu K, Nystad W, Handal M. Drug expo - sure: inclusion of dispensed drugs before pregnancy may lead to underesti- mation of risk associations. J Clin GW, Dyb G, Tverdal A, Schei B. Intimate partner violence and cardiovascular risk in women: A population-based cohort study. Journal of Women's Health 2013;22:250-8. Stephansson O, Kieler H, Haglund B, Artama Furu K, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of stillbirth and infant mortality. JAMA 2013;309:48-54. Thelle DS, Selmer R, Gjesdal K, Sakshaug S, Jugessur A, Graff-Iversen S, et al. Resting heart rate and physical activity as risk factors for lone atrial fibrillation: a prospective study of 309,540 men and women. Heart 2013;99:1755-60. Tvete IF, Bjorner T, Aursnes IA, Skomedal T. A 3-year survey quantifying the risk of dose escalation of benzodiazepines and congeners to iden - tify risk factors to aid doctors to more rationale prescribing. BMJ Open 2013;3:e003296. Westin AA, Bramness JG, Chalabianloo F, Rygnestad T, Slordal L. [Pregabalin should be moved Laegeforen 2013;133:615-6. Oedegaard KJ, Hundal O. Risk of depression in diabetes is highest for young persons using oral anti-diabetic agents. Diabet Med May]. Tidsskr Nor legemidler 1975-2010. [Patterns in - 2010] Tidsskr Bramness JG, Furu Engeland A. Effect of withdrawal of carisoprodol on use of other prescribed drugs with abuse potential. Clin Pharmacol Therap 2012;91:438-41. Bramness JG, Skurtveit S, M\u00f8rland J, Engeland A. An increased risk of motor vehicle accidents after prescription of methadone. Addiction 2012;107:967-72. Devold H, Furu K, Skurtveit S, Tverdal A, Falck JA, S\u00f8g\u00e5rd AJ. Influence of socioeconomic factors on the adherence of alendronate treatment in inci - dent users in Norway. Pharmacoepidemiol Drug Saf 2012;21:297-304. Devold HM, S\u00f8gaard AJ, Tverdal A, Falch JA, Furu K, Meyer HE. Hip fracture and other predictors of anti-osteoporosis drug use in Norway. Osteoporosis International 2012;24:1225-33. Fasmer OB, methadone: pharmacoepidemiological Opoid switching to methadone: a pharmacoepidemiological study from a national prescription database. Palliat Med 2012;26;804-812. Gedde-Dahl A, Devold HM, Molden E. Statin medication in patients treated with antiepileptic drugs in Norway. Pharmacoepidemiol Drug Saf 2012;21:881-5. Gjelsvik B, Heyerdahl F, Hawton K. Prescribed medication availability and deliberate self-poisoning: a longitudinal study. J Clin Psychiatry. 2012;73:e548-54. M, Skurtveit S. Hypnotic drug use among 0-17 year olds during 2004-2011: A nationwide prescription database study. Scandinavian Journal of Public Health 2012;40:704-11. Hjellvik V, Mahic M, Tverdal A. Utdanning in an asthma population 8-29 years old: A study from the Norwegian Prescription Database. Pharmacoepidemiol Drug Saf 2012;21:1045-52. Kieler H, Artama M, Engeland A, Ericsson O, Furu Gissler M, N\u00f8rgaard M, Nielsen RB, Stephansson H, Haglund B. Selec - tive serotonin-reuptake inhibitors during pregnancy and risks of persistent pulmonary hypertension of the newborn: population based cohort study from the five Nordic 2012;344:d8012.Legemiddelstatistikk 2019:2 glucometer and Laegeforen 2012;132:1453-7. Use of addictive anxiolytics and hypnotics in a national cohort of incident users in Norway. Eur J Clin Pharmacol 2012;68:311-9. Holmen J. The HUNT study: Participation is associated with survival and depends on socioeco- nomic status, diseases and symptoms. BMC Medical S, Fredheim OMS. Concomitant medication among persistent opioid users chronic malignant pain. Acta Anaesthesiologica Scandinavica 2012;56:1267-76. Neutel CI, Skurtveit the point of guidelines? Benzo- diazepine and z-hypnotic use by an elderly population. Sleep Medicine 2012;13:893-7. Neutel I, Skurtveit S, Berg C. Polypharmacy of potentially addictive medica- tion in the older persons - quantifying usage. Pharmacoepidemiol Drug Saf 2012;21:199-206 Neutel CI, Skurtveit S, C. Benzodiazepine and transdermal buprenorphine - long-term use drugs. Acta Anaesthesiol Scand. 2012;56:88-94. Nordfj\u00e6rn T. A population-based cohort study of anxiety, depression, sleep and alcohol outcomes among benzodiazepine and z-hypnotic users. Addic - tive Straand J, Brekke M. Inappropriate prescribing for the elderly - A modern epidemic? European Journal of Clinical Pharmacology 2012;68:1085-94. Pedersen L, Hansen AB, Svendsen K, Skurtveit S, Fredheim Lindbaek H. Pregnancy outcome after gestational exposure to erythromycin - a population-based register study from Norway. British Journal of Clinical Pharmacology 2012;74:1053-62. R\u00f8nning PA, Helseth E, Meling TR, population-based study on the effect temozolomide in the treatment of glioblastoma multiforme. Neuro-Oncology 2012;14:1178-84. Selmer R, Blix HS, Landmark K, Reikvam \u00c5. Choice of initial antihypertensive drugs and persistence of drug use--a 4-year follow-up Hartz I. Mental distress and subsequent use of psychotropic drugs among adolescents - a prospective register linkage study. J Adolescent Health 2012;50:578-87 Steffenak AKM, Wilde-Larsson B, Nordstrom G, Skurtveit S, Hartz I. Increase in psychotropic drug use between 2006 and 2010 among adolescents in Norway: A nationwide prescription database study. Clinical Epidemiology 2012;4:225-31. Stene LE, Dyb G, Tverdal A, Jacobsen GW, Schei B. Intimate partner violence and prescription of potentially addictive drugs: prospective cohort study of women in the Oslo Health Study. BMJ Open. 2012 Apr 5;2(2):e000614. Svendal G, Fasmer OB, Engeland A, Berk M, Lund A. Co-prescription of medi - cation for bipolar disorder and diabetes mellitus: A nationwide population- based study with focus on gender differences. BMC Medicine 2012;10:148. Svendsen K, Skurtveit S, Romundstad Differential patterns of opioid use: defining persistent opioid use in a prescription database. Eur J Pain 2012;16:359-69. Viktil KK, Engeland A, Furu K. Outcomes after antirheumatic drug use before and during pregnancy - a cohort study among 150 000 pregnant women and expectant fathers. Scand J Rheum 2012;41:196-201. Von Soest T, Bramness JG, Pedersen W, Wichstr\u00f8m L. The relationship between socio-economic status and antidepressant prescription: A longitudinal survey and register study of young adults. Epidemiology and Psychiatric Sciences 2012;21:87-95.\u00c5svold BO, Vatten LJ, Midthjell K, Bj\u00f8ro T. Serum TSH within the refer - ence range as a predictor of future hypothyroidism and hyperthyroidism: 11-year follow-up of the 2012;97:93-9. M, Tverdal A. Cigarette smoking and risk of subsequent use of antibacterials: a follow-up of 365 117 men and women. J Antimicrob Chemother 2011;66:2159-67. Bramness JG, Sexton JA. The M, Straand J. Does present use of cardiovascular medication reflect elevated cardiovascular risk scores estimated ten years ago? A population based longitudinal observation study. BMC Public Health. 2011;11:144. Dalen DM, Furu K, Locatelli M, Str\u00f8m S. Generic substitution: micro evidence from register data in Norway. Eur J Health Econ 2011;12:49-59. Engeland A, Bj\u00f8rge S, Vollset SE, Furu K. Risk of diabetes after gestational diabetes and preeclampsia. A registry- based study of 230.000 women in Norway. Eur J Epidemiol 2011;26:157-63. Espnes MG, Bj\u00f8rge T, Engeland A. Comparison of recorded medication use in the Medical Birth Registry of Norway with prescribed medicines registered in the Norwegian Prescription Database. Pharmacoepidemiol Drug Saf 2011;20:243-8. Fasmer OB, Riise opioid High validity of mother-reported use of antiasthmatics among children: a comparison with a prescription 2011;64:878-84. [Chlamydia South Tr\u00f8ndelag follow-up]. Tidsskr Nor Laegeforen Godman B, Sakshaug Wettermark B, Haycox A. Combination of prescribing restrictions and policies to engineer low prices to reduce reim- bursement costs. Expert Rev Pharmacoecon Outcomes Res. 2011;11:121-9. Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt T, Garuoliene K, Herholz H, Joppi J, Dalen H, Lindb\u00e6k M. Do general practitioners' consultation rates influence their prescribing patterns of antibiotics for acute respiratory tract infections? J Antimicrob Chemother 2011;66:2425-33. Hancock P , Nystad W, London SJ. Oral contraceptive pill use before pregnancy and respiratory outcomes in early childhood. Pediatr Allergy Immunol 2011;22:528-36. Handal M, Engeland A, of prescribed opioid analgesics and co-medication with benzodiazepines in women before, during and after pregnancy. A population based cohort study. Eur J Clin Pharmacol 2011;67:953-60 Harman C, Reid M, Thomas KV.In situ calibration of a passive sampling device for selected illicit drugs and their metabolites in wastewater, and subsequent year-long assessment of community drug usage. Environ Sci Technol. 2011;45:5676-82. Hartz I, Bramness JG, Skurtveit S. Prescription of antidepressants to patients on opioid maintenance - H. Boiled coffee intake and sub sequent risk for Type 2 Diabetes. Epidemiology 2011;22:418-21. Hofvind S, Sakshaug S, Ursin G, Graff-Iversen S. Breast cancer incidence trends in Norway -explained by hormone therapy or mammographic screening? International Journal S, Nafstad P , Furu K. A prospective study of asthma and subsequent use of hypnotics in young adults. Pharmacoepide - miol Drug Saf 2011;20:370-7 Kjosavik SR, Hunskaar S. Initial prescription of anti- psychotics and antidepressants in general practice and Acta Scand E, Johannessen SI. Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide population. Epilepsy Res. 2011;95:51-9. Langballe EM, Engdahl B, Selbaek G, Nordeng H. Concomitant use of anti- dementia drugs with psychotropic drugs in Norway--a population-based study. Pharmacoepidemiol Drug Saf. Handal M, Tverdal A, Furu K, Skurtveit S. The association between smoking and subsequent repeated use of prescribed opioids among adolescents and young adults - a population-based cohort study. Pharmacoepidemiol Drug Saf 2011;20:90-8. Log T, Skurtveit S, Tverdal A, Furu K, Hartz I. Dispensing of prescribed analgesics in Norway among young people with foreign- or Norwegian-born parents. Scand J Pain 2011;2:36-44. Mahic M, Skurtveit S, Selmer R, R\u00f8nning M, Furu K. Prevalence, incidence and persistence of etanercept and adalimimab in Norway 2005-2009. Phar - macoepidemiol 2011;20:457-63. Neubert A, Hsia , de Jong-van den Berg Janhsen K, Glaeske G, Furu K, Kieler H, N\u00f8rgaard M, Clavenna A, Wong IC. Comparison of anti-diabetic drug prescribing in children and adolescents in seven European countries. Br J Clin Pharmacol. 2011;72:969-77. , Fredheim O. To what extent does a cohort of new users of weak opioids develop persistent or probable problematic opioid use? Pain OB. Are migraine and bipolar disorders comorbid phenomena?: findings from a pharmacoepidemiological study using the J Clin Psychopharmacol. \u00d8degaard pharmaco-epidemiological study of migraine and antidepressant medica- tions: Complete one year data from the Norwegian population. J Affective Disorders 2011;129:198-204. 2010: Amundsen MO, Engdahl B, Berg C, Nordeng H. Cardiovascular co-medication among users of antiobesity drugs: a population-based study. Pharm World Sci. 2010;32:752-8. Amundsen MO, Engdahl B, Berg C, Nordeng H. Use of psychotropic drugs and analgesics among users of antiobesity drugs--a population based study. Pharmacoepidemiol Saf 2010;19:273-9. A, Owe JF, Gilhus NE. Myasthenia gravis requiring pyridostigmine treatment in a national population cohort. Eur J Neurol 2010;17:1445-50. Berg A, Furu analgetika [Use of for pain-relieving drugs]. Tidsskr Nor Laegeforen 2010;130:1463-6. Bramness JG, Rossow I. Can the total consumption of a medicinal drug be used as an indicator of excessive use? The case of carisoprodol. Drugs: Education, Prevention, and Bramness Engeland A, Skurtveit S. pregabalin (Lyrica) help patients reduce their use of benzodiazepines? A comparison with gaba-pentin using the Norwegian Prescription Database. Clin Devold HE, Falch JA, S\u00f8gaard AJ. Prescription of anti-osteoporosis drugs during 2004-2007 - a nationwide register study in Norway. Eur J Clin Pharmacol 2010;66:299-306. Fredheim OM, Skurtveit . Increasing use of opoids from 2004 to 2007 - Pharmacoepidemiological data from a complete national prescription database in Norway. Eur J Pain 2010;14:289-294. Fredheim OM, Log T, Olsen W, Skurtveit S, Sagen \u00d8, Borchgrevink P . Prescription of opioids to children and adolescents; a study from a national prescription database in Norway. Pediatric Anesthesia 2010;20:537-544. Furu K, Skurtveit Almarsdottir AB, S\u00f8rensen HT. The Nordic Countries as of Skille E, Skurtveit S. Disability pension as a predictor of later use of benzodiazepines among benzodiazepines users. Soc Sci Med 2010;70:921-5. Hausken AM, Furu K, Tverdal A, Skurtveit S. Mental distress and subsequent use of anxiolytic drugs - a prospective population-based cohort study of 16 000 individuals. Scand J Public Health 2010;38:465-73. Hjellvik V, Tverdal A, Furu K. Body mass index as predictor for asthma: a cohort study of 118 723 males and females. Eur Resp J 2010;35:1235-42. Hunskaar S, E, Lur\u00e5s H. Competition in general practice: prescriptions to the elderly in a list patient system. J Health Econ. 2010;29:751-64 K. Prevalence, incidence and persistence of anti-asthma medication use in 2- to 29-year-olds: a nationwide prescription study. Eur J Clin Pharmacol M, CJ. Psychiatric comorbidity in patients Sandberg S. The prevalence of self-monitoring of blood glucose and costs of glucometer strips in a nation - wide cohort. Diabetes Technol Ther 2010;12:701-5. Korn\u00f8r H, Pedersen W, Selmer Tverdal A. Benzodiazepines predict use of opioids- a follow-up study of 17 074 men and women. Pain Med 2010;11:805-14. Skurtveit S, Furu K, Selmer R, Handal M, Tverdal A. Nicotine dependence predicts repeated use of prescribed opioids. Prospective population-based cohort study. Ann Epidemiol drugs: use and co-treatment with potentially interacting medications Eur S. The risk of motor vehicle accidents involving drivers with prescriptions for codeine or i Sogn og Fjordane [Use of lithium in the Norwegian counties and og Fjordane]. The use of lithium, valproate or lamotrigine for psychiatric conditions in children and adolescents in Norway 2004-2007 - a prescription database study. J Affect Disord 2009; Bramness JG, Skurtveit S, Neutel I, M\u00f8rland J, Engeland A. An increased risk of road traffic accidents after prescriptions of lithium or valproate? Pharma - coepidemiol Weitoft GR, Hallas J. Use of lithium in the adult populations of Denmark, Norway and Sweden. J Affect Disord 2009;118:224-8. Devold H, Molden of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy. Brit J Clin Pharmacol 2009;67:234-41. Engeland Furu K. Validation of disease registration in pregnant women in the Medical Birth Registry of Norway. Acta Obstet Prescription of codeine for non-malignant pain in Norway- a pharmacoepidemio - logical study from The Norwegian Scand 2009;53:627-33. Gjerden P , Bramness and potential abuse of anticholin - ergic antiparkinson drugs in , L, the use of anticho - linergic antiparkinson drugs and safety and receptor drug-binding of Eur antipsychotic and anticholin - ergic antiparkinson drugs in Norway after withdrawal orphenadrine. J Clin Pharmacol 2009;68:238-42. Hartz I, Lundesgaard E, Tverdal A, Skurtveit S. Disability pension is associated with the use of benzodiazepines 20 years later: A prospective study. Scand J Public Health 2009;37:320-6. Hartz I, Tverdal A, Skurtveit S. A comparison of self-reported data on disability pension status with data from a nationwide administrative register. Nor J Epidemiol 2009;19:169-172. Hartz I, Tverdal A, Skurtveit S. Social inequalities in use of potentially addic - tive drugs in Norway - use among disability pensioners. Nor J Epidemiol 2009;19:209-218. Hauge Aavitsland P . Sales of oseltamivir in Norway prior to the emergence of oseltamivir resistant influenza A(H1N1) viruses in 2007-08. Bramness Starting insomnia treatment: the use of benzodiazepines versus z-hypnotics. A prescription database study of S. Psychotropic drug use in the Norwegian general population in 2005: data from the Norwegian Prescription Database Pharmacoepidemiol Drug Saf 2009;18:572-8. Landmark CJ, Larsson P , Rytter E, Johannessen SI. Antiepileptic drugs in epilepsy and other disorders - a population-based study of prescriptions. Epilepsy Res 2009; 87: 31-9. Selmer Sakshaug S, Skurtveit S, Furu K, Tverdal A. Statin treatment in a cohort of 20 212 men and women in Norway according to cardiovascular risk factors and level of education. Brit J Clin Pharmacol 2009;67:355-62. Skurtveit S, Furu K, Kaasa S, Introduction of low dose trans - dermal buprenorphine - did it influence use of potentially addictive drugs in chronic non-malignant pain patients? Eur J Pain 2009;13:949-53. Skurtveit Skrivarhaug T, M\u00f8rland J, Bramness J, Engeland A. Road traffic accident risk in patients with diabetes mellitus, receiving blood glucose-lowering drugs. Prospective follow-up Engeland A, Furu K. Use of antirheumatic drugs in mothers and fathers before and during pregnancy - a population-based cohort study Pharmacoepidemiol Drug Saf medika- Repeated dispensing of codeine is associated with high consumption of benzodiazepines. Nor J Epidemiol 2008;18:185-90. Berg A, Furu Skurtveit S. The role of pharmaco epidemiological studies in the market withdrawal of carisoprodol (Somadril\u00ae) in Europe. Nor J Epidemiol 2008;18:167-72. Bramness JG, Skurtveit S. Carisoprodol should be taken of the market. South Med J 2008;101:1074-5. Bramness JG , Skurtveit S, Neutel CI, M\u00f8rland J, Engeland A. Minor increase in risk of road traffic accidents after prescriptions of antidepressants. J Clin Psych T, Dalen I. Pharmacologically inappropriate prescriptions for elderly patients in general practice: How common? Baseline data from The Prescription Peer Academic Detailing (Rx-PAD) study. Scand J Prim Health Care 2008;26:80-5. Engeland JG, AK, R\u00f8nning M, Skurtveit S, Furu K. Prescription druguse among fathers and mothers before and during preg - nancy. A population-based cohort study of 106,000 pregnancies in Norway 2004-06. registerbasert kohortstudie. [Traffic accident risks associated with the prescription of medicinal drugs: a registry-based cohort study] Nor J Epidemiol 2008;18: 159-66. Furu K. Establishment of the nationwide Norwegian Prescription Database (NorPD) - New opportunities for research in pharmacoepidemiology in Norway. Nor J Epidemiol 2008; Neutel CI, M\u00f8rland J. Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, antipsychotic medication: linking population-based prescription data- base to the HUNT Pharmacoepidemiol Drug Saf 2008;17:372-7. Litleskare I, Blix H, norske kreftpasi - enter [Variable prescription of opioids cancer Tverdal A. Benzodiazepine use in all alcohol consumers predicts use of opioids in patients 20 years later - a follow-up study of 13 390 men and women aged 40-42 years. Pharmacoepidemiol Drug Saf 2008;17:926-933. Skurtveit S, Selmer R, Tverdal A, Furu K. The validity of self-reported prescription medication use among adolescents varied by therapeutic class. J Clin Epidemiol 2008;61:714-17. Str\u00f8m H, Sakshaug S, Skurtveit S. Use of statins in patients receiving oral blood glucose-lowering drugs. Nor J Epidemiol 2008;18:191-94. 2007: Al-Haroni M, Skaug N. Incidence of antibiotic prescribing in dental practice in Norway and its contribution to national consumption. J Antimicrob Chemother 2007;59:1161-6. Blix f\u00e6rre forskrivninger? [The use of antidepressants amongst children and adolescents - did the warnings lead to fewer prescriptions?] Tidsskr Nor Laegeforen S. Carisoprodol use and abuse in Norway. pharmacoepidemiological Br Clin Pharmacol 2007;64: 210-8. H. Benzodiazepine prescription for patients in opioid maintenance treatment in Norway. Drug Alcohol Depend 2007;90:203-9. Bramness JG, Skurtveit S, M\u00f8rland J, Engeland A. The risk of road traffic acci- after of A, Skurtveit S, M\u00f8rland J. Risk of road traffic accidents associated with the prescription of medicinal drugs: a registry-based cohort study. Ann Epidemiol of anti-asthmatic medica- tions as a proxy for prevalence of asthma in children and adolescents in Norway: a nationwide prescription database analysis. Eur J Clin Pharmacol S. Aspects of statin prescribing with high, average and Legemiddelstatistikk 2019:2 Folkehelseinstituttet 109low statin N, Hausken T, P . A large community outbreak of waterborne giardiasis-delayed detection in a non-endemic urban area. M, Skurtveit S. Switching statins in Norway after new reimbursement policy - a nationwide prescription study. Br J Clin Pharmacol 2007;64:476-81. Torkildsen O, Grytten N, Myhr S, R\u00f8nning M. [Changes in the sale and use of flunitrazepam in Norway, 1999 - 2004]. Tidsskr Lindback M. Can antibi - otic prescriptions in respiratory tract infections be improved? A cluster- randomized educational intervention in general practice--the Prescription Peer Academic (Rx-PAD) Study [NCT00272155]. Dalen I. A cluster- randomized educational intervention to reduce inappropriate prescription patterns for elderly patients in general practice--The Prescription Peer Academic Detailing (Rx-PAD) study [NCT00281450]. Sakshaug S, R\u00f8nning M. [How many and who are receiving for mellitus?] Nor Prescription An important tool for detailed information on drug use]. Nor J Epidemiol 2004;14:53-56. 2001: Furu K. Drug utilisation in a public health perspective: Establishing a national prescription register in Norway. Nor J Epidemiol 2001;11:55-60.Utgitt av Folkehelseinstituttet Published by Norwegian Institute of Public Health June 2019 Bestilling/Order: Kun tilgjengelig som PDF. Lastes ned fra www.fhi.no as PDF from "}